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ABSTRACT 
INTRODUCTION: Current clinical diagnostics are based on biochemical, 
immunological or microbiological methods. However, these methods are operator 
dependent, time consuming, expensive and require special skills, and are therefore not 
suitable for point-of-care testing. Recent developments in gas-sensing technology and 
pattern recognition methods make electronic nose technology an interesting 
alternative for medical point-of-care devices. METHODS: We applied a gas sensor 
array based on 14 conducting polymers to monitor haemodialysis in vitro and to 
detect pulmonary tuberculosis in both culture and sputum. RESULTS and 
DISCUSSION: The electronic nose is able to distinguish between control blood and 
“uraemic” blood. Furthermore, the gas sensor array is not only capable of 
discriminating pre- from post-dialysis blood (97% accuracy) but also can follow the 
volatile shift occurring during a single haemodialysis session. The electronic nose can 
be used for both dialysate side and blood-side monitoring of haemodialysis. The 
pattern observed for post- and pre-dialysis blood might reflect the health status of the 
patients and can therefore be related to the long-term outcome. Furthermore, the gas 
sensor array was also able to discriminate between Mycobacterium spp. and other 
lung pathogens such as Pseudomonas aeruginosa. More importantly the gas sensor 
array was capable of resolving different Mycobacterium spp. such as Mycobacterium 
tuberculosis, M. scrofulaceum, and M. avium in both liquid culture and spiked sputum 
samples. The detection limit for M. tuberculosis in both sputum and liquid culture is 1 
x 104 mycobacteria ml-1 and therefore partially fulfils the requirement set by the 
WHO. The gas sensor array was able to detect culture proven TB with a sensitivity of 
89% and a specificity of 91%. CONCLUSIONS: In conclusion, this study has shown 
the ability of an electronic nose as a point-of-care device in these areas. 
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Figure 3.29:  Discriminant function analysis showing the separate clusters of control 
blood (squares), post-dialysis blood (triangles) and pre-dialysis blood 
(squares). Cross-validation: 24 samples (8 of each), open symbols. 
Figure 3.30:  Principal component analysis showing the separate clusters of control 
blood (14 samples, squares) and control blood spiked with butanol (2% 
v/v) and acetic acid (2% v/v) (14 samples, diamonds). 
Figure 3.31:  Principal component analysis of control blood (12 samples, red 
squares), spiked control blood (12 samples, green/grey squares), post-
dialysis blood (12 samples, triangles), spiked post-dialysis blood (12 
samples, diamonds) and pre-dialysis blood (12 samples, circles).  
Figure 3.32:  Discriminant function analysis of control blood, spiked control blood 
post-dialysis blood, spiked post-dialysis blood and pre-dialysis blood. 
Cross validation: 15 samples (three of each type), open symbols. 
Figure 3.33:  Principal component analysis of 15 volunteers (control blood) and 14 
haemodialysis patients The uraemic blood samples were taken at the 
beginning, then every hour and at the end of a single dialysis session. 
Figure 3.34:  Discriminant function analysis of 15 volunteers (control blood) and 14 
haemodialysis patients The uraemic blood samples were taken at the 
beginning, then every hour and at the end of a single dialysis session. 
Figure 3.35:  Principal component analysis of clean dialysate and dialysate of 14 
haemodialysis patients. The dialysate samples were taken at the 
beginning, then every hour and at the end of a single dialysis session. 
Figure 3.36:  Discriminant function analysis of clean dialysate and dialysate of 14 
haemodialysis patients. The dialysate samples were taken at the 
beginning, then every hour and at the end of a single dialysis session. 
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Figure 3.37: Principal component analysis of control blood (45 volunteers, squares), 
post – dialysis (99 samples, triangles) and pre-dialysis blood (99 
samples, circles). The blood samples of 11 HD patients were taken at 
nine consecutive dialysis sessions. 
Figure 3.38:  Discriminant function analysis of control blood (45 volunteers, squares), 
post – dialysis (99 samples, triangles) and pre-dialysis blood (99 
samples, circles). The uraemic blood samples of 11 HD patients were 
taken at nine consecutive dialysis sessions. Cross-validation: open 
symbols (5 control samples, 18 uraemic samples). 
Figure 3.39:  Principal component analysis of Control blood (11 samples, squares), 
Post-dialysis blood (28 samples, triangles) and Pre-dialysis blood (28 
samples, circles) based on five biochemical parameters. (A) The first two 
principal components allow the discrimination between pre-dialysis 
blood and a mixed cluster containing post-dialysis blood samples and 
control blood samples. (B) The introduction of a third principal 
component allows the discrimination between post-dialysis blood and 
control blood. 
Figure 3.40:  Cluster analysis of control blood (squares), post-dialysis blood 
(triangles) and pre-dialysis blood (circles) based on five biochemical 
parameters (p=0.05) 
Figure 3.41:  Principal component analysis of Control blood (8 samples, squares), 
post-dialysis blood (11 samples, triangles) and pre-dialysis blood (11 
samples, circles) after 45 min incubation at 37 ºC. Post- and pre-dialysis 
blood samples with the same number belong to the same patient. 
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Figure 3.42:  Cluster Analysis of Control blood (11 samples, squares), Post- (28 
samples, triangles) and Pre-dialysis (28 samples, circles) blood after 45 
min incubation at 37 ºC. The post- and pre-dialysis samples with the 
same number belong to the same patient (p=0.05) 
Figure 3.43:  Correlation between Euclidean distance and urea removal. The 
Euclidean distance was calculated from the first two principal 
components of the pre- and post-dialysis samples.  
 
 
Figure 4.1:  Principal component analysis showing the distinguished clusters of 
liquid cultures of M. tuberculosis (triangles, 12 samples), M. avium 
(crosses, 12 samples), M. scrofulaceum (diamonds, 12 samples) and P. 
aeruginosa (circles, 12 samples) and blank medium (squares, 12 
samples). 
Figure 4.2:  Discriminant function analysis of liquid cultures of M. tuberculosis 
(triangles, 12 samples), M. avium (green squares, 12 samples), M. 
scrofulaceum (diamonds, 12 samples) and P. aeruginosa (circles, 12 
samples) and blank medium (red squares, 12 samples). Cross-validation: 
15 samples (three from each group) were withheld from building the 
DFA model but subsequently assigned correctly once the model was 
built (open symbols).  
Figure 4.3:  PCA plot showing the distinguished clusters of liquid cultures of 
different concentrated M. tuberculosis suspensions. The dashed line 
indicates the detection limit. 
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Figure 4.4:  Discriminant function analysis showing the different concentration of M. 
tuberculosis in culture. Six different concentrations ranging from 1 x 103 
to 1 x 108 mycobacteria ml-1 were analysed (seven samples for each 
concentration and seven blanks). Cross-validation: 14 samples (two 
samples from each group) were withheld from building the DFA model.  
Samples containing more than 1 x 104 mycobacteria ml-1 were correctly 
assigned (open symbols). In contrast, blank medium and samples 
containing 1 x 103 mycobacteria ml-1 could not be distinguish from each 
other.  
Figure 4.5:  Principal component analysis showing the distinguished clusters of a 
living M. tuberculosis suspension (14 samples, circles), a dead M. 
tuberculosis suspensions (14 samples, triangles), and a mixture of it (14 
samples, diamonds) compared to blank medium (14 samples, squares).  
Figure 4.6:  Discriminant function analysis of a living M. tuberculosis suspension 
(circles, 15 samples), a dead M. tuberculosis suspension (triangles, 15 
samples) and a mixture of it (diamonds, 15 samples) compared to blank 
medium (squares, 15 samples). Cross-validation: 12 samples (three of 
each group) (open symbols). 
Figure 4.7:  Principal component analysis showing the distinguished clusters of 
sputum samples spiked with M. tuberculosis (triangles, 12 samples), M. 
avium (green squares, 12 samples), P. aeruginosa (circles, 12 samples), 
and a mixture of M. tuberculosis and P. aeruginosa (diamonds, 12 
samples) and blank medium (red squares, 12 samples).  
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Figure 4.8:  DFA analysis of sputum samples spiked with M. tuberculosis (triangles, 
12 samples), M. avium (green squares, 12 samples), P. aeruginosa 
(circles, 12 samples), mixed infection (diamonds, 12 samples) and blank 
sputum (squares, 12 samples). Cross-validation: 10 samples (two from 
each group) were withheld from building the DFA model but 
subsequently assigned correctly once the model was built (open 
symbols).  
Figure 4.9:  Principal component analysis showing the separate clusters of spiked 
sputum (20 samples, triangles), control sputum (20 samples, diamonds) 
and control medium (20 samples, squares). The sputum was spiked with 
1 x 104 mycobacteria ml-1.  
Figure 4.10:  Discriminant function analysis showing the separate clusters of spiked 
sputum (triangles), control sputum (diamonds) and control medium 
(squares). The sputum was spiked with 1 x 104 mycobacteria ml-1. Cross-
validation: 12 samples (four samples of each group) were withheld from 
building the DFA model but subsequently assigned correctly once the 
model was built (open symbols).  
Figure 4.11:  Principal component analysis showing the analysis of negative control 
samples (50 samples, red diamonds), positive control samples (50 
samples, violet triangles), pneumonia samples (7 samples, green squares) 
and clinical samples (92 TB negatives samples, open red squares; 188 
TB positive samples, squares with grey background).  
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1.1 INTRODUCTION 
The increased knowledge in bionics and artificial intelligence has revolutionised 
many areas of human activity. The employment of these approaches in medicine will 
be no exception. New socio-economic factors and general globalisation of the world 
requires the development and application of new intelligent diagnostic devices 
(Armoni, 1998; Moret-Bonillo, 1998).  
Advances in information technology and satellite communications combined with 
novel intelligent sensors could result in the better management of epidemic diseases 
such as tuberculosis or AIDS by central organisations such as the World Health 
Organisation (WHO). Applying this information could lead to a better global control 
and thus, could reduce the risk of spreading the disease around the world.  
On the other hand, effective clinical care requires decision making based on 
multiple data inputs, e.g. symptoms, history, biochemical or physical tests. Such a 
general approach has not been implemented in current development strategies of 
diagnostic devices, which rely on a “one target – one result” approach (Woodman and 
Fend, 2004).  
In the past, nature often served as a provider of principles leading to astonishing 
innovations and hence, applications. One of the most incredible natural systems is the 
mammalian olfactory system. Today, the same principle is applied in machine 
olfaction and in “olfactory diagnosis” (Woodman and Fend, 2004) 
 
1.2 DIAGNOSTIC POWER OF SMELL 
The origins of “odours as diagnostic indicators” go back to around 400BC and the 
father of medicine – Hippocrates (Adams, 1994). Descriptions at that time of the 
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pouring of human sputum on hot coal to thermally generate a smell could very well be 
considered a primitive pyrolysis of long chain fatty acids, release of volatile 
hydrocarbons or possibly lipid peroxidation, bacterial or infected tissue products. 
Similarly, traditional Chinese medicine also exploited the power of olfactory 
diagnosis (Porter, 1997). Whilst early medical practitioners had not discovered 
bacterial pathogenicity, they clearly recognised that a disease-host interaction could 
change the odour of body excretions such as sweat, urine, vaginal fluid and sputum 
(Porter 1997). Diagnosis using the human sense of smell remained one of the most 
reliable methods in bedside medicine. For many years, paediatricians associated 
phenylkentouria with a mousy/honey smell of urine. Other disease like liver failure, 
chronic congestive heart failure of portcaval shunts are associated with characteristic 
odour of dimethyl sulphide (Smith, 1982). Certain conditions are associated with a 
malodour emerging form the skin. Among them are, squamous cell carcinoma, which 
is linked to a full-offensive skin aroma (Lidell et al, 1975), or Yellow fever, which is 
often related to the smell of a butchers shop (Lidell et al, 1976; Hayden 1980).  
A collection of recorded diseases and infections liberating specific odours is 
presented in Table 1.1. 
 
1.2.1 EARLY DIAGNOSIS OF VOLATILE BIOMARKERS 
During the 1950’s and early 1960’s, gas chromatography (GC) and GC-linked 
with mass spectrometry (GC-MS) provided the instrumentation with which to 
separate and identify volatile biomarkers. 
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Table 1.1: Diseases and their recorded liberated odours (adapted from Pavlou and 
Turner, 2000). 
 
 
One of the most obvious sources where volatile disease markers can be found is 
breath. Breath tests date from the earliest history of medicine because physicians in 
ancient times knew that the odour of the breath is altered in some diseases (Philips, 
1997). Some breath aromas are highly characteristic of disease: e.g. patients with 
diabetic ketoacidosis smell like rotten apples, mainly due to acetonemia. Chronic 
renal failure causes the breath to smell like stale urine (Phillips, 2002). 
However, the modern era of breath testing did not commence until 1971, when 
Linus Pauling used dry ice to freeze out breath volatile organic compounds (VOCs). 
Odour Site/Source Disease 
Baked brown bread Skin Typhoid 
Stale beer Skin Tuberculosis lymphadenitis 
Butchers shop Skin Yellow fever 
Grape Skin/sweat Pseudomonas infection 
Rotten apples Skin/sweat Anaerobic infection 
Over-ripe Camembert Skin Bacterial proteolysis 
Ammoniacal Urine Bladder infection 
Amine-like Vaginal discharge Bacterial vaginosis 
Rancid Stool Shigellosis 
Full Stool Rotavirus gastroenteritis 
Freshly plucked feathers Sweat Rubella 
Sweet Sweat Diphtheria 
Full Sputum Bacterial infection 
Putrid Breath Lung abscess, anaerobic infection, necrotising pneumonia 
Full-offensive Skin Squamous cell carcinoma 
Acetone-like Breath Diabetes mellitus 
Musty/horsey Infant skin Phenylketonuria 
Foul Infant stool Cystic fibrosis 
Sweaty feet Skin/sweat Isovaleric academia 
Burnt sugar Urine Maple syrup urine disease 
Sweet/fruity or boiled 
cabbage Infant breath 
Hypermethionemia 
Fishy Skin/urine Trimethylaminouria 
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To date more than 3000 volatile organic compounds in human breath have been 
identified, but the biochemical significance of most of these compounds is still 
unknown (Phillips et al, 1995; Phillips et al, 1999). A collection of GC-MS 
applications in clinical diagnosis is presented in Table 1.2 
 
Table 1.2: The application of GC-MS analysis of volatiles in clinical samples 
(adapted from Pavlou and Turner, 2000). 
Method Source/Disease Volatile 
GC Breath, urine VOCs 
GC Aerobic Gram(-) bacteria VOCs 
HSA-GC Intraperitoneal fluid VOCs 
GC Anaerobic bacteria Acetic, butyric acid 
GC Human pus, purulent fluid Isobutyric, isovaleric 
acid 
HSA-GC Urine/ metabolic disorder Isovaleric acid 
GC-MS Blood plasma, CSF/ liver disorder 3-methylbutanal 
FI-GC Breath/ liver disorder Methyl-mercaptan 
GC-MS Breath/ schizophrenia Pentane 
GC-MS Breath/ketosis Acetone 
GC-PI Breath/ Cardiopulmonary disease Acetone, ethanol 
Abbreviations: GC – gas chromatography, GC-MS – gas chromatography-mass 
spectroscopy, HSA – head space analysis, CSF – cerebrospinal fluid, PI – photo 
ionisation, VOCs – volatile organic compounds 
 
Recently, Phillips et al presented two studies, where volatile organic compounds 
(VOCs) were related to cancer. In the first study, the presence of VOCs, mainly 
alkanes and monomethylated alkanes were investigated in breath as tumour markers 
for lung cancer (Phillips et al, 2003a). The second study investigated the presence of 
VOCs as markers for breast cancer (Phillips et al, 2003b). The results of both studies 
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are promising, but will require validation in larger trials. Even inflammatory lung 
diseases such as asthma, chronic obstructive pulmonary disease, or cystic fibrosis 
have been associated with specific volatile markers in exhaled breath including nitric 
oxide or hydrocarbons (Kharitonov and Barnes, 1997; Kharitonov, 2004). 
The production of volatiles is not limited to humans. At the beginning of the 19th 
century, Liebig and Woehler (1837) described the production of benzaldehyde by 
microorganisms. Since then many reports have been published. Among the first was 
Omelianski (1923) who reviewed naturally liberated microbial odours. He reported 
the accumulation of organic acids and alcohols in cultures of Mycobacterium 
tuberculosis and Pseudomonas aeruginosa.  
Since the development of GC instruments, the characterisation of bacterial 
volatiles of pathogenic origin has been of interest. Davies & Hayward (1984) 
identified acetylcholine and suggested that it could act as a precursor of 
trimethylamine, a possible early biochemical marker of urinary tract infections (UTI) 
caused by Proteus spp. and Klebsiella spp. Grametbauer et al (1988) reported the 
production of a number of volatile compounds derived from 189 strains of 33 
bacterial species. They concluded that even when the volatile profiles 
(chromatograms) showed distinct peaks, it was not always possible to completely 
differentiate between strains of the same species. The GC-MS analysis of pathogenic 
bacteria such as Pseudomonas aeruginosa, Proteus mirabilis, Klebsiella pneumoniae, 
Staphylococcus aureus, and Clostridium septicum revealed that all of them produced 
complex odours pattern (Larsson et al, 1978). Similarly, species of the lactic acid 
family, important industrial bacteria were extensively studied using gas 
chromatographic techniques allowing a discrimination between Leuconostoc spp, 
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Pediococcus spp, and Lactobacillus spp (Radler and Gerwarth, 1971). Mayakova et al 
(1989) proposed a rapid method for detecting post-operative infections in abdominal 
and gynaecological surgery caused by non-clostridial anaerobes via GC-MS analysis 
of volatile fatty acids. 
 
Although the introduction of GC-MS enabled the comprehensive study of possible 
diseases markers, it has never emerged as a fully evaluated routine instrument for 
clinical diagnosis. Factors such as high capital costs, laborious and time-consuming 
methods requiring significant expertise and the shear complexity of volatiles detected 
using GC-MS have all conspired to limit the application of this technology (Manolis, 
1983; Phillips, 1997). However, the wealth of knowledge generated by GC-MS has 
significantly enriched the understanding of the way the human body responds to 
disease and in particular the potential role of volatile organic compounds (VOC) as 
diagnostic markers. The drive to develop instruments for routine clinical application 
without the drawbacks of GC-MS was on. 
 
1.3 PRINCIPLES OF OLFACTION 
The basic idea of electronic noses is to mimic the human olfactory system. This 
section describes the similarities and differences between human olfaction and 
machine olfaction.  
The human olfactory system comprises three basic elements, namely the olfactory 
receptor cells, the olfactory bulb and finally the brain (Pearce, 1997a). These three 
elements formed the basis for the development of the artificial olfaction devices 
(electronic noses). The main components of an electronic nose are an array of 
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chemical sensors, a data pre-processing unit and a pattern recognition engine (PARC) 
(Pearce, 1997b). The basic elements of both olfactory systems are as illustrated in 
Figure 1.1. 
 
 
 
 
 
Figure 1.1: Comparison of the human olfaction with artificial olfaction (adapted 
from Turner and Magan, 2004). 
1.3.1 HUMAN OLFACTORY SYSTEM 
The sensation of smell is caused by the interaction of odorant molecules with a 
group of specialised nerve cells called olfactory receptors. The olfactory cells are 
situated in the olfactory epithelium, a specialised tissue in the nose (Craven et al, 
1996; Bartlett et al, 1997; Pearce 1997a). Odorant molecules are typically small, 
polar, and hydrophobic molecules with a molecular weight between 30 and 300 Da, 
with one or more functional groups (Gardner and Bartlett, 1999).  The hydrophobicity 
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of the molecules is important, as the initial step in olfactory recognition is the 
dissolution of the molecules in an aqueous mucous layer, which covers the olfactory 
receptor cells and the epithelium (Craven et al, 1996; Bartlett et al, 1997a; Pearce 
1997a). The receptor surface area is increased by a number of cilia, which lie in the 
mucous layer (Pearce, 1997a). On the surface of the cilia are G-receptor binding 
proteins. The interaction of the odorant molecules with the G-receptor binding 
proteins stimulates the neurons (Craven et al, 1996). It is unknown how many 
different types of G-receptor proteins exist, but presumably between 100 and 1000 
(Craven et al, 1996). It is believed that olfactory cells (ca. 100 millions) are involved 
in both amplifying the signal and generating second messenger (Gardner and Bartlett, 
1994). Hence, many olfactory neurons appear to express only one of the many 
possible G-binding proteins, explaining the large number of olfactory cells (Pearce, 
1997a). The second messenger controls ion channels and thus generates signals, 
which travel from the neuron via axons to the glomeruli nodes in the olfactory bulb 
(Gardner and Bartlett, 1994; Pearce, 1997a). These signals are pre-processed by mitral 
cells and subsequently sent to the brain via a granular cell layer (Gardner and Bartlett, 
1994; Pearce, 1997a). The different G-binding proteins have an overlapping 
sensitivity to different odorant molecules (Gardner and Bartlett, 1994; Gibson et al, 
1997).  
The human nose can discriminate complex aromas without separating the mixture 
into individual components (Pearce, 1997a). Due to the high sensitivity of the human 
nose, it is possible to detect odorant molecules in very low concentrations (ppm, ppb) 
(Pearce, 1997a). 
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1.3.2 ARTIFICIAL OLFACTORY SYSTEM 
In the artificial olfactory system, the olfactory receptor cells are replaced by a 
chemical sensor array. The sensors generate a time-dependent electrical signal in 
response to the interaction of an odour with the sensor itself (Gardner and Bartlett, 
1994, Pearce, 1997b; Gardner and Bartlett, 1999). The olfactory bulb is represented 
by a data pre-processing unit, which compensates for sensor drift and noise (Pearce, 
1997b; Gardner and Bartlett, 1999). The final stage in artificial olfaction is the PARC 
engine, which is equivalent to the human brain (Pearce, 1997b). In summary, it can be 
said that electronic noses mimic the mammalian olfactory system by combining non-
specific gas sensors with a PARC software to analyse and characterise complex 
odours without prior separation of the mixture into individual components (Bartlett et 
al, 1997) 
 
1.4 DEFINITION OF ELECTRONIC NOSES  
Electronic nose is the informal name for an instrument made up of chemical 
sensors combined with some sort of pattern recognition system, enabling 
discrimination between, or recognition of, simple or complex odours (Gibson et al, 
2000). The term “electronic nose” was introduced by Julian Gardner in 1988 (Gardner 
and Bartlett, 1999). In 1964, Wilkins and Hatman built the first devices aimed at 
mimicking the human nose (Gardner and Bartlett, 1994). However, the first electronic 
nose, as an intelligent sensor system, was introduced by Persaud and Dodd (1982) at 
Warwick University. The first commercial electronic noses were launched in the 
earlier 1990s (Gibson et al, 2000). Among the first systems were devices from Alpha 
MOS in 1993, Neotronics and Aromascan in 1994 and Bloodhound Sensors and HKR 
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Sensorsysteme in 1995 (Gibson et al, 2000). A list of commercially available 
electronic noses is shown in Table 1.3.  
 
1.5 GAS SENSORS FORMATS 
The central part of an electronic nose is the chemical gas sensor array. Sensors 
used in electronic noses are non-specific gas sensors (Gardner and Bartlett, 1999). 
Hence, they should possess good stability and a high sensitivity coupled with a short 
response time (Bartlett et al, 1997).  
Currently the following types of sensors are used in electronic noses (Craven et 
al, 1996; Dickinson et al, 1998; Chang et al, 2000): 
 
· Metal Oxide Sensor (MO) 
· Conducting Polymers (CP) 
· Piezoelectric based Sensors    
Ø Sound Acoustic Wave Sensors (SAW) 
Ø Bulk Acoustic Wave Sensors (BAW) 
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Table 1.3: Commercially available electronic noses (adapted from Gibson et al, 
2000). 
Company Location Model 
Alpha MOS France 
Fox 2000, 3000, 4000, 5000 
Alpha Kronos, Alpha Gemini 
Bloodhound Sensors UK Bloodhound BH114 
Cyrano Science USA Cyranose 320 
Etherdata Iceland FreshSense 
Environics Industry Oy Finland MGD-1 
Electronic Sensor Technology USA GC/SAW System 
Hewlett Packard USA HP4440A 
Lennartz Electronic Germany MOSES II 
Marconi Applied Technology UK e-nose 5000 
Mo Tech Sensoric Germany VOCmeter, VOCcheck, OEM 
modules 
Osmetech (formerly Aromascan) UK and USA Multi-Sampler SP, CP sensors 
RST Rostock Germany Sam 
Smart Nose Switzerland Smart Nose – 300 
WMA Airsense Germany PEN 
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1.5.1 METAL OXIDE SENSORS 
These devices consist of an electrically heated ceramic pellet, onto which a thin 
porous film of SnO2 doped with metal ions has been deposited (Persaud and Travers, 
1997). The doped SnO2-film behaves as an n-type semiconductor and the 
chemisorption of oxygen at the sensor surface results in the removal of electrons from 
the conducting band. Gases in a sample interact with the absorbed oxygen and thereby 
affect the conductivity of the SnO2 film (Persaud and Travers, 1997; Dickinson et al, 
1998). The change in conductivity is typically used as the output signal (Dickinson et 
al, 1998).  
The devices are run at elevated temperatures (typically at 300 – 400 oC) to 
achieve a fast response time and to avoid interferences from water. The response 
characteristics can be tailored by varying the operating temperatures and the doping 
agent (Gardner and Bartlett, 1994; Dickinson et al, 1998). 
The sensor is characterised by a short recovery time, insensitivity to moisture and 
little drift over time, and the electrical output signal is proportional to the odour 
concentration (Harper, 2001). On the other hand, it must be mentioned, that the 
devices are typified by high power consumption and a poor selectivity (Harper, 2001).  
 
1.5.2 CONDUCTING POLYMERS 
The use of Conducting Polymers (CP) as sensors dates back to 1979, when Diaz 
and co-workers first electropolymerised a thin film of polypyrrole (Dickinson et al, 
1998). Since then, much attention has been paid to these materials and their unique 
properties (Dickinson et al, 1998).  
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Sensors are fabricated by electropolymerising thin polymer films across a narrow 
electrode gap (Bartlett et al, 1989; Dickinson et al, 1998). The reversible absorption 
of molecules onto the film induces a temporary change in the electrical conductivity 
of the film by altering the amount of active charge carriers in the polymer structure 
(Bartlett et al, 1989; Shurmer and Gardner, 1992; Dickinson et al, 1998). CPs in an 
electronic nose are typically based on either poly(pyrolle) or poly(aniline) (Bartlett et 
al, 1989; Dickinson et al, 1998). In both cases, it is easy to obtain a thin polymer film, 
and therefore reproducible sensors can be produced (Gardner and Bartlett, 1999). In 
CP-sensors, the molecular-interaction capabilities of the polymer can be selectively 
modified by incorporating different counterions during polymer preparation or by 
attaching functional groups to the polymer backbone (Dickinson et al, 1998),  
The advantages of CP include the low power consumption and the high selectivity 
of the sensors. The shortcomings are long response times, inherent time- and 
temperature drift, the sensitivity to water and the high cost of sensor fabrication 
(Dickinson et al, 1998; Harper, 2001). 
 
1.5.3 PIEZOELECTRIC BASED SENSORS 
The use of piezoelectric crystals as transducers for chemical analysis was first 
suggested by Sauerbrey in 1959 and demonstrated by King in 1964 (Dickinson et al, 
1998). The two most commonly used piezoelectric based sensors are the Surface 
Acoustic Wave sensor and the Bulk Acoustic Wave sensor (Gardner and Bartlett, 
1999). 
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Surface Acoustic Wave (SAW) sensor: 
SAW devices consist of interdigitated electrodes fabricated onto a piezoelectric 
substrate (e.g. quartz) onto which a thin film coating of a selective material is 
deposited (Persaud and Travers, 1997; Dickinson et al, 1998). An applied radio 
frequency produces an acoustic wave on the sensor surface (surface oscillation). The 
adsorption of odour molecules onto the thin film coating leads to an increase in mass 
and elastic module of the coating. This change in mass and elastic module perturbs the 
wave leading to a frequency shift (Persaud and Travers, 1997; Dickinson et al, 1998). 
To compensate for pressure and temperature effects the sample sensor is usually 
connected to a reference SAW device and the frequency difference is detected 
(Gardner and Bartlett, 1999).   
 
Bulk Acoustic Wave (BAW) sensor: 
BAW devices consist of a piezoelectric resonator with one or both surfaces 
covered by a membrane such as acetyl cellulose or lecithin (Bartlett et al, 1997; 
D’Amico et al, 1997). The BAW structure is connected to a suitable amplifier to form 
an oscillator. The resonant frequency of the oscillator is determined by the physical 
and geometrical properties of the device (D’Amico et al, 1997). Any changes in the 
physical properties of the membrane due to absorption of molecules affects the 
resonant frequency of the BAW device (Bartlett et al, 1997; D’Amico et al, 1997). 
This frequency shift is detected (Dickinson et al, 1998). 
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1.5.4 OTHER TECHNOLOGIES 
Other sensor formats are in development, but none of these alternative 
technologies are currently applied in commercial electronic noses. Among these are 
optical transducers (Sutter et al, 1997, Walt, 2002), surface plasmon resonance 
(Magan and Turner, 2004), electrochemical sensors (Baltruschat et al, 1997), or 
discotic liquid crystals (Magan and Turner, 2004).  
 
1.6 APPLICATION OF ELECTRONIC NOSES  
Since the introduction of the electronic nose, there is an increasing awareness of 
the potential of this technology and with it a broad range of possible applications. 
Electronic noses were designed to be used in numerous areas, ranging from food to 
modern medicine. 
 
1.6.1 MEDICAL APPLICATIONS 
When attempting to navigate through applications of this technology in medicine, 
it soon becomes apparent that there is one clear delineator:  Application of electronic-
nose in infectious diseases or non-infectious diseases. Using these two very broad 
subject headings, this section attempts to highlight both current and future 
applications of electronic-nose technology. 
 
Infectious Diseases 
The analysis of infectious diseases represents by far the largest clinical research 
area for electronic nose technology attracting both academic and commercial interest. 
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As a result it is safe to speculate that this area will be the first to deliver a routine 
medical application for the technology.  
The reasons for such widespread interest are many fold. Using conventional 
culture methods, diagnosis of infection can take 24-48 hours for bacterial infections 
(identification of Mycobacterium tuberculosis can require 4-8 weeks) and often 
around 7 days for fungal diseases. For appropriate early treatment including screening 
for therapeutic sensitivity, it is essential to obtain relevant rapid results in easily 
interpretable formats. Ideally such analysis should be amenable to use at “point-of-
care” and being the first step in rapid, responsive and appropriate anti-infectious 
therapy, reducing the incidence of unchecked infection and/or poorly targeted 
antibiotics. 
Diagnosis and management of sepsis in wound healing 
The “point-of-care” analysis of the odours over the headspace of 24 low adherent 
contact dressing collected from 21 patients with leg ulcers was in fact one of first 
clinical applications of electronic-nose technology (Parry and Oppenheim, 1995). 
Using 20 conducting polymer sensors, a two-dimensional odour map demonstrated 
clear differences between ulcers of differing bacterial aetiology. Ulcers infected with 
beta-haemolytic Streptococci formed a distinctive cluster away from the other three 
categories (mixed infection, Staphylococcus aureus and control), which could not be 
resolved from each other. Despite this, the unambiguous separation of at least one 
bacterial species provided proof that host-pathogen interactions are identifiable by an 
electronic nose (Pavlou and Turner, 2000).  
Today the analysis of wound healing remains at the forefront of clinical 
electronic-nose application. A recent European Union funded project “WUNSENS” 
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has integrated image capture technology with the electronic-nose technology of 
AlphaMOS to develop a portable integrated wound assessment system for use at 
“point-of-care” (IST-2001-52058). 
Diagnosis and management of urogenital infections 
One of the areas where appropriate and effective therapy is most dependant upon 
early diagnosis is that of urogenital infections. Urinary tract infections (UTI) are a 
significant cause of morbidity, with 3 million cases each year in the USA alone 
(Schaechter et al, 1993; Pavlou et al, 2002). Estimates suggest that 20% of females 
between the ages of 20 and 65 years suffer at least one episode per year, which in turn 
increase the risk of contracting complicated or chronic urological disorders such as 
pyelonephritis, urethritis and prostatitis (Orenstein and Wong, 1999; Lipsky, 1999). 
Approximately 80% of uncomplicated UTIs are caused by Escherichia coli and the 
remaining 20% by enteric pathogens such as Enterocci, Klebsiella, Proteus, and 
fungal opportunistic pathogens such as Candida albicans (Krcmery et al, 1983; 
Honiken et al, 1999; Pavlou et al, 2002). Current diagnostics and antibiotic sensitivity 
tests require 24-48 hours to identify pathological species in a midstream specimen 
containing at least 105 CFU ml-1.  
A similar story is true for bacterial vaginosis; in the US alone there are an 
estimated 10 million doctor visits for vaginal infections. Bacterial vaginosis (BV) is 
one of the most common causes of vaginal infection with high prevalence in women 
of childbearing age. Vaginal infection during pregnancy has been linked to pre-term 
delivery (McGregor and French, 1997), and spontaneous abortion in the third 
trimester and upper genital tract infections including histologic 
chorioamnionitis (Hillier et al, 1988).   
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With a requirement for simple, accurate and ideally “point-of-care” analysis, the 
application of electronic-nose technology in managing urogenital infection has 
received considerable academic and commercial interest. The premise that analysis of 
volatiles generated from urine is clinically relevant stems from several gas-
chromatographic studies during the 1970’s (Pavlou et al, 2002). Whilst these early 
studies lacked advanced computation to resolve data, they did demonstrate 
discrimination between E. coli and Proteus spp (Haywood et al, 1977). 
Almost 25 years later, electronic-nose technology replicated these studies both in 
“spiked” urine samples where discrimination between E. coli and P. mirabilis was 
obtained after just 4 hours in culture (Saini et al, 2001) and clinical specimens 
(Aathithan et al, 2001; Pavlou et al, 2002). Pavlou et al (2002) using an array of 14 
conducting polymer sensors (Bloodhound BH114) discriminated between E. coli, 
Proteus spp, Staphylococcus spp and no infection in a total of 70 patients with a 
combined positive predictive outcome of 99%, following 4.5 hour liquid culture 
incubation (Pavlou et al, 2002). Aathithan et al (2001) used an Osmetech Microbial 
Analyser (Osmetech plc, Manchester, UK), to diagnoses bacteriuria. Analysing 534 
clinical urine specimens, the sensitivity and specificity of this device were 83.5 and 
87.6 %, respectively compared to traditional culture, when the cut-off was defined as 
105 CFU ml-1. Whilst this data again shows the potential for electronic-nose 
technology, it is the Osmetech Microbial Analyser (OMA), which warrants further 
discussion. Osmetech has received 510(k) approval from the FDA for the use of its 
microbial analyser as a UTI sensor device. 
The OMA is also marketed for the diagnosis of bacterial vaginosis. A case study 
on bacterial vaginosis in the United Kingdom has shown that conducting-polymer- 
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based sensor arrays similar to that in the microbial analyser could be used to 
successfully diagnose 89% of test subjects as being positive or negative for both 
bacterial and yeast infections (Persaud et al, 2002; Turner and Magan, 2004). 
Following the evaluation of over 1000 patients, the Osmetech device was given 
501(k) approval by the FDA in January 2003, citing that the instrument had a 
sensitivity and specificity of 81.5% and 76.1% as compared to the current “gold-
standard” of the Amsel criteria but with significant improvements in speed and 
expertise required (Hay et al, 2003). 
Disease and management of tuberculosis and respiratory disease 
Pavlou and Turner (2000) investigated the possibility of applying electronic nose 
technology to diagnose tuberculosis (TB). Using a Bloodhound BH114 system 
comprising 14 conducting polymers, this group demonstrated the ability of this 
system to discriminate between different Mycobacterium spp. and other lung 
pathogens (Pseudomonas aeruginosa) with an accuracy of 99 %. The system 
performed equally well in spiked sputum and culture (Pavlou and Turner, 2000, 
Pavlou et al, 2004). 
Gardner and co-workers have applied an AlphaMos Fox 2000 to identify bacteria 
that cause infections of the ears, nose and throat. These diseases are often associated 
with microorganisms such as Staphylococcus aureus, Legionalla pneumphilia, and 
Escherichia coli. Currently, the diagnosis is based on taking a swab specimen of the 
infected area with subsequent culturing, assaying and staining for classification. The 
entire procedure can take many days causing a delay in treatment. In contrast, the 
electronic nose is not only able to detect the type of bacteria but also the growth phase 
in a relatively short period of time (» hours). Gardner and his group analysed 180 
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unknown samples using a neural network. 100 % of the Staphylococcus aureus and 92 
% of the Escherichia coli were correctly identified independent of the growth phase. 
These are remarkable findings since all Staphylococcus samples collected during the 
initial lag phase were correctly predicted and this after an incubation period of only 10 
min (Gardner et al, 2000) 
Whilst we have highlighted a few of the infectious diseases where electronic-nose 
technology has received considerable attention, it is by no means an exhaustive 
review, but it is an insight into which infectious areas may well see “point-of-care” 
applications. From “point-of-care” diagnosis of eye infections (Dutta et al, 2002) to 
detection of Helicobacter pylori in gastroesophageal isolates (Pavlou et al, 2000) and 
general clinical microbiology (Turner and Magan, 2004) new potential applications 
are being explored. 
 
Non-infectious Diseases 
The application of electronic-nose technology for the investigation of non-
infectious disease has not as yet received such detailed evaluation. The main 
specimens for these studies are blood, breath and sweat. These body fluids are very 
complex which combined with complex disease pathology, makes non-infectious 
analysis much more difficult, but as will be briefly reviewed not impossible. 
 
Application of electronic-nose technology in renal medicine 
One non-infectious area, which has received significant interest, is renal 
medicine. The motivation for this most probably lies in the fact that well characterised 
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markers of renal disease are available.  The first of these is microscopic haematuria. 
Di Natale and co-workers applied an electronic nose based on eight quartz 
microbalance sensors to analyse urine samples. Not only were they able to 
discriminate between urine containing blood compared to normal “healthy” urine, 
they were also able to correlate the sensor response to the amount of blood present in 
urine (Di Natale et al, 1999). However, this correlation was of a qualitative nature and 
no further attempts were made to find a quantitative correlation.  
Patients suffering form kidney failure generally have a characteristic breath odour 
mainly caused by dimethylamine (DMA) and trimethylamine (TMA). Lin et al using 
these two marker substances to investigate the potential of an electronic nose (6 
piezoelectric quartz-crystals) as a diagnostic tool for uraemia based on breath 
analysis, successfully distinguished between healthy individuals and chronic renal 
failure patients (Lin et al, 2001). There was, however, an overlap between patients 
suffering form renal insufficiency and haemodialysis patients. Nevertheless, the 
breath of kidney patients “smelt” significantly different to the breath of the healthy 
controls, indicating the potential of an electronic nose as an early, non-invasive 
diagnosis system for uraemia. 
 
Other non-infectious applications  
Two further interesting applications for electronic-nose technology are in the non-
invasive diagnosis and management of diabetes (Ping et al, 1997; Mohamed et al 
2002) and in the diagnosis of lung cancer (Di Natale et al, 2003). 
Ping et al used electronic nose technology to directly analyse exhaled breath from 
18 patients with type I diabetes and 14 healthy volunteers before and after eating, and 
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demonstrated that such non-invasive monitoring could be a reliable method for 
monitoring diabetics (Ping et al, 1997). Mohamed et al used an electronic-nose and 
artificial neural network analysis to demonstrate that type II diabetes could be 
detected via urine analysis with a 92% success rate (Mohamed et al, 2002). 
Di Natale et al have extended previous GC-MS studies (Phillips et al, 1999) and 
demonstrated the utility of electronic-nose technology in detecting lung cancer (Di 
Natale et al, 2003). All patients with lung cancer and 94% of patients free from the 
disease were correctly classified following the analysis of alkenes and aromatic 
compounds in expired breath. Whilst the sample size (42 patients) was relatively 
small, this study demonstrated just how broad the application of electronic-nose in 
clinical practice potentially is. 
 
1.6.2 NON-MEDICAL APPLICATIONS 
 Non-medical applications possess the biggest share in the global electronic nose 
market, with the food industry being the largest customer. Applications reach from 
monitoring the quality of food packaging (Forgren et al, 1999) and dairy products 
(Schaller et al, 1999; Magan et al, 2001; Ampuero and Bosset, 2003; Brudzewski et 
al, 2004), classification of vegetable oils (Martin et al, 1999) and olive oil 
(Guadarrama et al, 2001), wines (Baldacci et al, 1998), cheese (Schaller et al, 1998) 
and to monitoring sausage fermentation (Eklov et al, 1998). 
Aroma is not only essential in the food industry and therefore, electronic noses 
have been applied by different industries, where the smell of a product is as important. 
The car manufacturer Renault used electronic nose technology to analyse the emission 
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of plastic constituents into the passenger cabin (Guadarrama et al, 2002).  Schiffman 
et al (1997) applied an AromaScan system to analyse off-odours in pharmaceutical 
products caused by inappropriate packaging materials.  
 
1.7 PATTERN RECOGNITION 
Modern analytical instruments generate a vast amount of data. A modern 
electronic nose for example comprises up to 32 individual sensors, whereby each 
sensor provides several parameters with which the sample is described. This non-
specific description due to the nature of the electronic nose gives an overview of the 
sample (pattern) and not the chemical composition of it. The interpretation of such a 
vast data set is difficult and cannot be done by simply looking at the data.  
Analysing such multivariate data sets is a multi-step process including data 
preprocessing, visualising relevant information, and finally classification of samples. 
This multi-step process is collectively known as pattern recognition.  
 
1.7.1 DATA PREPROCESSING 
Electronic nose raw data might not be the most useful input variables for 
statistical analysis due to noise, sensor drift or inconsistency (Dickinson et al, 1998; 
Otto, 1999). Good results are only obtained from quality raw data. Data preprocessing 
is aimed to modify existing raw data with the hope to obtain more quality input 
variable (Bartlett et al, 1997).  
The most commonly used data preprocessing techniques are normalisation, mean 
centering and scaling.  
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Normalisation 
Normalisation is a procedure to eliminate quantitative information (concentration) 
from a data set. The concentration of a variable is represented by the magnitude 
(vector length) (Massart et al, 1988; Otto, 1999). Therefore, for qualitative assessment 
of the original data set, each sensor response is normalised according to: 
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 where 'ijx  is the normalised sensor response, ijx is the raw sensor response and 
ikx are the individual sensor responses.  
 
Mean-centering  
This method is aimed to eliminate a constant offset (drift) from a data set. 
Thereby, each variable, ikx , is centred by subtracting the column mean, kx , according 
to: 
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 where i is the row index, k the column index, 'ikx  is the mean-centered variable 
and kx is the column mean (Massart et al, 1988; Otto, 1999). 
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Scaling 
Often sensors with small signal changes are equally important as sensors showing 
large changes. To overcome this problem, the input variable can be scaled either to 
similar ranges (range scaling) or to similar variances (autoscaling). 
Range scaling is a procedure to eliminate the influence of absolute values by 
scaling them to values between zero and one according to:  
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 where i is the row index, k the column index, 'ikx  is the range-scaled variable, 
(min)kx  is the minimal value in column k, and (max)kx is the maximal value in column k 
(Massart et al, 1988; Otto, 1999). 
 
Autoscaling is a technique to scale the variables to similar standard deviations and 
thereby reduce the effect of signal changes (variance) according to:  
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 where i is the row index, k the column index, 'ikx  is the autoscaled variable, 
kx is the column mean, and ks  is the standard deviation of column k (Massart et al, 
1988; Otto, 1999). 
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 Unfortunately, no general guidelines exist to determine the appropriate 
preprocessing technique and thus the different techniques are controversially 
discussed in the literature (Despagne and Massart, 1998; Jurs et al, 2000). In many 
cases, normalisation can improve the quality of the input variables but in some case 
valuable quantitative information will be removed. Autoscaling for example, can 
enhance noise by treating sensors delivering little information equal to important 
sensors (Dieterle and Strathmann, 2000). The choice of pre-processing is also 
dependent on the application, i.e. the nature of the data obtained from the electronic 
nose.  
 
 1.7.2 MULTIVARIATE DATA ANALYSIS  
Understanding and interpreting multivariate data is the key to success. The list of 
available multivariate methods is long, but only a limited number are frequently used 
in gas sensing.  
Multivariate methods are generally described by terms such as parametric or non-
parametric, supervised or unsupervised, or linear and non-linear. A schematic 
representation of some of the most popular pattern recognition techniques employed 
in gas sensing is given in Figure 1.2. 
Parametric techniques model the probability density function of the parameters 
used to describe the sensor response and are based on the assumption that the data are 
normal (gaussian) distributed. In contrast, non-parametric do not require a defined 
statistical distribution of the data to model the sensor response (Massart et al, 1988).  
Unsupervised learning methods are generally used in exploratory data analysis 
because they show the relationship between samples and variables without prior 
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information on the nature of the sample (Schaller et al, 1998). Conversely, supervised 
learning techniques classify an odour by developing a mathematical model relating 
training data, i.e. samples with known properties, to a set of given descriptors. Test 
samples are then used to evaluate the model (Gardner and Bartlett, 1994).  
Linear methods calculate a model based on linear combinations of input data. In 
contrast, non-linear techniques are based on a non-linear description of the input data. 
Therefore, these methods can deal with more complex sample mixtures, i.e. more 
variation within the input data (Otto, 1999).   
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Figure 1.2: Schematic representation of the most frequent used pattern 
recognition techniques.  
Abbreviations: PCA – principal component analysis, HCA – hierarchical cluster 
analysis, SOM – self organising maps, DFA – discriminant function analysis, BP-
ANN – backpropagation-artificial neural network. 
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Principal Component Analysis (PCA)  
PCA is an unsupervised data reduction method. The basic idea of the method is to 
describe the variation of a multivariate data set in terms of a set of uncorrelated 
variables, each of which is a particular linear combination of the original variables. In 
other words, the original data matrix is projected from a high dimensional space into a 
less dimensional space, preferably a plane or a 3-dimensional space. During the 
process the original data set is reduced in dimensions, i.e. is compressed, with as little 
loss of information as possible. This is achieved by filtering out the noise in the 
original data matrix, without removing essential information described in the variance 
of the data (Massart et al, 1988; Otto, 1999).  
Mathematically, the key idea of PCA is to decompose the original i x j data matrix 
X into its i  x k score matrix T, its k x j loading matrix P and the residual matrix E 
according to: 
  X = TP + E (1.5) 
 
where i is the number of samples, j is the number of variables and k is the 
number of principal components (PCs).   
 
PCs are linear combinations of the original variables and can be calculated as 
follows: 
   111212111111 ... pp pxpxpxt +++=  (1.6) 
where 11t is the first element of the first PC, x are the original variables and p 
are the loadings.  
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The PCs are determined on the basis of the maximum variance criterion. Each 
subsequent PC describes a maximum of variance, which is not modelled by the 
previous one. According to this, the first PC contains the most of the variance of the 
data (Otto, 1999; Everitt and Dunn, 2001). The relationship between samples can be 
visualised by plotting the scores against each other (score plot).  
 
Hierarchical Cluster Analysis (HCA)  
HCA is an unsupervised method that combines individual samples to clusters 
according to their similarities to each other.  
The similarity between two samples is determined by the (Euclidean, that is one 
measure, but there or others) distance between them, which can be calculated for two 
samples p1(x1, y1) and p2(x2, y2) as follows: 
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where d(p1, p2) is the distance between the two samples. 
 
The next step is the reduction of the distance matrix by aggregation of clusters, 
whereby the clusters with the shortest distances between them are aggregated first. 
Several different formula exist for the aggregation of two clusters including single 
linkage, complete linkage, centroid linkage, median linkage and Ward’s method 
(Otto, 1999; Everitt and Dunn, 2001).  
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Discriminant Function Analysis (DFA)  
DFA is a supervised classification procedure aimed at formalising a decision 
boundary between different classes. The decision boundary is calculated so that the 
variance between different classes is maximised and within individual classes 
minimised. Different ways exist to calculate the decision boundary. In a multivariate 
data set, this is done by solving an eigenvalue problem.  
The eigenvector (w) with the greatest eigenvalue (l) provides the first 
discriminant function (s1) according to: 
 
 pp xwxwxws 12121111 ...+++=  (1.8) 
  
 where w is the eigenvector and x is the original variable.  
The second discriminant function (s2) is calculated from the eigenvector with the 
second greatest eigenvalue. This procedure is continued until all discriminant 
functions are found to solve the discrimination problem. The original data set is 
visualised by plotting the individual discriminant functions against each other (Otto, 
1999; Everitt and Dunn, 2001). 
 
Artificial Neural Network (ANN) 
The key idea of an ANN is to mimic the human brain by modelling the human 
nervous system (Kohonen, 1988).  An ANN consists of interconnected, and usually 
adaptive processing elements. The processing elements represent the biological 
(olfactory) neurons, and their interconnections, the synaptic links. In the biological 
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neurons the input signals arriving through the axon ends in the synapse. There the 
information is transformed and sent across the dendrites to the next neuron (Figure 
1.3a). In artificial neurons, this signal transfer is simulated by multiplication of the 
input signal, x, with the synaptic weight, w, to derive the output signal y ((Figure 1.3b) 
(Otto, 1999). 
  
a)        b) 
 
 
 
 
 
 
 
 
Figure 1.3: Analogy between biological (a) and artificial (b) neurons. 
 
The artificial neuron is the heart of every neural network. In reality, a single 
neuron receives input signals, xi, from n neurons, aggregates them by using the 
synaptic weights, wi, and passes the result after suitable transformation (transfer 
function) as the output signal yi  (Figure 1.4).  Important transfer functions are given 
in Table 1.3. 
These individual neurons are aggregated to layers. A general neural network 
consists of an input layer, one or more hidden layer(s), and an output layer. These 
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layers are usually fully connected (Figure 1.5). As pointed out in Figure 1.5, the 
output signals (yi) of the neurons of one layer act as the input signals (xi) for the 
neurons of the following layer (Shih, 1994). 
 
 
Figure 1.4: Operation of a single neuron. 
 
Table 1.3: Important transfer functions for neural networks (adapted Otto, 1999). 
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Figure 1.5: Architecture of a neural network. 
 
Generally, the input layer is considered a distributor of the signals from the 
external world. Hidden layers are considered to be categorisers or feature detectors of 
such signals. The output layer is considered a collector of the features detected and 
producer of the response (Shih, 1994).  
The main advantages of neural networks are the great adaptability in terms of 
learning, self-organisation, training, and noise – tolerance. Various algorithms can be 
used to train an ANN, but the most important one, and the one used in this report, is 
the back propagation technique (Gardner and Hines, 1997).  
 
The back-propagation algorithm relies on two stages, the first being the learning 
phase during which the ANN learns how to recognise each of the known odour 
classes. The second phase is the validation of the model during which the network is 
Hid en layer 
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used to classify unknown samples from the same classes as the training data (Gardner 
and Hines, 1997). As the name back-propagation indicates, the training of the 
networks starts at the output layer and goes backwards through the layers (Shih, 
1994). During the training period, the weights of individual neurons are adjusted so 
that the error between actual output and target signal is minimised (Otto, 1999).  
   
 
1.8 RENAL FAILURE AND HAEMODIALYSIS 
1.8.1 THE KIDNEYS 
The human body contains two kidneys. They form together with two ureters, one 
urinary bladder, and one urethra the urinary system. The kidneys filter the blood and 
return most of the water and solutes to the bloodstream. The remaining water and 
solutes form urine, which is excreted by each kidney through its ureter and stored in 
the urinary bladder. The urine is expelled from the urinary bladder through the urethra 
(Tortora and Grabowski, 2000). In Figure 1.6, the organs of the urinary systems are 
shown. 
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Figure 1.6: The organs of the urinary system (from Tortora and Grabowski, 
2000). 
 
Anatomy of the Kidney 
The paired kidneys are reddish, kidney-bean shaped organs located just above the 
waist between the peritoneum and the posterior wall of the abdomen. An average 
kidney in an adult is 10 – 12 cm long, 5 – 7 cm wide, and 3 cm thick and weighing 
135 – 150 g (Tortora and Grabowski, 2000). The concave medial border of each 
kidney faces the vertebral column and near the centre of this border is a deep vertical 
fissure, called the renal hilus (Figure 1.7) through which, the ureter, the blood vessels, 
the lymphatic vessels and nerves leave the kidney. A kidney has two distinct regions, 
namely the renal cortex and the renal medulla. The renal cortex is a smooth-textured 
layer underneath the renal capsule (Figure 1.7). The renal medulla consists of 8 – 18 
renal pyramids separated by the renal columns, which are an extended part of the 
renal cortex. Together, the renal cortex and the renal pyramids constitute the 
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functional portion (parenchyma) of the kidney. Within the parenchyma are the 
functional units of the kidneys called nephrons. A normal kidney contains about 1 
million nephrons (Clancy and Mc Vicar, 1995; Tortora and Grabowski, 2000). 
 
 
Figure 1.7: Internal anatomy of the kidneys (from Tortora and Grabowski, 2000). 
 
 
Functions of the Kidney – an overview 
The functions of the kidney are:  
 
· Regulation of the blood ionic composition: The kidney helps to regulate the blood 
concentrations of several ions, most importantly being sodium, potassium, 
calcium, chloride and phosphate ions (Tortora and Grabowski, 2000). 
.  
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· Regulation of blood osmolarity: The kidneys maintain a relatively constant blood 
osmolarity (» 290 mOsm/litre) by separately controlling the loss of water and the 
loss of solutes in the urine (Clancy and Mc Vicar, 1995; Tortora and Grabowski, 
2000).  
 
· Regulation of blood volume: The blood volume is regulated by either eliminating 
or conserving water and thus the volume of the interstitial fluid (Clancy and Mc 
Vicar, 1995; Tortora and Grabowski, 2000).  
 
· Regulation of blood pressure: Besides regulating the blood volume, the kidneys 
are able to contribute to the control of the blood pressure in other ways. Firstly, 
the kidneys secret the enzyme renin, which converts angiotensiogen to angiotensin 
I. Angiotensin I is converted into angiotensin II which has a direct action on 
peripheral vasoconstriction leading to an increased blood pressure. Secondly, the 
renal glands secret aldosterone which influences the sodium retention and hence, 
the blood pressure (Clancy and Mc Vicar, 1995; Tortora and Grabowski, 2000). 
 
· Regulation of blood pH: The kidneys excrete hydrogen ions (H+) into the urine 
and retain bicarbonate ions (HCO3-). The bicarbonate ion is an important buffer of 
H+ (Clancy and Mc Vicar, 1995; Tortora and Grabowski, 2000).  
 
· Release of hormones: The kidneys are responsible for the release of two 
hormones, namely calcitriol and erythropoietin.  Calcitriol is the active form of 
vitamin D, which regulates the calcium homeostasis. Erythropoietin stimulates the 
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production of red blood cells by the bone marrow (Clancy and Mc Vicar, 1995; 
Tortora and Grabowski, 2000).  
 
· Excretion of wastes and foreign substance: Waste products or useless substances 
(for the body) are excreted via urine. Waste products result from metabolic 
reactions, e.g. ammonia, urea (protein metabolism), creatinine (breakdown of 
creatine phosphate in muscles), uric acid (catabolism of nucleic acids) or bilirubin 
(catabolism of haemoglobin). Foreign substances include environmental toxins or 
drugs (Clancy and Mc Vicar, 1995; Tortora and Grabowski, 2000).  
 
1.8.2 EVALUATION OF KIDNEY FUNCTION 
The routine assessment of kidney function involves the evaluation of both the 
quality and quantity of urine and the concentration of waste products in blood 
(Tortora and Grabowski, 2000). 
 
Urine analysis (= Urinalysis) is the analysis of the volume, physical, chemical and 
visible (microscopic) properties of urine. A healthy adult excretes approximately 1 – 2 
litre of urine per day. The urine volume depends on fluid intake, blood pressure, blood 
osmolarity, diet as well as general health. Normal urine consists of about 95 % water 
and about 5 % electrolytes. Typical solutes present in urine are urea, creatinine, uric 
acid, sodium, potassium and small quantities of fatty acids, pigments, enzymes and 
hormones. If a disease alters the body metabolism or the kidney function, the 
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composition of the urine is changed or the concentration of normal constituents 
appears in abnormal amounts (Tortora and Grabowski, 2000).  
 
Blood tests are performed to measure either blood urea nitrogen (BUN) or creatinine. 
A number of factors can raise urea levels, and a decreased glomerular filtration rate as 
in renal diseases is one of them. However, it is a poor surrogate marker for assessing 
the renal function as it varies with protein intake (Tortora and Grabowski, 2000). 
Creatinine results from the catabolic degradation of creatine phosphate in muscle. 
Normally, the blood creatinine level remains constant since the rate of creatinine 
excretion (via urine) is equal to the production from muscle. A creatinine level above 
135 mmol l-1 indicates a poor renal function, but this also varies with age, sex and 
body weight, and renal function (Tortora and Grabowski, 2000). 
 
Renal Plasma Clearance is the volume of blood that is cleared of a substance per unit 
of time, usually expressed in units of millilitre per minute. A low plasma clearance 
indicates an inefficient excretion (Tortora and Grabowski, 2000). Generally the 
creatinine clearance is measured since creatinine passes easily across the glomular 
membrane and is not reabsorbed and only secreted in small quantities. Normal range 
for the creatinine clearance is 120 – 140 ml min-1 (Tortora and Grabowski, 2000).  Of 
more accurate determination of the GFR is the clearance of 51Cr-label 
ethylendiaminetetraacetic acid (EDTA) (Haslett et al, 1999).  
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The clearance of a substance can be calculated according to: 
 
plasma
urineurine
[S]
V[S]
  S  substance of Clearance
·
´
=  (1.9) 
 
 where [S] is the concentration of substance S in either urine or plasma  and V is 
the urine volume per minute (Clancy and Mc Vicar, 1995). 
 
Imaging Techniques are used to visualise the shape of the kidneys as well as to 
assess the renal function. The main methods are intravenous pyelogram, ultrasound, 
computer tomography and the application of radionucleotides (Haslett et al, 1999).  
 
Renal biopsy is performed to assess the nature and extend of the renal disease. The 
procedure is carried out under ultrasound guidance for an exact placement of the 
needle. The obtain tissue sample is then analysed using conventional light 
microscopes or electron microscopes (Haslett et al, 1999; nephrologychannel, 2004). 
 
1.8.3 RENAL FAILURE AND RENAL REPLACEMENT THERAPY 
Renal failure 
Glomerular and tubular functions are highly dependent on adequate blood supply 
(Kidneys receive about 20 % of cardiac output). If the blood supply is disturbed, both 
functions are impaired (Stevens and Lowe, 2000). If one part of a nephron is affected, 
it is likely that other parts will develop abnormalities due to the close structural and 
functional relationship of nephrons (Stevens and Lowe, 2000). Renal failure occurs 
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when a sufficient number of nephrons are damaged and therefore the kidneys unable 
to perform their tasks (Tortora and Grabowski, 2000; Stevens and Lowe, 2000). Renal 
failure can be divided into two main types, namely acute and chronic renal failure. 
 
Acute Renal Failure 
Acute Renal Failure (ARF) refers to a sudden and usually reversible failure of the 
renal function, i.e. the majority of the nephrons stop working simultaneously. ARF 
normally develops over a period of days or weeks (Haslett et al, 1999). The clinical 
manifestation includes oliguria or even anuria, disturbed fluid and electrolyte balance 
(Stevens and Lowe, 2000). Several diseases can cause ARF, such as central perfusion 
failure, tubular and interstitial diseases or glomerular diseases (Stevens and Lowe, 
2000). If the cause of renal failure is not rapidly corrected, temporary renal 
replacement therapy (RRT) may be necessary (Haslett et al, 1999). 
 
Chronic Renal Failure 
Chronic Renal Failure (CRF) is deterioration in renal function, which develops 
over a long period of time (years). As more and more nephrons are destroyed, renal 
function becomes progressively worse (Haslett et al, 1999; Stevens and Lowe, 2000). 
Several diseases can lead to CRF, all of which cause a slow, progressive destruction 
of the nephrons. The most common causes are diseases of the glomeruli 
(glomerulonephritis and diabetic glomerular disease) and diseases of tubules and 
interstitium (infective, toxic and obstructive damage to tubules) and vascular diseases 
(Stevens and Lowe, 2000). Among the main consequences of CRF are uraemia, 
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polyuria, abnormalities in biochemical homeostasis (electrolyte imbalances, metabolic 
acidosis, etc.), secondary hyperparathyroidism, bone disease (renal osteodystrophy) 
and finally anaemia (Stevens and Lowe, 2000). In contrast to the other forms of renal 
failure, CRF is not usually reversible and if it progresses may require permanently a 
kind of RRT.  
 
Renal Replacement Therapy 
The ability to replace the kidney function by means of “artificial devices” has 
been available for 40 years (Stevens and Lowe, 2000). Nowadays, several treatment 
modalities are available including haemodialysis (HD), haemofiltration (HF), 
continuous ambulatory peritoneal dialysis (CAPD), and transplantation. However, 
dialysis using an artificial kidney can only replace a part of the excretory function, 
whereas the endocrine and metabolic function of the kidney cannot be restored. In 
contrast, transplantation can replace all kidney functions (Stevens and Lowe, 2000). 
The distribution of the treatment modalities in the United Kingdom in 2002 is shown 
in Figure 1.8. As can be seen, transplantation accounts for 37 %, HD for about 46 % 
and CAPD for 17 %.   
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Treatment Modalities in 2002
Transplant
37%
HD
46%
CAPD
17%
 
Figure 1.8: Treatment modalities in the United Kingdom in 2002 (modified, UK 
Renal Registry Report 2003). 
Key: CAPD: Continous Ambulatory Peritoneal Dialysis, HD: Haemodialysis 
Haemodialysis, Haemofiltration and Continuous Ambulatory Peritoneal Dialysis 
These three treatment modalities apply semipermeable membranes to separate the 
dialysis fluid from the blood stream. Accumulated waste products and excessive body 
fluid diffuse from the blood stream across the membrane into the dialysis fluid. 
Haemodialysis and haemofiltration employ artificial membranes, whereas CAPD 
utilises the body’s own peritoneal membrane (Haslett et al, 1999). Haemodialysis 
removes waste product via diffusion across a transmembrane concentration gradient. 
In contrast, haemofiltration provides solute clearance solely by convection, as solutes 
are dragged down a pressure gradient with water (Levy et al, 2001). A more detailed 
description of haemodialysis is given in section 1.8.4. 
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Transplantation 
This is the only possibility to restore normal kidney function and correcting all 
metabolic abnormalities of CRF (Haslett et al, 1999). The kidney graft is taken either 
by a dead donor or from a living relative. It is essential, that blood group compatibility 
is guaranteed. Donor kidneys are usually matched with the recipient human leukocyte 
antigens (HLA) to increase the graft survival (Haslett et al, 1999). The problem 
associated with transplantation is the requirement for long-term immunosuppression 
leading to a higher incidence of infections and malignant neoplasm, especially of the 
skin. However, transplantation is the best treatment modality and is also the most 
cost-effective treatment for CRF (Haslett et al, 1999).  
 
 
1.8.4 HAEMODIALYSIS  
The invention of dialysis dates back to the 19th century, when Thomas Graham 
discovered a method for separating gases by diffusion  (Drukker, 1983). However, 
haemodialysis was not widely available till 1960, when the first patient was treated 
for CRF by intermittent haemodialysis. The milestones in the development of 
haemodialysis are shown in Figure 1.9. 
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Figure 1.9: Milestones in the development of haemodialysis (Drukker, 1983).  
Key: CRF: Chronic Renal Failure, HD: Haemodialysis, AV: Arteriovenous 
 
Fundamentals of Haemodialysis 
Insufficient kidney function can lead to the accumulation of excess electrolytes, 
waste products and fluid. The concentrations of these compounds can reach toxic 
levels and need to be removed from the blood stream (Patzer, 2001). To perform 
haemodialysis, vascular access is required, which is normally obtained by an 
arteriovenous (AV) fistula (Figure 1.10). The fistula, usually in the forearm of the 
patient, should be formed before the treatment starts, so that it has time to become 
established (distension and arterialisation). Large-bore needles can then be inserted 
into the vein for each HD session. HD is normally performed 3 – 5 hours three times a 
week (Haslett et al, 1999).  
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Figure 1.10: Schematic diagram of the fistula and the dialyser (Patzer, 2001). 
 
 
A typical hollow-fibre dialyser is shown in Figure 1.11. The dialyser consists of a 
bundle of semi-permeable tubes (hollow-fibre) surrounded by a hard plastic shell. At 
the top and bottom of the shell, distribution caps are placed. Blood from the AV-
fistula enters the dialyser through a distribution cap on one side, flows along the 
interior of the fibres and exits on the other side through a distribution cap and re-
enters the blood circulation via AV-fistula. The dialysate (composition see Appendix 
C) flows counter-current to the blood on the outside of the fibres (Patzer, 2001). 
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Dialysate In
Dialysate Out
Blood In
Blood Out
 
Figure 1.11: Schematic diagram of a hollow-fibre dialyser. 
  
 
Molecules in the blood, with a molecular size smaller than the pore size of the 
membrane, can diffuse across the semi-permeable membrane into the dialysate. The 
driving force for the diffusion is the concentration difference between the blood (high 
concentration) and the dialysate (low concentration). The diffusion is governed by 
Fick’s law according to:   
 
x
c
DA
dx
dc
DAJ
D
D
-=-=  (1.10) 
 
where J is the flux [mmol l-1], D is the diffusity [cm2 s-1], A is the area of the 
membrane [m2], and dx
dc  is the concentration gradient (Sargent and Gotch, 1983). 
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The diffusity D is a unique property of the solute-solvent system at a specific 
temperature. The sign convention is adopted, which states that diffusion occurs in 
positive direction, i.e. from the region of higher activity (conc.) to that of lower so that 
the concentration will be decreasing in the direction of flux. Therefore, the right hand 
side of equation 1.10 must carry a negative sign (Sargent and Gotch, 1983). The 
Diffusity D is a constant at any particular temperature. Therefore, equation 1.10 can 
be written as: 
CAKJ D-= 0  (1.11) 
 
where K0 is the mass transfer coefficient [cm min-1] and CD  is the concentration 
difference [mmol l-1] (Sargent and Gotch, 1983).  
 
Equation 1.11 states that with a specific dialyser (K0A is constant), the transfer of 
solutes from blood into dialysate will depend directly on the concentration difference 
(DC). This concentration difference is the driving force of dialysis. The concentration 
of solutes in blood and dialysate will linearly change, when solutes are transferred 
from one to the other (Figure 1.12). The solute concentration in blood decreases 
whilst in the dialyser (cBi è cBo). In contrast, the concentration in the dialysate 
increases (cDi è cDo). The concentration difference at any point in the dialyser is the 
difference between these two lines (red and blue) and this concentration (violet line) 
determines the flux.  
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Figure 1.12: Blood and dialysate concentration as a function of flux between the 
two fluids in counter current flow (Sargent and Gotch, 1983). 
 
 
On the other hand, excessive body fluid has also to be removed from the body. 
However, the driving force for the removal of excessive body fluid is not same as for 
the solute removal (DC). The transfer of water form the patient to the dialysate is 
determined by a pressure difference (DP).  The water flux can be calculated as 
follows: 
 
)( DBUFF PPKQ -´=  (1.12) 
 
where QF is the ultrafiltration rate [ml min-1], and DB PP -  is the pressure 
difference (driving force) between the pressure on the blood side and the dialysate 
side (Sargent and Gotch, 1983). 
 
 
 
 
 
 
 
 
 
  
Flux out of blood, J 
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Adequacy (dialysis dose) of Haemodialysis 
Dialysis dose can be defined as the amount of haemodialysis received per dialysis 
and the dialysis frequency per week (De Palma and Pittard, 2001). It is a measure of 
how effective a dialysis treatment (HD or CAPD) removes waste products from the 
body (NIH, 1999) 
The concept of dialysis adequacy was developed in the early 1970s to assess the 
treatment efficiency of end-stage renal disease (ESRD) patients (Canaud et al, 2000). 
From the very beginning the removal of small molecules was considered important as 
they were directly linked to the symptoms and signs of renal failure (Lindsay and 
Sternby, 2001; Keshaviah, 2002). Therefore, urea has been suggested as a surrogate 
marker for small toxic solutes (Keshaviah, 2002). In 1975 urea gained wide 
acceptance as a marker of solute removal in dialysed patients (Vanholder et al, 1994).  
 
Urea Reduction Ratio (URR) 
The URR is a formula (equation 1.13), which expresses the reduction in blood 
urea during a dialysis session (De Palma and Pittard, 2001).   
 
100
BUN
)BUN(BUN
URR
spredialysi
ispostdialysspredialysi ´
-
=   (1.13) 
 
where BUN is the blood urea nitrogen.  
 
The URR is the simplest way to measure the delivered dialysis dose. It does not 
include the time of dialysis, the body size and effects of ultrafiltration (Levy et al, 
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2001). Hence, the URR does not consider the residual renal function. The URR 
should be continuously higher than 65 % (with a three times per week HD schedule) 
to ensure an adequate treatment (UK Renal Registry Report, 2003) 
 
Normalised dose of dialysis (Kt/V) 
Gotch and Sargent (1985) introduced the Kt/V ratio as a result of their 
“mechanistic” analysis of the National Cooperative Dialysis Study (NCDS). The 
study was performed between 1976 and 1981 in the USA with the aim to find a 
correlation between the dialysis dose and morbidity (Lindsay and Sternby, 2001). 
K represents the dialyser urea clearance (known from in-vitro studies), t is the 
dialysis time and V is the urea distribution volume (Levy et al, 2001). The Kt/V – 
value is the ratio between the volume of blood cleared of urea during a dialysis 
session (Kt) and the distribution volume of urea (V) which is equivalent to the total 
body water (Kemp et al, 2001). The gold standard for determining Kt/V in HD is by 
urea kinetic modelling (UKM) (Kemp et al, 2001). UKM is based on the principle of 
mass balance to describe urea nitrogen production and urea removal in the body 
(Shak, 1999).   
The analysis of the NCDS by Gotch and Sargent (1985) revealed that a Kt/V < 
0.8 (three times per week HD schedule) was associated with an increased morbidity. 
They concluded that a Kt/V of 1.0 was adequate (Gotch and Sargent, 1985). Since 
then, there is a controversial discussion about the appropriate Kt/V value to ensure an 
adequate treatment (Kemp et al, 2001). The UK Renal Registry (2003) recommends a 
Kt/V value greater than 1.2 as an appropriate dialysis dose. 
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1.8.5 MONITORING OF HAEMODIALYSIS  
Urea Monitoring 
As mention above, the Kt/V –value and the URR value are the most commonly 
used parameter to judge the adequacy of HD treatment. For both values, the 
determinations of pre- and post-dialysis urea concentrations are necessary (Levy et al, 
2001; Lindsay and Sternby, 2001). The urea concentrations can be measured either on 
the blood side (BUN) or on the dialysate side (Dialysate Urea Nitrogen: DUN). BUN 
values can be inferred from DUN values using well-established relationships (Knocki 
et al, 2000a).  
In the past few years, several devices have been developed that can measure urea 
more of less continuously in blood or in spent dialysate (Lindsay and Sternby, 2001). 
The majority of urea measurements are based on an enzymatic reaction. The enzyme 
urease catalyses the following reaction (Sternby, 1999):   
 (NH2)2CO + 2H2O  Û  NH3 + NH4+ + HCO3- (1.14) 
The amount of urea is measured indirectly by measuring the products of reaction 
in equation 1.14. This can be done by either measuring the breakdown products 
directly (NH4+) or indirectly by measuring a secondary parameter (pH, conductivity) 
(Sternby, 1999; Lindsay and Sternby, 2001). It is important, that enough urease is 
present to convert all of the urea (Sternby, 1999). 
There are at least four devices commercially available, which can measure urea 
on-line in spent dialysate or ultrafiltrate (Sternby J., 1999). Three of them, namely the 
Baxter Biostat 1000 (Baxter Healthcare Corp., McGaw Park, IL), the Bio Care Device 
(Bio-Care Corp., Hsinchu, Taiwan), and the DQM 200 – Device (Gambro Lund AB, 
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Lund, Sweden) measure the urea concentration on the dialysate side, whereas the 
Bellco – Device (Bellco SpA, Miranda, Italy) measures the urea concentration on the 
blood side.  
The following table summarises the four commercial available urea-monitoring 
devices.  
 
Table 1.5: Summary of the four commercial available urea-monitoring systems.  
Device  Place and Method of Measurement Reference 
Dialysate 
Baxter Biostat 1000 
Ammonium-sensitive electrode 
Depner et al, 1996 
Hasper et al, 1997 
   
Dialysate 
Bio – Care  
Ammonium-sensitive electrode 
Sternby, 1999 
Lindsay and Sternby, 2001 
   
Dialysate 
DQM 200 
Conductivity change  
Sternby, 1999 
Lindsay and Sternby, 2001 
   
Blood - ultrafiltrate 
Bellco – Device  
Conductivity change  
Colasanti et al, 1995 
Santoro et al, 1996 
 
The Bellco – Device is designed for a combined Haemofiltration/Haemodialysis 
treatment. The urea concentration is measured in the ultrafiltrate from the haemofilter 
(Lindsay and Sternby, 2001).  
Knocki et al (2000a) could show that a potentiometric urea sensor (urease – 
coupled ammonium – selective electrode) is useful for fast and accurate DUN 
determination in a wide concentration range from 50 to 500 mg l-1. This group also 
observed that cations influence the sensor response, which leads to an overestimation 
of the urea concentration.  However, using an uncoated ammonium – selective 
electrode as a reference electrode, can eliminate the interferences. The urea 
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concentration is equal to the difference between the two sensor responses (Knocki et 
al, 2000b). Current research is focused on the development of new urea kinetic 
models, in particular multi-compartment models to provide a more accurate estimate 
of the Kt/V value (Shinzato et al, 1994; Daugirdas et al, 1997; Canaud et al, 2000). 
The single pool model assumes that urea equilibrates instantaneously among all body 
compartments, but in fact urea behaves as if it is distributed between two distinct 
compartments, intra- and extracellular. As urea is removed from the blood during 
dialysis, a concentration gradient is set up between the compartments. Single pool 
models are overestimating the dialysis efficacy by ignoring the intracorporeal 
compartment urea disequilibrium phenomenon. In contrast, multi-compartment 
models account for intracorporeal dialysis disequilibrium and post-dialysis urea 
rebound effects. However, multi-compartment models require multiple blood tests to 
solve the complex equations. These difficulties preclude its use in routine clinical 
practice (Daugirdas et al, 1997; Canaud et al, 2000).  
Another area of research is based on the spectroscopic determination of urea and 
other small molecules retained in ESRD patients. Recently, two research groups 
published their results. Fridolin et al (2002) applied UV – spectroscopy to measure 
small waste products in spent dialysate. This group observed a good correlation 
between the UV – absorbance (285 nm) and the removal of small molecules such as 
urea, creatinine and uric acid. Similar results were found by Olesberg and co-workers 
(2002), who used an FTIR (Fourier Transform Infrared) spectrometer. They found, 
that the absorption spectrum of urea in the range between 5000 – 4000 cm-1 (l = 2.0 –
2.5 mm) is relative strong and distinct from other components. In both cases, the 
results need to be validated. 
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Monitoring of Ionic Dialysance 
Dialysance (D) is a measure of the magnitude of flux (leakiness) of a dialysis 
membrane as a function of the concentration of solute across the membrane. It is an 
indicator of how easy molecules will pass across a membrane from blood into the 
dialysis fluid. The measurement of the ionic dialysance provides an estimation of the 
urea clearance with good correlation (Mercadel et al, 1998; Petitclerc, 1999; Lindsay 
et al, 2001). Other authors suggest that the ionic dialysance may be equivalent to the 
effective urea clearance (urea clearance corrected for recirculation), however the topic 
remains controversial (Polaschegg, 1993; Manzoni et al, 1996; Di Filippo et al, 2001; 
Teruel et al, 2001).  
For the measurement of the ionic dialysance, two conductivity probes are placed 
at the dialyser inlet and outlet (Manzoni et al, 1996; Petitclerc, 1999). The 
conductivity of a solution is a function of the concentration of the ionic substance and 
their electrical charges (Santoro et al, 2000). In other words, the difference between 
the two conductivity probes varies as a function of the ionic dialysance and thus the 
dialyser efficiency (Santoro et al, 2000). Hence, from the difference in the 
conductivity an indirect measurement of the effective dialysance can be obtained 
(Santoro et al, 2000).  
A commercially available biosensor (DiascanTM, Hospal, Italy) enables the on-
line monitoring of HD based on ionic dialysance measurements (Levy et al, 2001; 
Teruel et al, 2001). Katopodis et al (2002) compared the Kt/V value with the Dt/V 
value, derived from ionic dialysance measurements for assessing the dialysis dose. 
The findings of this group are similar to those of Del Vecchio et al (1998), who found 
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that the Dt/V value is a suitable and promising parameter for quantifying the dialysis 
dose. 
 
Monitoring of the nutritional status of Haemodialysis patients 
The prevalence of protein/energy malnutrition is high in patients undergoing RRT 
(Wolfson and Strong, 1996; Kemp et al, 2001). It has been shown in several studies, 
that nutrition is as important as the quality of dialysis in determining the outcome 
(Laird, 1983; Mc Cusker et al, 1996).  
Among many parameters indicating protein malnutrition, the most commonly 
used are serum albumin, dietary protein intake (indicated by PCR), creatinine and pre-
dialysis serum urea nitrogen (Kopple, 1997; Qureshi et al, 1998). 
The protein catabolic rate (PCR) is derived from the urea generation rate (GU), 
which is calculated during UKM (equation 1.15). PCR is the amount of protein that 
the patient is catabolising per day. In a nutrionally stable dialysis patient (zero 
nitrogen balance) the PCR equals the dietary protein (Shak, 1999; Levy et al, 2001).  
  
 )]031.0(81.1[25.6 mxGxPCR U ++=   (1.15) 
 
where GU is the urea generation rate (g day-1) and m is the lean body weight (kg). 
 
The PCR is often normalised to the body weight (nPCR) (Levy et al, 2001). In 
nutritional stable patients the PCR is equal to the dietary protein intake (Shak, 1999). 
Patients with nPCR > 1.0 g kg-1day-1 can show a positive nitrogen balance and hence, 
a lower morbidity and mortality (Levy et al, 2001). 
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Creatinine is a routinely measured parameter and its production rate reflects the 
magnitude of the muscle mass (Bergström, 1997). In haemodialysis patients, high 
serum creatinine levels correlate with lower morbidity and mortality which may seem 
paradoxical but the higher creatinine reflects higher protein stores (muscle mass) and 
hence implies better overall nutritional status (Bergström, 1997; Olesberg et al, 2002). 
Almost all commercial available laboratory analysers are based on spectroscopic 
detection of the Jaffe reaction (Soldatkin et al, 2002). The reaction itself is not very 
specific and many substances present in blood such as glucose, pyruvate can interfere 
(Soldatkin et al, 2002).  
A promising step towards the on-line measurement of creatinine is the progress in 
the development of creatinine – selective biosensors (Soldatkin et al, 2002). Several 
different types of sensors were developed. They can be divided into two main groups, 
namely amperometric – based sensors (Schneider et al, 1996; Kahn and Wernet, 
1991) and potentiometric – based sensors (Campanella et al, 1990; Narinesingh et al, 
1991). Soldatkin et al (2002) presented a new type of creatinine – selective biosensor. 
This sensor is based on ion-sensitive field – effect transistors (ISFET) coated with 
creatinine deiminase. The results are promising but more work need to be done before 
the sensor can be implemented into routine monitoring of HD (Soldatkin et al, 2002). 
 
1.8.6 URAEMIA AND URAEMIC TOXINS 
The uraemic syndrome, one of the main consequences of CRF is attributed to the 
retention of a number of different molecules, collectively termed uraemic toxins. 
However, the toxicity of the syndrome has not been attributed to any single 
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compound; it is most likely to be due to a spectrum of compounds, and indeed the list 
of potential candidates is complex and growing, and now numbers over 90 
(Bergström, 1997; Vanholder et al, 2003). Their molecular weight, and degree of 
protein binding have largely defined the categorisation of these retained compounds in 
renal failure. They comprise a) small water-soluble compounds, MW < 500Da, b) 
protein bound solutes, and c) ‘middle molecules’ MW >500Da. Which compounds 
exert a toxic effect within the body, and which accumulate innocently, is currently not 
known with certainty (Vanholder et al, 2003). 
Uraemic toxicity has been studied for several years. Indirect evidence has been 
obtained from bioassay studies in vivo and in vitro (Bergström, 1997).  Substances 
known to be present in an elevated concentration in uraemic serum have been given to 
humans or experimental animals, or added to tissues, cells, or enzymes in vitro to 
prove whether they exert toxic effects (Bergström, 1997).  It has been observed that 
after infusion of plasma, serum, ultrafiltrate or dialysate of uraemic patients into 
animals, several biological processes are affected (Bergström, 1997).  
 Patel and co-workers (1994) found that infusion of uraemic ultrafiltrate to normal 
rats results in a decreased number of intestinal calcitriol receptors and an increase of 
receptor mRNA concentration. Whereas uraemic serum inhibits in vitro erythropoiesis 
(Kuroyanagi and Saito, 1966), fibroblast growth (Mc Dermott, 1971), natural killer 
cell activity (Asaka et al, 1988), mononuclear phagocyte function (Wessel-Aas, 1981) 
as well as platelet function (Bergström, 1997). 
The characterisation of the specific toxins that may be responsible for the uraemic 
symptom has been evolving over the years and so has the application of these ideas 
into general clinical practice (Vanholder et al, 1994). Initially, small molecules (e.g. 
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urea and creatinine) were held responsible for causing the uraemic syndrome. In the 
period between 1965 and 1975 a new group of pathobiological active substances were 
discovered, the so-called middle-molecules (Bergström, 1997). This discovery is 
based on the observation of Scribner and his group, who found that CAPD is superior 
to HD in the management of uraemic neuropathy. The peritoneal membrane is more 
effective at removing middle molecules than a dialysis membrane presumably due to 
the difference in the pore size of the membrane. (Bergström, 1997). 
The composition of the middle molecule fraction is chemically diverse. Different 
authors reported the presence of peptides, oligosaccharides, organic acids, alcohols, 
and derivates of glucuronic acid (Le Moel et al, 1980, Zimmermann et al, 1980; 
Vanholder et al, 1994; Henderson et al, 2001). However, the main attention was 
directed to the peptides, which were thought to be the primary cause of endogenous 
intoxication signs in the organism (Zimmermann et al, 1980; Kovalishin, 1987) 
Among the many effects caused by peptides are the following: neurotoxicity 
(Kumegawa et al, 1980), cardiotoxicity (Bernard et al, 1982), inhibition of platelet 
aggregation (Bazilinski et al, 1985), inhibition of protein synthesis and amino acid 
transport (Cernacek et al, 1982), polymerisation of tubulin (Brauger et al, 1983) and 
the inhibition of various enzymes such as lactate dehydrogenase (Lutz et al, 1974), 
adenylate cyclase (Cloix et al, 1976), catalase (Leber et al, 1980) and 
acetylcholinesterase (Smolenski et al, 1993). 
With improved analytical techniques, it has become evident that several presumed 
middle molecules are in fact heterogeneous mixtures containing numerous lower 
molecular weight compounds (Vanholder et al, 1994), but these molecules behave 
like middle molecules during HD, due to steric configuration, electrostatic charge, 
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lipophilicity and multicompartmental behaviour (Vanholder et al, 1994; Bergström, 
1997).  
A selection of major  “small”, “middle” and “large” molecules found in uraemic 
blood are summarised in Table 1.6 (Vanholder et al, 2003). 
 
Table 1.6: Established and Suspected (*) Uraemic Toxins.   
Small Molecules Middle and Large Molecules 
Urea, Uric acid Oxalate Advanced glycosylated end products (*) 
Creatinine Myoinositol (*) Parathormone (PTH) 
Phenols Guanidine Derivates 
Methylguanidine 
Guanidinosuccinic acid Magnesium 
b2-microglobulin 
Sodium 
Water 
Pyrimidine Derivates 
Pseudouridine 
Orotic acid 
Orotidine, Uridine 
Peptides 
Beta-endorphin 
Methionine-enkephalin 
Granulocyte inhibiting protein I and II (*) 
Degranulation-inhibiting protein (*) 
 
Protein bound 
Indoles and Indoxyl sulphate 
Purines 
Uric acid 
Xanthine, Hypoxanthine 
Guanosine 
Amines 
 Methylamine 
 Tyramine 
 Putrescine 
 Spermidine 
Hippuric acid, P-cresol 
Indoxyl Sulphate Hydrogen ions Homocysteine, Polyamines 
 
The uraemic syndrome itself comprises a wide variety of signs and symptoms 
(Hörl, 1998) including neuropathy, encephalopathy, hypertension and 
cardiomyopathy (Smogorzewski and Massry, 1997). Several identified (and yet 
unidentified) uraemic toxins are at least partially removed by HD which may result in 
an improvement of the many clinical signs and symptoms (Hörl, 1998; Dhonth et al, 
2000).   
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1.9 PULMONARY TUBERCULOSIS 
Pulmonary tuberculosis (TB) is a notifiable infectious disease affecting the lungs 
of humans, and certain mammals such as cattle and badgers. In humans, pulmonary 
TB is caused by Mycobacterium tuberculosis. In 1993, the World Health Organisation 
(WHO) declared TB a global emergency (Dolin et al, 1994). There are yearly an 
estimated 8 – 9 million new case, killing nearly 2 million people each year (Frieden et 
al, 2003). The majority of these new cases occur in sub-Saharan Africa, South and 
Southeast Asia, Latin America and the former Soviet Union (Raviglione et al, 1992; 
Raviglione et al, 1995; Frieden et al, 2003). In contrast, case numbers in the past have 
continuously declined in Western and Central Europe, North and South America 
(Frieden et al, 2003). Nevertheless, a global increase of TB is observable. The 
reasons, however, depend strongly on the country/region. In Africa, the increase is 
mainly caused as a result of the burden of HIV infection, and in the former Soviet 
Union due to socio-economic change and decline of the health care system 
(Raviglione et al, 1995; Shilova and Dye, 2001). Immigration and increased travel are 
the main reasons for the remaining prevalence in the western world (Rieder et al, 
1994).  
1.9.1 PATHOPYSIOLOGY OF PULMONARY TUBERCULOSIS  
TB is spread by airborne droplets, particles of 1 – 5 mm diameter, which contain 
M. tuberculosis. Due to their small size, these particles can remain airborne for hours 
after expectoration by infected patients through coughing, sneezing or talking (Riley 
et al, 1959; Louden and Roberts, 1966).  
The infectious droplets are inhaled and stay in the alveoli of the lung. M. 
tuberculosis is taken up by alveolar macrophages initiating a cascade of events 
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resulting either in successful containment or progression to active TB (Woolf, 2000). 
M. tuberculosis is able to replicate slowly but continuously inside macrophages. Cell-
mediated immunity occurs in most individual within 8 weeks after infection. Alveolar 
macrophages infected with the organism interact with T-lymphocytes via several 
cytokines. The released cytokines (especially IL 12 and IL 18) stimulate T 
lymphocytes (predominantly CD4-positive T lymphocytes) to produce interferon-g 
(Schluger and Rom, 1998). Interferon- g, in turn, stimulates the phagocytosis of M. 
tuberculosis in the macrophage. However, interferon-g does not directly stimulate the 
killing of the organism but is important in the control of the infection via the 
stimulation of the macrophage to release tumour necrosis factor a (TNF-a). TNF, in 
turn, plays a key factor in the formation of a granuloma. The T-lymphocyte response 
is specific (Flynn et al, 1999).  
When the host immune response cannot inhibit the replication of M. tuberculosis 
associated with the initial infection, active disease occurs (Frieden et al, 2003). This 
progression is most common in young children (under 5 years of age) and adults with 
severe immunosuppression (e.g. AIDS/HIV). Primary tuberculosis can affect almost 
every organ of the human body, but predominantly the lungs.  
1.9.2 CURRENT DIAGNOSTIC TOOLS FOR PULMONARY TUBERCULOSIS  
 
Rapid and accurate diagnosis of symptomatic patients is a cornerstone of the 
global tuberculosis control strategy. Diagnostic tests for TB can be divided into direct 
and indirect methods (Figure 1.13). Direct methods are based on the detection of the 
causative bacilli (M. tuberculosis) or their product including chromatographic 
methods or immunoassays. Indirect methods measure either the specific host immune 
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response (anti-mycobacterial antibodies) or the cellular response (skin test or 
lymphocyte stimulation assays). 
 
 
 
 
 
 
 
 
 
 
Figure 1.13: Overview of current diagnostic tests for pulmonary tuberculosis. 
Diagnosis of TB 
Direct Methods  Indirect Methods 
· ZN staining followed by microscopy  
· Culture 
· Nucleic Acid Amplification 
· Detection of mycobacterial antigens  
· Detection of tuberculostearic acid 
· Measurement of humoral response 
· Measurement of cellular response 
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Direct methods for the diagnosis of pulmonary tuberculosis 
Microscopy 
Robert Koch was the first who isolated the tubercle bacilli in 1882. In the same 
year, a simple staining procedure was developed by Ziehl and later modified by 
Neelsen. The method is based on the staining of Mycobacteria in a sputum smear 
followed by direct microscopic examination. The method is based on the stability of 
mycobacteria towards acids: the bacteria withstand the acidic decolourisation step 
during the staining procedure. 
A positive ZN (smear-positive), however, is only an indicator for the presence of 
mycobacteria in sputum, but is no definite diagnosis for pulmonary TB. Sputum 
microscopy for acid-fast-bacilli (AFB) is recommended by the WHO and IUATLD as 
the most appropriate technique for case finding especially in high-prevalence 
countries. Nevertheless, about 40 – 60 % of patients with pulmonary TB and up to 
75% of extra-pulmonary cases remain undiagnosed by this method (Garg et al, 2003).  
 
Culture 
Culture is still widely accepted as the “gold standard” for the diagnosis of TB. In 
the past, solid media were used for the isolation of M. tuberculosis. The main 
disadvantage of this method is the slow growth rate of mycobacteria resulting in 
incubation periods ranging from three weeks (AFB positive) to eight weeks (AFB 
negative). Traditional solid media are either egg-based (e.g. Löwenstein-Jensen) or 
agar-based media (e.g. Middlebrook 7H10 or 7H11). The most common used liquid 
media are the Middlebrook 7H9 or 7H12 broth. Over the years, culture systems have 
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been improved to reduce the incubation period. These improvements were achieved 
by combing mild specimen decontamination, antibiotics, liquid media and growth 
indicators (Kolk, personal communications).  Nowadays, automated systems are 
available to detect the bacterial growth. The BACTEC 460 (Becton Dickinson 
Instrument Systems, Sparks, MD, USA) is a radiometric system based on the 
production of radioactive carbon dioxide (14CO2) by growing bacteria. Bacteria 
convert 14C-labelled palmitic acid present in Middlebrook 7H12 broth into radioactive 
carbon dioxide (Garg et al, 2003). The mean detection time of the radiometric system 
for mycobacteria is 13 days, which in turn means a dramatic time reduction compared 
to traditional culture (Roggenkamp et al., 1999). The second commercial available 
automated culture system is the BacT/Alert instrument (BioMerieux, Marcy-l’Etoile, 
France). The BacT/Alert utilises a colorimetric sensor to continuously monitor the 
production of CO2 concentration in the culture medium. The sensor placed at the 
bottom of the culture tube changes its colour in the presence of mycobacteria from 
dark green to yellow. The specificity and sensitivity of the BacT/Alert is comparable 
to the radiometric system (Brunello et al, 1999; Palacios et al, 1999).  
Traditionally the identification of mycobacteria cultured on conventional solid 
media was based on growth characteristics or biochemical properties such as growth 
rate, colony morphology and pigmentation, niacin production, catalase test. New 
identification methods include specific DNA probes or polymerase chain reaction. 
DNA probes have been developed to identify M. tuberculosis, M. avium, M. kansaii, 
M. intracellulare, and M. gordonae directly in broth or solid culture (Ichiyama et al, 
1997; Badak et al., 1999). 
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Nucleic acid amplification 
Nucleic acid amplification techniques include polymerase chain reaction (PCR), 
strand displacement amplification (SDA) (Walker et al, 1992) and transcription-
mediated amplification (TMA) (Jacobs et al, 1993). These techniques are based on the 
detection of mycobacterial DNA or RNA in clinical specimens. PCR technique uses 
oligonucleotide primers to direct the amplification of target nucleic acid sequences via 
a three-step process: denaturation, primer annealing, and primer extension (Mullis et 
al, 1987). 
The most commonly used target in “home-made” tests is IS6110, a specific 
sequence for bacterial strains belonging to the M. tuberculosis complex (Kolk et al, 
1992, Kox et al. 1994). PCR is an important tool for the diagnosis of extrapulmonary 
TB but also valuable for the diagnosis of pulmonary TB. The sensitivity of PCR in 
extra-pulmonary TB is lower than for pulmonary TB. Nevertheless, in modern 
laboratories PCR on cerebrospinal fluid is the method of choice for the detection of 
tuberculosis meningitis (Nguyen et al, 1996). 
Several commercial nucleic acid amplification kits are available. The 
AMPLICOR MTB assay (Roche Diagnostic System, Based, CH) is based on the 
amplification of the 16s rDNA sequence followed by hybridisation with a M. 
tuberculosis complex specific capture probe. The AMTD assay from Gen-Probe 
(Gen-Probe Inc San Diego, CA, USA) combines the amplification of rRNA and 
detection with an acridinium ester-labelled DNA probe specific for M. tuberculosis 
complex. PCR procedures are nowadays widely used in microbiological laboratories. 
Nevertheless, the high costs and required expertise have limited the implementation of 
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these methods as routine tests for TB in high burden countries (Ross et al, 1998) but 
also in the Western world (Doern, 1996). 
Detection of mycobacterial antigens 
Mycobacterial detection assays were largely developed 20 years ago but still need 
to prove their value in a routine laboratory. Sada et al (1983) develop an enzyme-
linked immunosorbent assay (ELISA) for the detection of mycobacterial antigens in 
cerebrospinal fluid for patients with tuberculous meningitis. A few “defined” antigens 
have been identified for the detection of TB. Among these, are the Antigen 5 and a 
45/47 kDa protein complex. Antigen 5, a 38 kDa protein is excreted by growing 
mycobacteria found in serum (Radhakrishnan et al, 1992), cerebrospinal fluid 
(Radhakrishnan et al, 1991) or bronchoalveolar lavage fluid (Raja et al, 1988). The 
45/47 kDa protein complex is immunodominant and is excreted by growing 
mycobacteria.  Chanteau et al (2000) developed an ELISA for the detection of this 
protein complex in sputum and serum. The sandwich ELISA is based on a polyclonal 
capture antibody and a mixture of three monoclonal antibodies as secondary 
antibodies.  
Another interesting antigen is lipoarabinomannan (LAM), an immunodominant  
lipopolysaccharide with a molecular weight between 30 and 40 kDa. LAM is a major 
cell wall component of mycobacteria. LAM has been detected in serum (Sada et al, 
1992), sputum (Pereira et al, 2000) and cerebrospinal fluid (Chandramuki et al, 1985) 
using different ELISA formats. None of these tests have been properly validated.  
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Detection of tuberculostearic acid 
One easily detectable marker of M. tuberculosis is tuberculostearic acid (TBSA), 
which can be detected by liquid chromatography (Garg et al, 2003). TBSA is a lipid 
component present in the mycobacterial cell wall. It can be detected in clinical 
samples using liquid chromatography or gas chromatography – mass spectroscopy. 
The presence of TBSA in cerebrospinal fluid is thought to be a marker for tuberculous 
meningitis (Brooks et al, 1990) and in sputum for pulmonary TB (French et al, 1987). 
Organisms other than M. tuberculosis present in pulmonary specimens can generate 
false-positive results (Garg et al, 2003).  
 
Indirect methods for the diagnosis of pulmonary tuberculosis 
Measurement of the humoral response 
The measurement of the humoral response is based on the detection of specific 
anti-mycobacterial antibodies. Arloing first described the idea of serodiagnosis of TB 
in 1898. Since then, many reports describing new methods have been published. In 
the past, the majority of tests were made with crude mycobacterial preparations and 
therefore lacking in specificity (Verbon et al, 1990).  The use of purified antigens has 
improved the serodiagnostic tests in terms of specificity (Jacket et al, 1988). 
Nevertheless, the sensitivity of antibodies to single antigens is 75% at best, even in 
patients with smear-positive pulmonary TB (Bothamley, 1995).  
Examples of purified antigens are the 38 kDa protein , 30/31 kDa protein, and 
several heat shock proteins such as 14 kDa, 65 kDa and 70 kDa proteins (Garg et al, 
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2003). Over-expression of recombinant proteins, e.g. the 38 kDa protein in E. coli has 
dramatically simplified the production of antigens (Wilkinson et al, 1997). 
The diagnostic antigen of choice is currently the 38 kDa protein (Garg et al, 
2003). This protein was evaluated in an ELISA by Bothamley et al (1992). In smear-
positive TB patients a sensitivity and specificity of 85% and 97%, respectively was 
achieved. However, the sensitivity in smear-negative patients was with 15% 
dramatically lower.  
Commercially available serological kits are based on the detection of antibodies 
against lipoarabinomannan (LAM) (MycoDotTM assay, Genelabs, Geneve, CH) or the 
38 kDa protein (ICT Diagnostics, Sydney, Australia). Both tests lack sensitivity when 
properly evaluated (Perkins, 2000).  
 
Measurement of the cellular response 
The Mantoux test is by far the most frequently used test in the history of TB 
diagnosis. A purified protein derivative (PPD) is used as a skin test reagent for 
measuring the delayed hypersensitivity reaction of a patient or infected person. PPD 
contains many mycobacterial antigens, not all of them belong to the M. tuberculosis 
complex. A positive test may be caused by active TB, past infection, BCG vaccination 
or through environmental mycobacteria (Garg et al, 2003).  Recently, a recombinant 
antigen encoded by a gene specific to the M. tuberculosis complex replaced the PPD. 
It showed better results leading to increased diagnostic value of the Mantoux test 
(Garg et al., 2003). 
Recently, the gamma interferon (IFN-g) assay was evaluated as a potential 
replacement of the Mantoux test. The IFN-g test is comparable to the Mantoux test in 
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terms of sensitivity and specificity. However, it requires better-equipped laboratories 
to culture viable lymphocytes and an ELISA to quantify IFN-g (Garg et al, 2003).  
 
1.9.3 DIAGNOSTIC NEEDS OF LOW AND HIGH PREVALENCE COUNTRIES 
The diagnostic pathway for pulmonary TB depends strongly on the setting, i.e. on 
the available resources. The usefulness of a test depends not only on specificity and 
sensitivity but also on factors given in by local circumstances such as costs, available 
laboratory facilities and skills of technicians.  
Low-income countries are often characterised by high TB prevalence and poor 
laboratory facilities. The only means of diagnosis TB is the ZN stain followed by 
microscopic examination. In these endemic regions, the result has to be obtained 
quickly before patients disappear and no adequate treatment is possible. Since the 
prevalence is high, the identification of the causative mycobacterium is often not 
required. In TB endemic areas, infection with non-tuberculous mycobacteria remains 
uncommon and therefore the positive predictive value of AFB microscopy is high. 
Nevertheless, new tests are urgently needed to directly replace microscopy and culture 
(Perkins, 2000).  
 
The situation in developed countries is different. The low prevalence and the 
well-equipped laboratories allow a definite diagnosis of TB. Identification of the 
infecting mycobacterium and drug-susceptibility testing is routine.  The diagnostic 
needs for low prevalence countries are those in support of the elimination of TB and 
include tests for the identification of latent infections, the detection of TB in 
immigrants or other high risk groups, the identification of outbreaks and 
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characterisation of transmission, and the discrimination between M. tuberculosis and 
other non-tuberculous species (Perkins, 2000).  
The WHO recommends the following specifications for a new diagnostic test for 
developing countries: 
· Detection limit <³ 104 AFB ml-1 sputum 
· Sensitivity of 85 % compared to culture 
· Specificity of 95 % compared to culture 
· Require less than 15 minutes preparation time 
· Long shelf-life (> 6 months) 
· Cost-effectiveness 
· Simple and robust 
 
 
 
1.10 AIMS AND OBJECTIVES 
This thesis is divided into two parts. In the first part, the potential of an electronic 
nose as a monitoring tool for haemodialysis is investigated (non-infectious 
application). In the second part, the electronic nose is applied as an early detection 
system for pulmonary tuberculosis (infectious disease).  
 
1.10.1 AIM  
To evaluate the potential of electronic nose technology in point-of-care human 
diseases management: Studies in renal diseases and tuberculosis. 
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1.10.2 OBJECTIVES FOR THE MANAGEMENT OF RENAL FAILURE 
·  To find the optimal sample incubation parameters including incubation 
temperature and time as well as the minimal sample volume for uraemic blood 
samples. 
· To determine the maximal dilution for uraemic blood samples which allow 
discrimination between pre- and post-dialysis samples. 
· To evaluate the sensor reproducibility towards uraemic blood samples. 
· To study the influence of urea and creatinine on the sensor response.  
· To evaluate the long term stability of the electronic nose towards uraemic blood 
samples. 
· To evaluate the volatile shift occurring during a single haemodialysis session in 
both blood and dialysate.  
· To compare the electronic nose pattern with traditional biochemical markers 
 
1.10.3 OBJECTIVES FOR THE EARLY DIAGNOSIS OF PULMONARY TUBERCULOSIS  
· To investigate the potential of an electronic nose to discriminate between 
different Mycobacterium spp. and Pseudomonas aeruginosa in both culture and 
sputum. 
· To determine the detection limit of the electronic nose for M. tuberculosis in 
both culture and sputum. 
· To investigate the influence of dead M. tuberculosis bacteria on the sensor 
response. 
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· To determine the specificity and sensitivity of the electronic nose for M. 
tuberculosis in sputum.  
 
1.11 OUTLINE OF THE THESIS 
 
Chapter 2 describes the general materials and methods used throughout the report. 
However, to keep a certain structure and clearness, the specific methods including 
sample procurement and sample preparation are described in Chapter 3 and 4.  
 
Chapter 3 describes the development of an electronic nose protocol for the 
management of haemodialysis. It also includes specific materials and methods.  
 
Chapter 4 describes the application of an electronic nose as a diagnostic tool for 
pulmonary tuberculosis. It also contains specific materials and methods. 
 
Chapters 5 and 6 set the results presented in this thesis in perspective to current 
diagnostic practise and also discuss their implications in the future. It also describes 
which steps need to be addressed to make electronic nose technology a modern 
diagnostic instrument. 
 
 
 
  
 
 
 
Chapter 2 
General  
Materials and Methods 
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2.1 ETHICAL APPROVAL 
Ethical approval for this study was obtained either from the Gloucestershire 
Research Ethics Committee (Study No’s: 01/149G; 03/44G) or from the ethics 
committee of the Academic Medical Centre (Amsterdam, The Netherlands) (Study 
No: MEC98/034). All patients and volunteers participating in this study gave 
informed written consent before samples were taken after oral and written information 
was provided. Each sample was encoded to ensure anonymity (Appendix A.1 and 
A.2).  
 
 
2.2 GAS-SENSING SYSTEM  
2.2.1 GAS SENSING SYSTEM AND HEADSPACE ANALYSIS  
The electronic nose (Bloodhound BH-114, Bloodhound Sensors, Leeds, UK) used 
in this study employed 14 conducting polymer sensors (Appendix B.1). The BH114 
instrument consists of a fully integrated sampling system with the sensor array and 
hardware controlled by proprietary Windows based software, which also incorporates 
data collection and processing software. 
The sensor unit automatically sets two calibration points. The first one is the 
baseline, which is obtained when activated carbon filtered (Carbon Cap 150, 
Whatman, UK) air is passed over the sensor (purple arrow, Figure 3.1) at a flow rate 
of 4 ml min-1. The second calibration point is a reference point obtained from the 
headspace of a control sample vial containing 9 ml of reverse osmosis (RO) -water 
(blue arrow) (Figure 2.1). The interaction of the volatile compounds and the 
conducting polymer surface produces a change in resistance, which is measured and 
Material and Method  77 
Cranfield University at Silsoe Reinhard Fend 2004 
subsequently displayed on the computer screen. 
For the analysis of the sample headspace, the sample vials were connected to the 
electronic nose by inserting a needle into the headspace of the sample vials (Figure 
3.1). The unknown headspace is passed over the sensor surface (red arrow, Figure 3.1) 
at a flow rate of 200 ml min-1, which was automatically set by the sensor unit. 
Between each measurement, a time delay of 2 minutes was set. The individual 
samples were analysed in a random order. 
 
 
 
Figure 2.1: Overview of idealised electronic-nose configuration. The set-up 
consists of the electronic nose sensor array, a sample and a control vial as well as two 
activated carbon filters and a HEPA-Vent filter. The carbon filters ensure an odourless 
airflow over the sensor surface and control and sample headspace, whereas the 
HEPA-VENT filter prevents the fouling of the sensor surface. The electronic nose is 
connected to a PC running the control software and an appropriate data analysis 
package. 
Electronic Nose - 
Bloodhound BH 114 
Activated Carbon Filter 
Control Sample Vial 
Headspace Vial with Aluminium  
Silicone/Teflon Pressure Release Seal 
Needle 
PC with control and data 
acquisition software 
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2.2.2 EXPERIMENTAL PARAMETERS FOR ELECTRONIC NOSE 
The adjustable sampling profile consists of five parameters: time delay, 
adsorption time, baseline length, desorption time, and hold time. The sampling 
profiles used in this report were set according to Table 2.1. 
 
Table 2.1: Sample profiles used in this report. 
 Samples 
 Blood Dialysate Culture Sputum 
Time delay (s) 5 5 5 5 
Adsorption time (s) 10 10 6 7 
Desorption time (s) 15 15 14 21 
Baseline length (s) 5 5 5 5 
Hold time (s) 0 0 0 0 
 
 
2.3 DATA ANALYSES AND PATTERN RECOGNITION 
To analyse the electronic nose data, two Excel add-in software programs were 
employed. Principal component analysis, hierarchical cluster analysis, and 
discriminant function analysis was performed using XLstat (XLstat©, version 3.4, 
France) and for the neural network analysis the program NeuralystTM (version 1.4, 
Cheshire Engineering Corporation, Pasadena, CA, USA) was used.  
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2.3.1 SENSOR PARAMETERS 
Figure 2.2 displays a typical sensor response to a sample headspace taken over 
time. The parameters extracted from the sensor response are as follows: 
A. Maximum step response (divergence) 
B. Maximum adsorption  
C. Maximum desorption  
D. Ratio between adsorption and desorption  
E. Area under the curve (Langmuir adsorption spectrum) 
 
 
 
 
 
 
 
 
Figure 2.2: A typical sensor response to a sample headspace with the extractable 
sensor parameters. 
 
However, only two parameters, namely the maximum sensor response and the 
area under the curve showed good reproducibility and were therefore considered in 
the data analysis.  
 
A 
C B 
Time 
% Response 
E 
A: Divergence 
B: Absorption 
C: Desorption 
D: Ratio of B to C 
E: Area under curve 
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2.3.2 PATTERN RECOGNITION 
Throughout this report, a common structure for pattern recognition was applied. 
Figure 2.3 illustrates the two different idealised pathways employed. The 
normalised/non-normalised raw data were either used as input variables for PCA or 
ANN. The principal components had a central position and were input variables for 
DFA and HCA  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3: Schematic illustration of the data analysis pathways. The blue 
pathway indicates the central position of PCA (red box). PCs were used as input 
variables for DFA and HCA (green boxes). In contrast, artificial neural networks were 
built directly on the pre-processed data matrix (red pathway). 
Electronic nose raw data 
Data pre-processing? 
Artificial Neural 
Networks 
Principal Component 
Analysis 
Discriminant Function 
Analysis 
Hierarchical Cluster 
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Data pre-processing 
The raw data were under circumstances pre-processed to improve the quality of 
the input data. The method of choice was normalization to vector length one (see 
equation 1.1). This step was only possible, where no quantitative information was 
required to solve the discrimination problem. 
 
Principal Component Analysis (PCA) 
PCA represents the central point, whereby the principal components were utilized 
in two separate ways. On one side, they were used to reveal hidden structures 
(relationships) within the input matrix (score plot), and on the other side, they were 
used as input variables for DFA and HCA.  
However, not all principal components (PC) were used as input variables for the 
subsequent methods. The number of PCs was determined by the Kaiser criterion, 
which states, that only principal components with an eigenvector greater or equal than 
1 are significant (Jackson, 1991). Applying this rule implicates that approximately 90 
– 95 % of the variance (information) of the original data matrix is used for subsequent 
methods. 
 
Hierarchical Cluster Analysis (HCA) 
HCA was used to calculate the distance between individual samples. The result is 
displayed as clusters of related samples. The initial distance matrix, i.e. the distance 
between principal components was calculated using the Euclidean distance. The 
Ward’s method was used to aggregate individual sub-clusters. The key idea of this 
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method is to aggregate clusters in such a way that a minimum increase in the within-
group error sum of squares results (Otto, 1999). Two individual clusters were 
considered significantly different when the distance between them exceeds the 95 % 
confidence interval (p=0.05) (indicated by the dashed line in dendrograms).   
 
Discriminant Function Analysis (DFA) 
DFA, a classification method, was applied to assign unknown samples to one of 
the pre-defined classes. The model itself was built on a sub-set of the original data and 
validated with the remaining (unknown) samples. To validate the model, the variables 
of the withheld samples were inserted into the discriminant functions (obtained during 
the training period) and subsequently assigned to that class for which its centroid has 
the smallest Euclidean distance to the unknown sample (Otto, 1999).  
 
Artificial Neural Network (ANN) 
The ANN was trained using the backpropagation algorithm with a sigmoid 
transfer function. The original data set was divided into two groups: the training and 
the test data set.  
 
Approximately 70 % of the original data were randomly selected and used to train 
the ANN. The remaining 30 % of the data were used to evaluate the performance of 
the ANN.   
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Optimisation of the ANN – Genetic supervisor 
To find the optimal network architecture and parameters, a genetic algorithm was 
applied (genetic supervisor). The key characteristic of a genetic supervisor (GS) is to 
improve the learning and therefore the discriminatory performance of the neural 
network. The genetic supervisor optimises the input columns (variables), the 
configuration, and the network parameters so that the final ANN will perform well as 
a successful model with a minimum amount of training. Each ANN solution is 
described by a structure composed of three strings, whereby the strings represent the 
selection of input variables, ANN configuration, and the ANN parameters (Figure 
2.4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4: Graphic illustration of a single network solution.  
String 1: 
 Input data matrix · Number of sensor 
parameters selected 
String 2: 
 ANN configuration 
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· Learning rate 
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String 1 – Input data selection (data matrix): Each sensor parameter is treated 
separately, i.e. the GS can exclude or include individual parameters to obtain the 
optimal input data.  The inclusion rate determines, how many of the original variables 
have to be included in the final ANN architecture.  
 
String 2 – ANN configuration: The number of inputs and outputs defined for each 
ANN solution automatically determines the first and last layer of each neural network. 
The number of inputs is determined by string 1, and the user defines the number of 
outputs. The number of outputs is usually equal to the number of different odour 
classes.  It is up to the GS to determine the optimal number of  hidden layers and for 
the optimal number of neurons per layer.  
 
String 3 – ANN parameters: The ANN parameters (momentum, learning rate, and 
input noise) predominantly control the training behaviour of the neural network. The 
learning rate applies an amount of correction as a result of the error derived form a 
given case. The moment averages the current error to a greater or lesser extend with 
previous errors.  
 
The GS looks for the optimised ANN architecture by selecting input variables, 
varying the configuration and parameters. Each of the resulting structures is then 
evaluated in terms of neural network fitness. The network fitness is normally 
evaluated by calculating the error between ANN output and target output. The 
optimised neural network is characterised by the smallest error and used ready for 
training (Shih, 1994).  
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The following parameters were used for the genetic supervisor. 
 
· Inclusion rate: 75 % 
· Momentum: 1 
· Learning rate: 0.5 
· Input Noise: 0.03 
  
 
 
 
Chapter 3 
Electronic Nose in Renal Medicine 
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3.1 INTRODUCTION 
An ever-increasing number of patients have to undergo regular renal dialysis to 
compensate for acute or chronic renal failure. The estimated annual rate of patients 
starting renal replacement therapy (RRT) for end stage renal failure in England and 
Wales is 101 per million population indicating that approximately 5940 patients 
started RRT in 2002 (UK Renal Registry Report, 2003). Approximately 800,000 
patients with end stage renal disease (ESRD) are currently alive throughout the world 
while being treated with various modes of regular treatment, haemodialysis being the 
predominant form of RRT (Tetta et al, 1999; UK Renal Registry Report, 2003). The 
annual growth rate of ESRD patients is estimated to be about 9% worldwide (Tetta et 
al, 1999).  
Data from renal registries have shown that the average age of patients newly 
admitted to RRT show a steady increase being now closely to 65 years of age  (UK 
Renal Registry Report, 2003). Such an elderly population shows a variety of co-
morbid conditions such as cardiovascular disease or atherosclerosis (Tetta et al, 1999; 
Movilli, 1999). Cardiovascular complications account for 50 – 60 % of all deaths 
among ESRD patients (Nourooz-Zadeh, 1999). Despite significant improvements 
achieved in dialysis technology, there is substantially no evidence for a decrease in 
the prevalence of cardiovascular diseases or amyloidosis during the last decade (Tetta 
et al, 1999; Canaud et al, 1999; Levy et al, 2001).  
The uraemic syndrome is attributed to the retention of a number of different 
molecules, collectively termed uraemic toxins. However, the toxicity of the syndrome 
has not been attributed to any single compound; it is most likely to be due to a 
spectrum of compounds, and indeed the list of potential candidates is complex and 
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growing, and now numbers over 90 (Bergström, 1997). Which compounds exert a 
toxic effect within the body, and which accumulate innocently, is currently not known 
with certainty (Vanholder et al, 2003). 
Our current approach to the dialytic management of ESRF is to employ urea as a 
surrogate marker for retained solutes and toxins, and to model the quantity of 
treatment upon its removal from the body. Urea as such is generally not a particularly 
toxic compound, and designing treatment strategies using more biologically relevant 
compounds would be more appropriate, however defining these compounds is 
problematic (Vanholder et al, 1994). 
 An alternative approach would be to gain information about a wide spectrum 
of compounds that accumulate in renal failure, and apply the knowledge of changes in 
the pattern of these compounds to devise and monitor treatment strategies. We have 
employed the electronic nose (EN) to provide such information. 
 
3.2 SPECIFIC MATERIALS AND METHODS 
3.2.1 STUDY DESIGN 
The study was divided into four parts to optimise and evaluate the sensor response 
of the electronic nose to pre and post dialysis blood, and to dialysate samples, from 
haemodialysis (HD) patients, and to compare responses to blood samples from normal 
controls (Figure 3.1). 
The first part was aimed to find the optimal conditions for the sample pre-
treatment to obtain a sufficient sensor response allowing discrimination between pre- 
and post –dialysis blood. The first part of this study was further divided into four steps 
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(Figure 3.2). The experimental model obtained from part I was then validated (part II) 
and finally the performance evaluated in terms of long-term performance and ability 
to follow the dialysis shift (part III). In the last part (IV) the performance of the 
electronic nose was compared with biochemical markers traditionally used to assess 
the efficiency of haemodialysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Overview of the study design to optimise and evaluate the sensor 
response of the electronic nose to “uraemic” blood and control blood. 
Part I: Optimisation of sampling 
parameter 
 
· Incubation temperature and time 
· Sample volume 
· Blood dilution 
Part II: Validation of Electronic Nose 
 
· Reproducibility of sensor response 
· Analysis of large number of patients 
under optimised conditions 
· Spiking of samples 
 
Part III: Evaluation of performance 
 
· Long term stability 
· Shift during dialysis 
 
Part IV: Comparison of Electronic Nose 
with Biochemical Markers  
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Figure 3.2: The four principal steps for the optimisation of sampling parameters.  
OPTIMISATION:  
 
Incubation temperature 
OPTIMISATION: 
 
Incubation time 
 
STEP 1 
STEP 3 
STEP 2 
Optimal Temperature (Topt) 
Optimal Volume (Vopt) 
Optimal Time (topt) 
Optimal Conditions (Topt, topt, Vopt, Dopt) 
PART I: Optimisation of Sampling Parameter 
OPTIMISATION: 
 
Sample volume 
 
OPTIMISATION: 
 
Sample dilution 
 
STEP 4 
Optimal Dilution (Dopt) 
Electronic nose in renal medicine  91 
Cranfield University at Silsoe Reinhard Fend 2004 
3.2.2 SAMPLE PROCUREMENT 
 
All blood samples were collected either from patients undergoing intermittent 
HD-treatment at Gloucestershire Royal Hospital (Gloucester, UK) or healthy 
volunteers (Control blood).  All patients are treated either with a Fresenius F6 or 
Fresenius F8 dialyser (Fresenius AG, Bad Homburg v.d.H., Germany) The surface 
area of the polysulfone membrane is either 1.3 m2 (F6 dialyser) or 1.8 m2 (F8 
dialyser). The blood flow varied between 200 and 350 ml/min, depending on the 
patient, whereas the dialysate flow rate was kept constant at 500 ml min-1. All patients 
included in this study undergo haemodialysis treatment three times a week for four 
hours per session.  
 
Blood and dialysate collection for analysis of volatiles 
 Blood samples (4 ml) from patients were collected directly from the HD circuit 
(pre dialyser) into tubes containing EDTA. (Greiner bio-one, Vacuetteâ, coagulation 
tubes). Control samples (10 ml) were obtained by venepuncture. Samples were then 
immediately frozen and stored at – 20 °C until analysis. Dialysate samples (15 ml) 
were collected directly from the post dialyser circuit tubing into sterile tubes and 
stored at –20 °C until analysis. 
 
Blood collection for biochemical analysis 
 
The biochemical analysis was performed on blood serum, therefore sampling 
tubes with clot-activator (Greiner bio-one, Vacuetteâ, serum tubes) were used for 
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blood sampling. From each patient, 10 ml of pre- and post-dialysis blood, respectively 
and from each volunteer 10 ml of control blood have been taken and analysed by the 
Clinical Chemistry Laboratory at Gloucestershire Royal Hospital (UK).  
 
3.2.3 SAMPLE PREPARATION  (INCUBATION) 
All blood samples were stored at - 20 oC until analysis was performed. The frozen 
samples were defrosted on ice to minimise the loss of volatiles. Sample aliquots were 
transferred into a 5 ml headspace vials (Macherey and Nagel, UK) and immediately 
sealed with a crimp cap with Silicon/Teflon-septum (Jaytee Bioscience Ltd., UK). 
The sealed headspace vials were subsequently incubated. After the incubation period, 
the samples were analysed using the electronic nose. 
 
The original sample volume of 2.5 ml of “uraemic” blood was incubated for 30 
minutes. As indicated in Figure 3.2, the first step was to find the optimal incubation 
temperature. The samples were incubated at 20 °C, 37 °C and 70 °C. Thirty seven 
degree Celsius was chosen because it is the human body temperature. The third 
incubation temperature of 70 °C was deliberately set very high to investigate if a 
higher incubation temperature liberates more volatiles compared to 37 °C or 20 °C. 
After finding the optimal incubation temperature (Topt), the incubation time was 
varied. Two point five ml of blood was incubated for 30 minutes, 45 minutes and 60 
minutes at Topt. In the next step (Step 3, Figure 3.2) all samples (pre- and post-
dialysis) were incubated under the best conditions (Topt and topt). The sample volume 
was reduced to 2.0 ml, 1.0 ml and 0.5 ml. To reduce the amount of required blood, the 
smallest possible sample volume was used and further diluted with 0.9 % NaCl 
Electronic nose in renal medicine  93 
Cranfield University at Silsoe Reinhard Fend 2004 
(Sigma, UK). The following dilutions were investigated: 1:2, 1:4 and 1:10. For all 
subsequent experiments the following parameters were used: optimal incubation 
temperature, optimal incubation time, optimal sample volume and optimal sample 
dilution.  
 
3.2.4 SPIKING OF BLOOD SAMPLES 
Blood samples were spiked with a) butanol/acetic acid mixture and b) 
urea/creatinine solution. The samples were prepared and incubated under the 
optimised conditions (Topt, topt, Vopt, and Dopt). 
 
Spiking with butanol/acetic acid mixture 
Control blood samples were spiked with a mixture containing butanol (Sigma, 
UK) and acetic acid (Sigma, UK). The final concentration (in the sample) of each 
substance was 2 % (v/v).  
 
Spiking with urea/creatinine mixture 
Blood samples were spiked with a solution containing urea (Sigma, UK) and 
creatinine (Sigma, UK). Control blood samples were spiked to a urea and creatinine 
level found in the average post-dialysis blood, and post-dialysis blood samples were 
spiked to pre-dialysis concentrations. The average concentrations were calculated 
from 55 haemodialysis patients and 15 volunteers (Table 3.1).  
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Table 3.1: Average urea and creatinine concentrations in control and “uraemic” 
blood. 
 Control blood Post-dialysis Pre-dialysis 
Urea 
(mmol l-1) 4.5 5.5 21.0 
    
Creatinine 
(mmol l-1) 100 400 850 
 
 
3.2.5 ANALYSIS OF SENSOR REPRODUCIBILITY 
The sensor reproducibility (drift) was studied by analysing one sample for 25 
times on three different days. The same experiment was performed with undiluted and 
diluted (Dopt) blood samples (Control blood). An aliquot (Vopt) of the same sample 
was transferred into a headspace vials and immediately sealed. The samples were 
incubated under the optimal conditions (Topt, topt).  
 
 
3.2.6 HEADSPACE ANALYSIS  
The incubated sample vials were connected to the electronic nose by inserting a 
needle into the headspace of the sample (see chapter 2). The sampling profiles used in 
this study are summarised in Table 3.2.  
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Table 3.2: Sampling profiles used for the analysis of blood and dialysate samples. 
 
 
 
3.2.6 DATA ANALYSIS  
The original data set was not pre-processed, since the concentration of retained 
molecules in “uraemic” blood is contains essential information for the discrimination 
of the different blood types.  Only for the analysis of the volatile shift (section 3.3.4), 
the samples within individual classes (control, pre- and post-dialysis) were normalised 
to length one prior to the multivariate analysis. This was done by dividing the sensor 
responses for all samples within a class by the standard deviation of this particular 
class.  
 
Principal component analysis and hierarchical cluster analysis were applied for 
the initial experiments, i.e. optimisation of the sampling parameter (part I, Figure 3.1). 
The purpose was to find a visual difference between the different blood types and not 
to classify unknown samples.  
For all other experiments, principal component analysis and discriminant function 
analysis were used.  
 Samples 
 Blood  Dialysate 
Time delay (s) 5 5 
Adsorption time (s) 10 10 
Desorption time (s) 15 15 
Baseline length (s) 5 5 
Hold time (s) 0 0 
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3.3 RESULTS 
3.3.1 OPTIMISATIONS OF ELECTRONIC NOSE 
Determination of the optimal incubation temperature (Topt) 
Three different temperatures were studied, namely 20 °C, 37oC, and 70oC. All 
samples were incubated for 30 minutes. Hence, a sample volume of 2.5 ml was used 
for the following experiments. The data were analysed using PCA and HCA.  
In all three cases, it was possible to discriminate between pre-dialysis blood and 
post-dialysis blood as indicated by the dotted line in the PCA-charts (Figures 3.3, 3.4, 
and 3.5). Based on these observations, it seemed that the incubation temperature had 
little or no influence on the outcome (discrimination). However, when the PCA results 
were compared with the HCA results, this conclusion appears to be incorrect. No clear 
discrimination (homogeneous clusters) between pre- and post-dialysis blood was 
possible to obtain using HCA, independent of the incubation temperature (Figures 3.6, 
3.7, and 3.8). In all three dendrograms (Figures 3.6, 3.7, and 3.8), the two different 
blood types were clustered into three clusters (C1 – C3). The best differentiation was 
observed at an incubation temperature of 70 oC as the blood samples of only one 
patient (patient 1) could not be discriminated (Figure 3.8).  
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Figure 3.3: Principal component analysis showing separate clusters of post-
dialysis blood (6 samples, triangles) and pre-dialysis samples (6 samples, circles). The 
samples were incubated at 20 °C for 30 min. The blood samples with the same 
number belong to the same patient. 
 
 
 
 
 
 
 
 
Figure 3.4: Principal component analysis showing separate clusters of post-
dialysis blood (6 samples, triangles) and pre-dialysis samples (6 samples, circles). The 
samples were incubated at 37 °C for 30 min.  
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Figure 3.5: Principal component analysis showing separate clusters of post-
dialysis blood (6 samples, triangles) and pre-dialysis samples (6 samples, circles). The 
samples were incubated at 70 °C for 30 min. The blood samples with the same 
number belong to the same patient. 
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Figure 3.6: Hierarchical cluster analysis of post-dialysis blood (6 samples, 
triangles) and pre-dialysis samples (6 samples, circles). The samples were incubated 
at 20 °C for 30 min. The blood samples with the same number belong to the same 
patient. C1, C2, and C3 represent the three distinguishable clusters (p=0.05). 
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Figure 3.7: Hierarchical cluster analysis of post-dialysis blood (6 samples, 
triangles) and pre-dialysis samples (6 samples, circles). The samples were incubated 
at 37 °C for 30 min. The blood samples with the same number belong to the same 
patient. C1, C2, and C3 represent the three distinguishable clusters (p=0.05). 
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Figure 3.8: Hierarchical cluster analysis post-dialysis blood (6 samples, triangles) 
and pre-dialysis samples (6 samples, circles). The samples were incubated at 70 °C 
for 30 min. The blood samples with the same number belong to the same patient. C1, 
C2, and C3 represent the three distinguishable clusters (p=0.05). 
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The best discrimination was obtained at 70oC. However, one of the problems 
encountered at 70 °C was that blood proteins started to denature and therefore made 
this temperature unsuitable for an on-line monitoring system. Having the end 
application in mind, 37 °C is the incubation temperature of choice since the dialyser 
circuit is operated at 37 °C and therefore no additional heating element has to be 
installed in an on-line monitoring device. For further experiments, the incubation 
temperature  was set at 37 °C. This decision is justified since enough information 
could be extracted as indicated in Figures 3.4 and 3.7.  
 
Determination of the optimal incubation time (topt) 
All samples were incubated at 37 oC for the following times: 45, 60 and 90 
minutes. The sample volume was kept constant at 2.5 ml during the experiments  
With all three incubation times, a separation of pre-dialysis blood and control 
blood could be obtained as indicated by the dotted line in the PCA – charts (Figures 
3.9, 3.10, and 3.11). The best separation was obtained after an incubation period of 45 
min (Figure 3.9). These results were confirmed by HCA as shown in Figure 3.12. As 
can be seen, post-dialysis samples formed a homogenous cluster (C1), whereas pre-
dialysis blood is split into two clusters (C2, C3). However, no clear discrimination 
(homogenous clusters) was observed after an incubation period 60 and 90 minutes 
when using HCA. Although the pre- and post-dialysis samples of individual patients 
were distinguishable from each other (e.g.: patients 3 and 4 in Figure 3.13 or patients 
1, 2, and 4 in Figure 3.14). Similar results were obtained when the experiments were 
repeated. For all further experiments, the chosen incubation time was 45 minutes.  
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Figure 3.9: Principal component analysis showing separate clusters of post-
dialysis blood (6 samples, triangles) and pre-dialysis samples (6 samples, circles). The 
samples were incubated at 37 °C for 45 min. The blood samples with the same 
number belong to the same patient. 
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Figure 3.10: Principal component analysis showing separate clusters of post-
dialysis blood (6 samples, triangles) and pre-dialysis samples (6 samples, circles). The 
samples were incubated at 37 °C for 60 min.  
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Figure 3.11: Principal component analysis showing separate clusters of post-
dialysis blood (6 samples, triangles) and pre-dialysis samples (6 samples, circles). The 
samples were incubated at 37 °C for 90 min.  
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Figure 3.12: Hierarchical cluster analysis of post-dialysis blood (6 samples, 
triangles) and pre-dialysis samples (6 samples, circles). The samples were incubated 
at 37 °C for 45 min. The blood samples with the same number belong to the same 
patient. C1, C2, and C3 represent the three distinguishable clusters (p=0.05). 
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Figure 3.13: Hierarchical cluster analysis of post-dialysis blood (6 samples, 
triangles) and pre-dialysis samples (6 samples, circles). The samples were incubated at 
37 °C for 60 min. The blood samples with the same number belong to the same patient. 
C1, C2, C3 and C4 represent the four distinguishable clusters (p=0.05). 
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Figure 3.14: Hierarchical cluster analysis of post-dialysis blood (6 samples, 
triangles) and pre-dialysis samples (6 samples, circles). The samples were incubated at 
37 °C for 90 min. The blood samples with the same number belong to the same patient. 
C1, C2, C3 and C4 represent the four distinguishable clusters (p=0.05). 
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Determination of the optimal sample volume (Vopt) 
All samples were incubated at 37oC for 45 min. The sample volume was varied as 
follows: 2.0 ml, 1 ml, and 0.5 ml. The sample volume had no influence on the 
separation between pre-dialysis blood and control blood as can be seen in the PCA – 
plots (Figures 3.15, 3.16, and 3.17). For a sample volume of 2.0 ml, the HCA plot was 
divided into three subclusters (C1-C3) (Figure 3.18). Nevertheless, it was possible to 
discriminate between all pre- and post-dialysis samples of individual patients (Figure 
3.18). However, with a sample volume of 1 ml and 0.5 ml, respectively, no 
homogenous clusters were obtained using HCA as shown in Figure 3.19 and 3.20. As 
can be seen in Figure 3.19, only one patient (no. 6) was misclassified, i.e. no 
discrimination between pre- and post-dialysis sample was possible. In contrast, with a 
sample volume of 0.5 ml it was impossible to distinguish between all pre- and post-
dialysis samples of individual patients (Figure 3.20).  
The HCA results are indicating a deterioration of the ability to separate between 
pre-dialysis blood and post-dialysis blood with a decrease in sample volume. 
Nevertheless, all further experiments were performed with a sample volume of 0.5 
ml because it was still possible to discriminate between pre- and post-dialysis 
samples of the same patient, even when no homogenous clusters were obtained.  
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Figure 3.15: Principal component analysis showing separate clusters of post-
dialysis samples (6 samples, triangles) and pre-dialysis samples (6 samples, circles). 
The samples were incubated at 37 °C for 45 min with a sample volume of 2 ml. 
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Figure 3.16: Principal component analysis showing separate clusters of post-
dialysis samples (6 samples, triangles) and pre-dialysis samples (6 samples, circles). 
The samples were incubated at 37 °C for 45 min with a sample volume of 1.0 ml. 
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Figure 3.17: Principal component analysis showing separate clusters of post-
dialysis samples (6 samples, triangles) and pre-dialysis samples (6 samples, circles). 
The samples were incubated at 37 °C for 45 min with a sample volume of 0.5 ml. 
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Figure 3.18: Hierarchical cluster analysis post-dialysis blood (6 samples, triangles) 
and pre-dialysis samples (6 samples, circles). The samples were incubated at 37 °C for 
45 min with a sample volume of 2 ml. The blood samples with the same number belong 
to the same patient. C1, C2, C3 and C4 represent the four distinguishable clusters 
(p=0.05). 
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Figure 3.19: Hierarchical cluster analysis post-dialysis blood (6 samples, triangles) 
and pre-dialysis samples (6 samples, circles). The samples were incubated at 37 °C for 
45 min with a sample volume of 1 ml. The blood samples with the same number belong 
to the same patient. C1, C2, C3 and C4 represent the four distinguishable clusters 
(p=0.05).  
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Figure 3.20: Hierarchical cluster analysis of post-dialysis blood (6 samples, 
triangles) and pre-dialysis samples (6 samples, circles). The samples were incubated at 
37 °C for 45 min with a sample volume of 0.5 ml. The blood samples with the same 
number belong to the same patient. C1, C2, and C3 represent the three distinguishable 
clusters (p=0.05). 
 
 
Determination of the optimal blood dilution (Dopt) 
Dialysis patients are anaemic. Hence, one limiting factor is the availability of 
blood of HD patients. Therefore, the aim was to minimise the required amount of 
blood needed to obtain a sufficient discrimination between post- and pre-dialysis 
blood samples. After reducing the sample volume to 0.5 ml, the possibility of diluting 
blood was investigated. The blood samples were diluted with a sterile 0.9 % NaCl 
solution to obtained the following dilutions: 1:2, 1:4 and 1:10. The experiments were 
performed with control blood and after finding the optimal dilution validated with 
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post- and pre-dialysis blood samples. A visual difference (PCA plot) between diluted 
control blood samples and blank sodium chloride will be used to determine the 
optimal dilution, i.e. the highest dilution, which still can be distinguished from the 
negative controls (0.9 % sodium chloride) will be regarded as optimal dilution.    
All samples were incubated under optimal conditions obtained so far (Topt,  topt, 
and Vopt). Undiluted, as well as blood in all dilutions, were analysed together, i.e. in 
the same experiment. Blank sodium chloride solution served as a negative control. 
The result of this experiment is shown in Figure 3.21. As can be seen, it is possible to 
distinguish between undiluted samples and the diluted samples up to a dilution of 1:4. 
It was impossible to discriminate 1:10 diluted samples from the negative control 
samples (0.9 % NaCl) indicating that the last concentrations was too low to 
discriminate between pre- and post-dialysis samples.  
Interestingly, on the left hand side of the graph are the concentrated samples 
(undiluted), whereas the highest diluted samples (1:10) are on the right hand side of 
the graph together with the negative controls.  
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Figure 3.21: Principal component analysis of different diluted control blood 
samples and blank sodium chloride solution (0.9 % w/v). Different diluted blood 
samples formed separate clusters, apart from the highest dilution (1:10), which could 
not be discriminated from blank sodium chloride solution (dashed line).  
Key: Undiluted blood (8 samples, dark blue diamonds), 1:2 diluted (8 samples, 
red squares), 1:4 diluted (8 samples: blue triangles), 1:10 diluted (8 samples, orange 
diamonds), and blank sodium chloride solution (8 samples, violet circles). 
 
 
Based on the PCA score plot, a classification model was built using discriminant 
function analysis. For calculating the model, 2 samples of each sample treatment were 
withheld and used for cross-validation. As can be seen in Figure 3.22, undiluted blood 
samples and diluted blood samples (1:2 and 1:4) formed separate clusters. However, 
1:10 diluted samples formed a cluster with the negative controls. The analysis of 
unknown samples (2 of each class) revealed that it is impossible to distinguish 1:10 
diluted samples from a sodium chloride solution, whereas the other unknown samples 
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were correctly identified (Figure 3.22). The result shown in Figure 3.22 indicated that 
a dilution of 1:4 should not affect the ability to discriminate between pre- and post-
dialysis blood samples.  
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Figure 3.22: Discriminant function analysis of different diluted control blood 
samples (Undiluted, 1:2, 1:4, and 1:10 diluted) compared to a sodium chloride 
solution.  
Key: Undiluted blood (diamonds), 1:2 diluted (squares), 1:4 diluted (triangles), 
1:10 diluted (orange diamonds), and blank sodium chloride solution (circles). Cross-
validations: 10 samples (2 of each) were withheld form building the DFA (open 
symbols). 
 
 
This observation was evaluated by the analysis of pre- and post-dialysis blood 
(1:4 diluted). As can be seen in Figure 3.23, it was possible to distinguish between 
pre- and post-dialysis samples at a dilution of 1:4. Control blood (healthy volunteers) 
formed a separate cluster compared to “uraemic” blood (Figure 3.23). 
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Figure 3.23: Principal component analysis of control blood (6 samples, squares), 
post-dialysis blood (6 samples, triangles) and pre-dialysis blood (6 samples, circles). 
The samples were incubated at 37 °C for 45 min with a sample volume of 0.5 ml and 
a dilution of 1:4. The dialysis blood samples with the same number belong to the 
same patient. 
 
 
A perfect discrimination could not be achieved using hierarchical cluster analysis 
(Figure 3.24). The dendrogram is divided into four sub-clusters (C1 – C4). Cluster C1 
contains all post-dialysis blood samples as well as two pre-dialysis samples (patients 
3, and 5). Three of the remaining pre-dialysis samples were grouped together in 
cluster C2. The post-dialysis sample of patient 1 was grouped together with control 
samples (C3). The control samples itself were divided into two clusters (C3, C4).  
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Figure 3.24: Hierarchical cluster analysis of control blood (squares), post- 
(triangles) and pre-dialysis samples (circles). The samples were incubated at 37 °C for 
45 min with a sample volume of 0.5 ml and a dilution of 1:4. The blood samples with 
the same number belong to the same patient. C1, C2, C3 and C4 represent the four 
distinguishable clusters (p=0.05). 
 
 
 
The overall aim of this study was to discriminate between pre- and post-dialysis 
blood samples. Therefore, the control samples were removed from the original data 
set and the remaining data were re-analysed. As can be seen in Figure 3.25, a good 
separation was obtained between pre- and post-dialysis samples (dashed line). This 
observation was confirmed by HCA (Figure 3.26). Figure 3.26 shows two separate 
clusters (C1, C2). Cluster C1 contains all pre-dialysis samples, whereas cluster C2 
includes all post-dialysis samples.  
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Figure 3.25: Principal component analysis of post-dialysis blood (6 samples, 
triangles) and pre-dialysis blood (6 samples, circles). The samples were incubated at 
37 °C for 45 min with a sample volume of 0.5 ml and a dilution of 1:4. The dialysis 
blood samples with the same number belong to the same patient. 
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Figure 3.26: Hierarchical cluster analysis of post- (triangles) and pre-dialysis 
samples (circles). The samples (0.5 ml, 1:4 diluted) were incubated at 37 °C for 45 min. 
The blood samples with the same number belong to the same patient. C1, and C2 
represent the two distinguishable clusters (p=0.05). 
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 The parameters chosen for further experiments are summarised in Table 3.3. 
 
Table 3.3: Summary of the chosen sampling parameters. 
Sampling Parameter  
Incubation Temperature (Topt) 37 oC 
Incubation Time (topt) 45 min 
Sample Volume (Vopt) 0.5 ml 
Sample Dilution (Dopt) 1:4 
 
 3.3.2 VALIDATION OF ELECTRONIC NOSE 
After finding the optimal incubation parameters, which allowed a separation of 
pre- and post-dialysis blood samples it was necessary to validate the electronic nose. 
The validation included the analysis of more samples (bigger sample size), spiking of 
blood samples, and investigating the sensor drift. 
Reproducibility of sensor response 
The sensor drift was determined with 0.5 ml control blood (undiluted and 1:4 
diluted). The samples were incubated at 37 oC for 45 min.  
The sensors are generally characterised by a low drift as indicated by the coloured 
bars in Figures 3.27a/b. Only sensor 11 showed a large variation in the sensor 
response to undiluted blood on day 1 (Figure 3.27a). However, on following days the 
drift of sensor 11 was comparable with the others. The day-to-day reproducibility was 
good as illustrated in both figures. All sensors apart from sensor 11 and 14 showed 
similar sensor responses, independent on the day and sample dilution (Figures 
3.27a/b). The high sensor response of sensor 14 on the second day (Figure 3.27a/b) 
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might be due to the fact, that the electronic nose was not used for a few days. This 
break may lead to a full recovery of the sensor and subsequently lead to an increased 
sensor response.  
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Figure 3.27: The mean sensor response as well as their minimal and maximal 
response to A) undiluted and B) diluted control blood measured on three different 
days.  
A 
B 
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However, it was decided to eliminate sensor 11 and 14 from the data analysis for 
all further experiments presented in this report due to their lack of reproducibility.    
 
Analysis of larger sample size 
The optimisation of the sampling parameter was done on a relatively small 
sample size due to the blood consumption during the experimental phase. The first 
part of the validation phase was the analysis of 55 patients and 40 volunteers based on 
the findings described in section 3.3.1 (Table 3.3).  
 
Blood samples were obtained from 55 patients undergoing intermittent HD. The 
samples were taken before and after a single dialysis session directly from the HD 
circuit. Control blood (40 volunteers) samples were obtained by venepuncture.  
The result of this experiment is shown in Figure 3.28. The two first principal 
components account for 88 % of the variance of the original data matrix, and this 
information was sufficient to easily discriminate between “uraemic” blood and control 
blood. However, more importantly is the fact that the odour of pre-dialysis blood 
differs to the odour of post-dialysis samples (Figure 3.28).  
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Figure 3.28: Principal component analysis showing the separate clusters of 
control blood (40 samples, squares), post-dialysis blood (55 samples, triangles) and 
pre-dialysis blood (55 samples, circles).   
 
Based on the analysis presented in Figure 3.28 (PCA) a classification model was 
built (DFA) using samples from 47 patients and 32 controls selected at random. The 
result of the classification model is presented in Figure 3.29. The samples grouped 
into three clusters (pre-, post- dialysis, and control) with good separation.  The model 
was validated by analysis of the 24 samples (8 of each class) that were not used to 
construct the classification model, and all 24 samples were correctly classified as 
either control, post-dialysis or pre-dialysis blood indicating the validity of the model. 
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Figure 3.29: Discriminant function analysis showing the separate clusters of 
control blood (squares), post-dialysis blood (triangles) and pre-dialysis blood 
(squares). Cross-validation: 24 samples (8 of each), open symbols. 
 
Spiking of blood samples 
Spiking of blood samples by adding highly volatile substances was done to 
investigate if it would give rise to an altered sensor response. In the first set of 
experiments, control blood was spiked with butanol and acetic acid. In a second 
experimental series “uraemic” blood (post- and pre- dialysis) was spiked with urea 
and creatinine.  
Spiking of control blood with butanol and acetic acid 
Control blood samples were spiked with highly volatile pure chemicals. The aim 
was to investigate if the electronic nose was able to differentiate between modified 
samples and unmodified samples. A positive result (discrimination possible) was an 
indicator that the electronic nose was working properly under the given conditions. 
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Control blood samples were spiked with butanol and acetic acid so that the 
concentration of both substances was 2 % (v/v) in the final sample. Two % was 
chosen because the manufacturer of the electronic nose recommends a 2 % butanol 
solution as a reference standard (Bloodhound Operating Manual, Version 1.4.2).  
The result of the experiment is shown in Figure 3.30. As can be seen, a clear 
separation between the control blood samples and the spiked samples is observable 
(dashed line). The two highly volatile compounds caused an additional odour in the 
spiked samples. Hence, these volatiles gave rise to the altered sensor response 
allowing the discrimination between the samples (Figure 3.30).  
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Figure 3.30: Principal component analysis showing the separate clusters of 
control blood (14 samples, squares) and control blood spiked with butanol (2% v/v) 
and acetic acid (2% v/v) (14 samples, diamonds). 
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Spiking with urea and creatinine 
The aim of the second experimental series was to investigate if the sensor 
response is influenced by urea and creatinine. Urea and creatinine are two substances, 
which are elevated levels in HD patients and currently used to assess the treatment 
adequacy.  
For this reason, blood samples were spiked with urea and creatinine. Control 
blood (obtained from healthy volunteers) was spiked to an averaged level observed in 
post-dialysis samples (urea: 5.5 mmol l-1, creatinine: 400 mmol l-1), whereas post-
dialysis samples were spiked to an averaged pre-dialysis level (urea:  21.00 mmol l-1, 
creatinine: 850 mmol l-1). 
The result of the spiking experiment is shown in Figure 3.31. As can be seen, it is 
possible to distinguish between control blood, post- and pre-dialysis blood. The 
spiking itself did not influence the ability to distinguish between the different sample 
types. No difference between spiked and unspiked samples was observable, i.e. the 
formed one cluster.   
Based on the PCA, a classification model was built (DFA) using 45 samples (9 of 
each sample type). The result is shown in Figure 3.32. As can be seen, three different 
distinctive clusters for control blood, post-dialysis and pre-dialysis blood were 
formed. It was impossible to distinguish between spiked and unspiked blood samples. 
The cross-validation revealed that it was only possible to allocate the unknown 
samples either to control, post-dialysis or pre-dialysis cluster independent of the 
spiking status. This result indicates that urea and creatinine do not actively influence 
the sensor response.  
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Figure 3.31: Principal component analysis of control blood (12 samples, red 
squares), spiked control blood (12 samples, green/grey squares), post-dialysis blood 
(12 samples, triangles), spiked post-dialysis blood (12 samples, diamonds) and pre-
dialysis blood (12 samples, circles).  
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Figure 3.32: Discriminant function analysis of control blood, spiked control 
blood post-dialysis blood, spiked post-dialysis blood and pre-dialysis blood. Cross 
validation: 15 samples (three of each type), open symbols. 
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3.3.4 EVALUATION OF THE ELECTRONIC NOSE PERFORMANCE 
The aim of this research project was to investigate the potential of an electronic 
nose as a new monitoring tool for haemodialysis. In this section, the performance of 
the gas sensor array is studied in terms of its ability to follow the volatile shift 
occurring during a single haemodialysis session and also its long-term performance 
(stability).  
 
Analysis of the dialysis (volatile) shift 
This study was designed to explore and characterise alterations in the spectrum of 
volatile compounds that can be detected by the electronic nose in the blood and 
dialysate of patients undergoing haemodialysis treatment. 
 
Analysis of the blood-side shift 
Blood samples were obtained before, and then hourly until the end of dialysis, 
from 14 haemodialysis patients. Blood samples were obtained also from 15 healthy 
controls. The blood samples were diluted and incubated under the parameters 
described in Table 3.3. 
 
The result of the EN analysis of the blood samples is shown in Figure 3.33. The 
first two principal components account for 81 % of the variance of the original data 
matrix, which was sufficient to clearly discriminate the sample groups at different 
time points.  
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Figure 3.33: Principal component analysis of 15 volunteers (control blood) and 
14 haemodialysis patients The uraemic blood samples were taken at the beginning, 
then every hour and at the end of a single dialysis session. 
Key: Pre-dialysis blood (circles), 1 hour after the start of the treatment (circles with 
green background), 2 hour after the start of the treatment (triangles with grey 
background), 3 hour after the start of the treatment (diamonds), Post-dialysis blood 
(triangles), Control blood (squares). 
 
 
The classification model was built using results of samples from 12 patients and 
13 controls and validated by correct classification of the results from 2 patients and 2 
controls. As can be seen in Figure 3.34, each group of samples from different time 
points formed a separate cluster, pre-dialysis samples are clustered on the right, and 
during the time course of the HD session the sample clusters are plotted progressively 
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towards the left. Post-dialysis blood samples and control samples are clearly separated 
at the extreme left of the graph. The discrimination problem was solved by using the 
first two discriminant functions (s1, s2). When the data of 4 unknown samples were 
inserted into these two discriminant functions, the model reliably predicted the type of 
sample, i.e. correct classification was possible.   
 
 
 
 
 
 
 
 
 
 
Figure 3.34: Discriminant function analysis of 15 volunteers (control blood) and 
14 haemodialysis patients. The uraemic blood samples were taken at the beginning, 
then every hour and at the end of a single dialysis session. 
Key: Pre-dialysis blood (circles), 1 hour after the start of the treatment (circles with 
green background), 2 hour after the start of the treatment (triangles with grey back 
ground), 3 hour after the start of the treatment (diamonds), Post-dialysis blood 
(triangles), Control blood (squares), Cross-validated samples (open symbols). 
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Analysis of the dialysate--side shift 
Dialysate samples (15 ml) were collected directly from the post dialyser circuit of 
14 haemodialysis patients (same patients as for blood-side). An aliquot of 2 ml of 
dialysate was used and incubated at 37 °C for 45 minutes. The larger volume was 
chosen due to the dilution effect of dialysate and dialysis fluid itself is available in 
unlimited amounts.  
 
 
The result of the principal component analysis of dialysate taken at different time 
points is shown in Figure 3.35. As with blood sample analysis each sample type 
(corresponding to the time point of sampling) formed a separate cluster, and the first 
two principal components account for 88 % of the original variance. The inter-cluster 
variability of the dialysate samples however appears larger than that of the blood 
samples (Figure 3.33 vs. Figure 3.35).   
 
Again a classification model was built using discriminant function analysis, using 
60 samples of dialysate from patients and 13 samples of control dialysate. Different 
clusters were formed for the different sample types, and the model was validated by 
cross-validation. Unknown dialysate samples of 2 patients and 2 controls were 
analysed and correctly identified using the first two discriminant functions (s1, s2) 
(Figure 3.36). 
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Figure 3.35: Principal component analysis of clean dialysate and dialysate of 14 
haemodialysis patients. The dialysate samples were taken at the beginning, then every 
hour and at the end of a single dialysis session. 
Key: Start dialysate (circles), 1 hour after the start of the treatment (circles with green 
background), 2 hour after the start of the treatment (triangles with grey background), 3 
hour after the start of the treatment (diamonds), end-dialysate (triangles), clean 
dialysate (squares). 
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Figure 3.36: Discriminant function analysis of clean dialysate and dialysate of 14 
haemodialysis patients. The dialysate samples were taken at the beginning, then every 
hour and at the end of a single dialysis session. 
Key: Start dialysate (circles), 1 hour after the start of the treatment (circles with green 
background), 2 hour after the start of the treatment (triangles with grey background), 3 
hour after the start of the treatment (diamonds), end-dialysate (triangles), clean 
dialysate (squares). 
 
 
Long-term Performance (stability) 
One of the main drawbacks of electronic nose technology is its lack of long-term 
reproducibility. This experiment was designed to study the performance of the gas 
sensor array to blood samples taken over a period of three weeks (9 consecutive 
dialysis sessions). 11 HD patients were selected and followed for nine consecutive 
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dialysis sessions. The blood samples were obtained before and after the treatment of 
each single session.  
 
The result of this long-term experiment is shown in Figure 3.37. As can be seen, 
control blood is on the left hand side of the graph, post-dialysis is in the middle and 
pre-dialysis blood is located on the right hand side. No clear discrimination could be 
obtained as indicated by the overlapping circles (added by author) in Figure 3.37. The 
first principal components account for 87 % of the variance of the original data 
matrix. The introduction of a third principal component (see Figure D.1, Appendix D) 
did not contain any significant information allowing a clear discrimination of the 
different sample types.  
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Figure 3.37: Principal component analysis of control blood (45 volunteers, 
squares), post – dialysis (99 samples, triangles) and pre-dialysis blood (99 samples, 
circles). The blood samples of 11 HD patients were taken at nine consecutive dialysis 
sessions. 
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Based on the principal component analysis a classification model was build using 
DFA and artificial neural network.  
 
The result of the DFA is shown in Figure 3.38 using 40 control samples and 174 
uraemic blood samples (87 samples each). As can be seen, it was impossible to obtain 
clearly separated clusters (overlapping circles, Figure 3.38). The model was validated 
by cross-validation. The data features of the withheld samples (5 control samples, 18 
uraemic samples) were inserted into the first two discriminant functions (S1, S2). The 
cross-validation revealed that it was impossible to predict the nature of eight unknown 
samples. One control samples was mistakenly classified as a post-dialysis sample. 
Among the wrongly classified uraemic samples were four post-dialysis samples and 
three pre-dialysis samples. Two post-dialysis samples were wrongly identified as 
control samples and the other two samples were thought to be pre-dialysis samples. 
All three pre-dialysis samples were mistakenly classified as post-dialysis samples 
(Figure 3.38).  
 
Based on the cross-validation, the validity of the DFA model was questioned and 
a more sophisticated classification model was used. The artificial neural network was 
trained using 60 % of the original data set (27 control samples, 58 post-dialysis 
samples, and 58 pre-dialysis samples), selected at random. The remaining 40 % (18 
control samples, 38 post-dialysis samples, and 38 pre-dialysis samples) of the data set 
was used to validate the neural network (test data).  
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The analysis of the test data revealed that the ANN was able to correctly predict 
all control samples, all pre-dialysis samples and 35 (out of 38) post-dialysis samples. 
One of the three misclassified post-dialysis samples was identified as a control 
sample, and two samples were classified as pre-dialysis samples. The result of the 
ANN validation is summarised in Table 3.4. 
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Figure 3.38: Discriminant function analysis of control blood (45 volunteers, 
squares), post – dialysis (99 samples, triangles) and pre-dialysis blood (99 samples, 
circles). The uraemic blood samples of 11 HD patients were taken at nine consecutive 
dialysis sessions. Cross-validation: open symbols (5 control samples, 18 uraemic 
samples). 
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Table 3.4: Validation results of the neural network. 
 To Control To Post To Pre  Total 
From Control 18 (19.0%) 0  0  18 (19.0%) 
From Post 1 (1.0%) 35 (37.5%) 2 (2.0%) 38 (40.5%) 
From Pre  0  0  38 (40.5%) 38 (40.5%) 
Total 19 (20.0%) 35 (37 5%) 40 (42.5%) 94 (100 %) 
 
 
 
3.3.4 COMPARISON OF TRADITIONAL BIOCHEMICAL MARKERS WITH ELECTRONIC 
NOSE DATA 
 
This study was designed to compare traditional biochemical markers with 
electronic nose data. A biochemical blood profile was obtained from 28 HD patients 
and 15 healthy volunteers. A randomly selected subset (8 controls, 11 HD patients) 
was used to perform the electronic nose analysis (volatile profile). Finally, any 
correlation between volatile profile (shift between pre- and post-dialysis samples) and  
urea reduction ratio (URR). The URR was chosen because it is one most frequently 
used parameter for assessing the haemodialysis adequacy.  
Electronic nose in renal medicine  133 
Cranfield University at Silsoe Reinhard Fend 2004 
 Biochemical Analysis 
Five biochemical parameters (urea, creatinine, carbon dioxide, phosphate, and 
calcium phosphate product) were selected for this analysis and are summarised in 
Table 3.5. 
 
 
Table 3.5: Summary of results of biochemical analysis, showing minimal (min) 
and maximum (max) concentration as well as the mean concentration of control 
blood, post- and pre-dialysis blood. 
  Control blood N=15 
Post – dialysis 
Blood 
N=28 
Pre – dialysis 
Blood 
N=28 
Min 3.61 3.0 9.6 
Max 7.37 16.6 36.1 
Urea 
[mmol L-1] Mean 4.87 7.45 21.4 
Min 63.7 183 402 
Max 100.2 659 1194 
Creatinine 
[mmol L-1] Mean 77.2 366.5 788.5 
Min 23.12 26.0 20.00 
Max 30.38 35.0 31.00 
CO2 
[mmol L-1] Mean 25.76 29.8 25.39 
Min 1.07 0.52 0.79 
Max 1.30 1.65 2.78 
Phosphate 
[mmol L-1] Mean 1.16 0.94 1.64 
Min 2.56 1.26 1.90 
Max 3.50 4.31 6.67 
Ca2+ x PO42- 
[mmol L-1] Mean 2.90 2.37 4.17 
 
 
 
As expected, small uraemic toxins such as urea and creatinine were effectively 
removed during haemodialysis. However, the post-dialysis concentrations of these 
molecules were higher than compared to healthy subjects. These results are well 
known, but it is almost impossible to present this multivariate data set in a reasonable 
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way (two- or three-dimensional space) in their raw form. Therefore, the original 
matrix was reduced in dimensionality using PCA. The results of the PCA are shown 
in Figure 3.39.  
Figure 3.39(a) demonstrates that it was possible to discriminate between post- and 
pre-dialysis blood (dashed line) by using the first two PCs (axis 1 and 2), which 
account for 83 % of the variance of the original data matrix. However, it was 
impossible to separate control blood from post-dialysis blood, but according to Table 
3.5, there is a notable difference. After introducing a third PC (vertical axis 3, Figure 
3.39b), which accounts for 14 % of variance, it was possible to distinguish between 
control blood and post-dialysis blood.  
 
The HCA revealed similar results to the PCA, as shown in Figure 3.40. From the 
original 28-dialysis patients used in this analysis, only in 3 cases (patient: 9, 15, and 
24) was it not possible to distinguish between post- and pre-dialysis blood. This is due 
to small difference between pre – and post-dialysis blood, i.e. there is just a slight 
decrease of the concentrations of the five biochemical parameters during dialysis 
treatment  (Table D.1, Appendix D). 
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Figure 3.39: Principal component analysis of Control blood (11 samples, 
squares), Post-dialysis blood (28 samples, triangles) and Pre-dialysis blood (28 
samples, circles) based on five biochemical parameters. (A) The first two principal 
components allow the discrimination between pre-dialysis blood and a mixed cluster 
containing post-dialysis blood samples and control blood samples. (B) The 
introduction of a third principal component allows the discrimination between post-
dialysis blood and control blood.  
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Figure 3.40: Cluster analysis of control blood (squares), post-dialysis blood 
(triangles) and pre-dialysis blood (circles) based on five biochemical parameters 
(p=0.05) 
95 % Confidence Interval 
Electronic nose in renal medicine  137 
Cranfield University at Silsoe Reinhard Fend 2004 
Analysis of volatile compounds in blood using an electronic nose 
As can be seen in Figure 3.41, a good separation between control blood, pre- and 
post-dialysis blood was obtained (dashed lines). The first two principal components 
(PC) account for 94 % of the variance in the original data matrix. The third PC 
accounts for just 2 % of the variance, and therefore made no significant contribution 
to the discrimination of the samples. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.41: Principal component analysis of Control blood (8 samples, squares), 
post-dialysis blood (11 samples, triangles) and pre-dialysis blood (11 samples, circles) 
after 45 min incubation at 37 ºC. Post- and pre-dialysis blood samples with the same 
number belong to the same patient.  
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Similar results were obtained when using HCA, as shown in Figure 3.42. In one 
case (patient 9), no difference between pre- and post-dialysis blood was observable. It 
can be seen that the odour of the post-dialysis sample of patient 1 (PoD1) resembled 
the odour of control blood, and the odour of the pre-dialysis sample (PD1) was similar 
to post-dialysis blood. 
 
11
10
9
8
7
6
5
4
2
3
1
11
9
10
7
8
6
4
5
3
2
1
0 5 10 15 20
distance between samples
 
Figure 3.42: Cluster Analysis of Control blood (11 samples, squares), Post- (28 
samples, triangles) and Pre-dialysis (28 samples, circles) blood after 45 min 
incubation at 37 ºC. The post- and pre-dialysis samples with the same number belong 
to the same patient (p=0.05).  
95 % Confidence Interval 
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Correlation between volatile profile and urea removal 
This experiment was aimed to examine the relationship between the urea removal 
(expressed as the difference between pre- and post-dialysis concentration) and the 
volatile shift occurring during a haemodialysis session. In mathematical terms, the 
volatile shift was expressed as the Euclidean distance between the first two principal 
components of the pre- and post-dialysis sample of the same patient (see equation 
1.7). Blood samples were obtained from 48 HD patients at two different treatment 
sessions. From all samples, the pre- and post-dialysis urea concentration was 
determined by the Department of Chemical Pathology at Gloucestershire Royal 
Hospital (Gloucester, UK). The result of this experiment is shown in Figure 3.43. As 
can be seen, the urea removal is independent of the distance between the samples. In 
other words, no correlation between urea removal and volatile shift is observable (R2 
= 0.73).   
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Figure 3.43: Correlation between Euclidean distance and urea removal. The 
Euclidean distance was calculated from the first two principal components of the pre- 
and post-dialysis samples.  
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3.8 SPECIFIC DISCUSSION 
The uraemic syndrome is attributed to the retention of a number of different 
molecules, collectively termed uraemic toxins. However, the toxicity of the syndrome 
has not been attributed to any single compound; it is most likely to be due to a 
spectrum of compounds, and indeed the list of potential candidates is complex and 
growing, and now numbers over 90 (Bergström, 1997). The categorisation of these 
retained compounds in renal failure has been largely defined by their molecular 
weight, and degree of protein binding. They comprise a) small water-soluble 
compounds, MW < 500Da, b) protein bound solutes, and c) ‘middle molecules’ MW 
>500Da. Which compounds exert a toxic effect within the body, and which 
accumulate innocently, is currently not known with certainty (Vanholder et al, 2003).  
Renal replacement therapy is inevitable for end-stage renal failure (ESRF) 
patients. The concept of dialysis dose (or adequacy) was introduced around 20 years 
ago (Canaud et al, 2000). Since the early days, urea was and still is employed as a 
surrogate marker for retained solutes and toxins, and to model the quantity of 
treatment upon its removal from the body. However, there is still a controversy among 
nephrologists, whether urea is a suitable surrogate marker molecule or not. Urea is, on 
one hand, a small molecule with a molecular weight of 60 Da and thus its removal 
from the blood stream might not reflect the behaviour of other solutes especially 
larger molecules or protein bound molecules. On the other hand, urea, as such is 
generally not a particularly toxic compound, and designing treatment strategies using 
more biologically relevant compounds would be more appropriate, however defining 
these compounds is problematic and cumbersome (Vanholder et al, 1994).  
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An alternative approach would be to gain information about a wide spectrum of 
compounds that accumulate in renal failure, and apply the knowledge of changes in 
the pattern of these compounds to devise and monitor treatment strategies. In this 
study we employed an electronic nose to provide such information.  
 
3.8.1 OPTIMISATION OF SAMPLING PARAMETER 
The aim was to find the optimal conditions under which a separation between pre- 
and post-dialysis samples is possible with a reasonable amount of blood. As 
illustrated in Figure 3.2, the initial phase of this research project involved the 
optimisation of volatile generation (sampling parameters). In other words, it was 
attempted to release enough volatiles naturally present in uraemic blood only by 
altering the incubation parameters (temperature, time and volume). This direct release 
of volatiles from samples was utilised in the past for a broad range of applications. 
For instance, Guadarrama et al (2001) applied it to identify and classify virgin olive 
oil from different regions. In contrast, for many gas chromatographic (GC) 
applications pre-column derivatisation is necessary to convert non-volatile substances 
into volatile derivates. Among the many non-volatile substances analysed by GC are 
amino acids, steroids or sugars, which are either methylated, acetylated or 
trimethylsilyliated to become volatile (Pauschmann, 1990). Chandiok et al (1997) 
treated the human vaginal tissue with 10% KOH to release amine compounds which 
were subsequently detected by an AromaScan electronic nose (today known as 
Osmetech).  
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Incubation Temperature 
Only a slight improvement in separation of clusters was observed by increasing 
the static incubation temperature (20 °C è 70 oC). An incubation temperature of 37 
°C was chosen due to two main factors. Firstly, the natural body temperature is 37 °C 
and therefore the HD circuit is operated at this temperature, and secondly a 
temperature of 70 °C caused a denaturation of the plasma proteins. Both facts mean a 
simplification of the design of an eventual on-line device. On one hand, an incubation 
temperature equal to the operating temperature means that no additional heating or 
cooling element is required. On the other hand, a denaturation of plasma proteins 
leads to a “fouling” of the flow cell containing the sensor array, which might lead to 
serious consequences such as cross-infection due to imperfect cleaning and 
sterilisation process of the on-line device.   
Roussel et al (1999) reported that the headspace temperature highly influences the 
repeatability of the measurements, whereby lower temperature (35 oC) yield better 
results compared to high temperature (> 65 °C). They also found that higher 
incubation temperatures result in a higher concentrated headspace without 
significantly improving the outcome (discrimination). Gilbert et al (1997) were able 
to distinguish 12 pure volatile solvents such as butanol and pentanone using a 
Bloodhound electronic nose after incubation of the samples at 25 °C. Gonzalez-
Martin et al (2001) used an incubation temperature of 35 °C to characterise vegetable 
oils. This group found that this temperature is sufficient to release enough information 
from the samples allowing discrimination between the different types of oil using six 
metal oxide sensors. In contrast, Guadarrama et al (2002) applied a self-made gas 
sensor array to analyse different plastic films used in the car industry. They were able 
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to discriminate between different “plastic odours” after a relatively short incubation 
period of 9 minutes at a high temperature of 80 °C.  
For the detection of microorganisms, the incubation temperature is vital since 
each microorganism has an optimal temperature for growth during which volatile 
compounds are generated and accumulated in the headspace (Schleger, 1992). Magan 
et al (2001) used an incubation temperature of 30 °C to discriminate between the 
bacterium Staphylococcus aureus and the yeast Kluyveromyces lactis in skimmed 
milk samples. Pavlou et al (2000) were able to distinguish between different Proteus 
mirabilis, Enterococcus faecalis, Escherichia coli and Heliobacter pylori after an 
incubation period of approximately 5 hours at 37 °C.  
 
Incubation time 
In this specific application, the equilibrium between liquid and gaseous phase was 
reached after 30 minutes and therefore, an increase of the incubation time from 30 to 
90 minutes did not result in a better separation of the individual clusters. The general 
rule states that the time to reach equilibrium between liquid and gas phase in a given 
sample vial depends on the ratio between liquid and gas volumes. The higher the 
liquid volume is the longer the time to reach the equilibrium (Pauschmann, 1990). 
Gardner and Bartlett (1999) suggest that a longer incubation period should lead to a 
more homogenous headspace and thus positively influences the sensor response and 
hence the reproducibility. The incubation times reported in the literature are ranging 
from a few minutes to several hours depending on the samples. Guadarrama et al 
(2002) for instance, were able to discriminate different plastic films after an 
incubation time of only nine minutes. Gonzalez-Martin et al (2001) choose a volatile 
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generation time of 7 minutes, which was sufficient to discriminate between different 
vegetable oils. In contrast, the incubation times are much longer for microbial samples 
to allow the microorganisms to develop a unique volatile “signature”.  Canhoto and 
Magan (2003) found that it was impossible to distinguish between control samples 
and Pseudomonas aeruginosa at a concentration of 102 CFU ml-1 after an incubation 
period of 24 hours, however, they were able to distinguish between the same samples 
after 48 hours of incubation. In a different report Magan et al (2001) showed that it 
was possible to discriminate Staphylococcus aureus and Kluyveromyces lactis 
suspensions incubated for two and five hours, respectively from each other 
independent of the incubation time. However, both microbial suspensions (S. aureus 
and K. lactis) “smelled” differently when the incubation time was increased from two 
to five hours indicating that increasing the incubation period leads to a different 
headspace.  
Nevertheless, an incubation period of 45 min was chosen for the analysis of 
blood/dialysate samples to ensure equilibrium between liquid phase and headspace as 
well as a well-mixed headspace.  
 
Sample Volume  
The results of these experiments showed that the sample volume did not influence 
the outcome. This is not a surprise since the only difference between the samples is 
the concentration of volatiles in the headspace. The applied conducting polymers are 
able to detect molecules in the ppm range (Gardner and Bartlett, 1999; Frank et al, 
2000). Stetter et al (2000) were investigating the detection thresholds of electronic 
noses for a range of pure volatile organic compounds (VOCs). For instance, they 
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found the threshold of ethyl acetate to be between 5 – 25 ppm, for diacetyl between 50 
– 100 x 10-3 ppm and for butyric acid less than 1 ppm using 13 metal oxide sensors 
(Fox 3000, Alpha MOS).  Therefore, the chosen sample volume of 0.5 ml should 
generate enough volatiles to cause a notable sensor response and hence, allow 
discrimination between the samples. Doleman and Lewis (2001) performed similar 
experiments to Stetter but using conducting polymers. They found that the detection 
thresholds for VOCs such as pentanol, butanol, heptane and hexane are less than 10 
ppm.  
 
Blood Dilution 
Blood is the limiting factor in this study, therefore reducing the required amount 
of blood is a major aim. It was possible to discriminate between the different 
concentrated blood samples up to a dilution of 1:4. It was impossible to distinguish 
between a 0.9 % saline solution and 1:10 diluted blood samples. The applied 
conducting polymers are sensitive enough to be able to distinguish between pre- and 
post-dialysis blood at a dilution of 1:4. In other words, the headspace concentration at 
this particular dilution (1:4) was high enough to generate a notable sensor response.   
Frank et al (2000) reported, that the higher the headspace concentration is the 
smaller is the deviation of data points within a cluster. This statement is based on the 
analysis of organic solvents such as toluene, octane, and propanol in concentrations 
between 1 and 100 ppm. The minimum concentration at which a clear discrimination 
was still possible was 10 ppm. Our findings presented in this report are in agreement 
with the findings of Frank et al (2000). As shown in Figure 3.21, undiluted blood 
samples were narrower clustered than the diluted blood samples with the highest 
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dilution showing the highest intra-sample variability. Therefore, a 1:4 dilution was 
considered as a good compromise to reduce the blood consumption, as it was possible 
to discriminate between control blood and a blank sodium chloride solution. The 
analysis of 1:4 diluted pre- and post-dialysis blood samples revealed that sufficient 
information could be extracted from the samples to distinguished between them 
(Figures 3.23 and 3.25). 
 
3.8.2 VALIDATION AND EVALUATION OF ELECTRONIC NOSE 
The validation and evaluation of the electronic nose involved the analysis of 
“uraemic” blood samples under optimised conditions as well as the study of the 
reproducibility of the sensor array.  
 
Reproducibility of sensor response  
As shown in Figure 3.27, the individual sensors showed a small variation between 
different days except sensors 11 and 14, which showed a significant difference.  In 
general, electronic nose sensors are characterised by a high sensor drift (Gardner and 
Bartlett, 1999). Sensor 11 had with about 60 % the biggest variation. Sensor drift is 
generally caused by environmental factors such as humidity or temperature or through 
contaminations (Gardner and Bartlett, 1999; Persaud and Travers, 1997). 
Environmental factors can probably be excluded as a reason for the observed sensor 
drift due to the air-conditioning of the laboratory. Contamination drift in conducting 
polymers is primarily caused by strong acids (Gardner and Bartlett, 1999). Our 
findings are in agreement with Gibson et al (1997), who also used a Bloodhound 
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BH114 instrument. This group analysed different bacterial specimens and discovered 
the existence of consistent patterns, characteristic for each microbial species without 
the presence of a significant sensor drift. Vanneste (1997) observed that conducting 
polymers were sensitive to water vapour. In addition, they reported a slow, but 
significant increase of the sensors' resistance with time (drift) generated by a slow 
dedoping of the sensor material. Although no significant drift was observed in this 
work, all sensors showed small differences from day to day (5 – 15 %), even though 
extreme care was taken to reproduce all experimental conditions completely. 
Nevertheless, sensor 11 and 14 were not considered in further experiments due to 
their high variability (Figure 3.27).  
 
Analysis of control blood and “uraemic blood” under optimised conditions 
The results of our studies show that by EN analysis, blood samples of 
haemodialysis patients can be reliably distinguished from those of normal control 
subjects (Figures 3.28). A slight overlap between pre- and post-dialysis samples was 
observed when different dialysis sessions were considered, as illustrated in Figure 
3.38. The reasons for this overlap are not entirely clear. It could be caused by day-to-
day variation of the sensors (drift), which is, however, not very likely (compare 
Figure 3.27). There is a huge variability within individual patients (Table 3.5), which 
might influence the data analysis. In contrast, the day-today variation within a patient 
is minimal (stable HD patients). Nevertheless, it was still possible to distinguish 
between the majority of pre- and post-dialysis samples (Table 3.4) when a more 
sophisticated data analysis method was applied. Artificial neural networks are able to 
cope with non-linear relationships between samples. During the dialysis procedure 
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there is a shift in the profile towards that of the control sample profile, and the similar 
phenomenon is detectable in dialysate samples (Figures 3.33, 3.34, 3.35, and 3.36). 
The conducting polymers used in the EN are very sensitive (0.1 - 5 ppm) and there is 
a linear relationship between sensor response and concentration (Schiffman et al, 
1997). Through our data pre-processing (normalisation), the concentration impact on 
the sensor response was only removed within a particular sample group but not 
between different groups (time points). This was necessary due to the variability 
between individual patients. Consequently, each sample is described by numerous 
volatiles present at the time rather than a single highly concentrated compound.  The 
alteration in the blood profiles in the direction of the control suggests that the changes 
measured are due to substances being removed from the blood during dialysis. The 
dialysate profile differs most from control dialysate at the start of dialysis, and the 
profile changes towards the control sample with time, which corresponds to a higher 
dialysate concentration of reacting compounds at the start of dialysis compared to the 
end. This would correspond to the higher removal of substances from the blood at the 
start of dialysis, and lower concentrations towards the end. This approach would 
accommodate the current thoughts about the dialysis procedure. 
 
Like the human olfactory system, the EN responds to volatile compounds. The 
volatility of molecules is influenced by many parameters including concentration, 
equilibration temperature, equilibration time, and viscosity of the sample (Seto, 1994). 
Volatile substances are generally characterised by a small molecular weight (MW < 
500 Da) and their polarity (Gardner and Bartlett, 1999). At this level of the research 
project, it is unknown which molecules in the blood/dialysate samples are responsible 
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for the sensor response. Chronic renal failure is characterised by the accumulation of 
waste products and excessive body fluids. These metabolic waste products as well as 
body fluids are normally excreted in urine. Therefore, “uraemic” blood contains 
numerous compounds, some of them are volatile others are not. In the past, many 
groups tried to identify “uraemic” molecules, which are generally divided into three 
groups: small, middle and large molecules (Levy et al, 2001). Volatile compounds are 
generally small and polar (Gardner and Bartlett, 1999). In the past, several research 
groups identified these molecules using mainly gas chromatography and gas 
chromatography – mass spectroscopy. The range of molecules retained in uraemia is 
broad including free organic acids, phenolic compounds, aliphatic amines, alcohols, 
aldehydes, ketones and guanidines  (Liebich and Woell, 1977; Niwa et al, 1981; Baba 
et al, 1984; Liebich et al, 1984). All of them are present in elevated concentrations in 
CRF patients. Bowen et al (1975) investigated benzyl alcohol present in blood of CRF 
patients. They found elevated values of benzyl alcohol in dialysis patients before the 
session and lower levels after the treatment. Benzyl alcohol was not found in normal 
controls. Baba et al (1984) analysed serum aliphatic amines using HPLC. They found 
a six-fold increase of methylamine and dimethylamine in uraemic serum compared to 
normal control subjects.  The degree of removal of these compounds is smaller than 
for urea and creatinine and is approximately 55% (Baba et al, 1984; Lichtenberger et 
al, 1993). The same group found similar concentration of the volatile ethanolamine in 
pre-dialysis serum and control serum, but a two-fold increased level in post-dialysis 
samples (Baba et al, 1984).  Other investigators found volatiles such as 
methylmercaptan (Dowty et al, 1975), acetone, 2-butanone, chloroform, benzene, 
toluene, pyridine, dipropylketone, cycloheaxanone, and 4-heptanone in uraemic blood 
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(Liebich and Woell, 1977). All these substances are characterised by a relatively small 
molecular weight (MW < 500) and are retained in CRF patients. However, due to 
their low molecular weight they are most likely to be effectively removed during a 
haemodialysis session, leading to a decreased concentration in post-dialysis samples.  
In addition to substances being removed from the blood by dialysis, which will 
appear in the dialysate, compounds are also generated during dialysis procedure due 
to increased oxidative stress (Tetta et al, 1999; Erdogan et al, 2002). The increased 
oxidative stress in HD patients is caused by the bioincompatibility of the 
haemodialysis membrane and the imbalance between oxidant production and anti-
oxidant activity. It is reported, that haemodialysis membranes can induce the 
production of free radical, in particular oxygen radicals, as a result of neutrophil or 
monocytes activation (Ceballos-Piot et al, 1996; Nourooz-Zadeh, 1999; Hegebrant 
and Hultkvist-Bengtsson, 1999; Srinivasa et al, 2001). Reactive free radicals can 
induce lipid peroxidation, a chain reaction in which one radical can cause the 
oxidation of a comparatively large number of substrate molecules (polyunsaturated 
fatty acids) (Abuja and Albertini, 2001). The end products of lipid peroxidation are 
aldehydes (malonaldehyde, propanal), ketones (acetone) and small carbohydrates 
(ethane, pentane) (Hageman et al, 1992; Capodicasa et al, 1999). One example of this 
is the volatile compound isoprene, which has been detected in the breath of dialysis 
patients following dialysis (Lirk et al, 2003). Isoprene is a highly lipophilic compound 
that is dialysed minimally, and it is unlikely that it is responsible for any of the 
changes that we have seen in the profile of the dialysate. But, as we are observing 
changes in the pattern of sensor response, we cannot exclude the possibility that 
compounds may appear and disappear during dialysis, and contribute to the pattern of 
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response that we see in the blood samples. In addition, the currently used marker 
substances urea and creatinine are not contributing to the sensor response as 
illustrated in Figures 3.30 and 3.31. There was no observable difference between 
unspiked and spiked samples leading to the conclusion that urea and creatinine are not 
volatile under the conditions used in this work. 
 
3.8.3 ELECTRONIC NOSE VS TRADITIONAL BIOCHEMICAL MARKERS 
This experiment has shown that by application of multivariate methods combined 
with traditional biochemistry (Figures 3.39 and Figure 3.40) and modern electronic 
nose technology (Figure 3.41 and 3.42), respectively, it was possible to discriminate 
“uraemic” blood from control blood. However, more important is the possibility to 
distinguish between pre- and post-dialysis blood. It has to be mentioned, that PCA as 
well as HCA are exploratory data analysis techniques, whose main goal is to visualise 
the original data matrix, i.e. they are not classification methods. The application of 
these methods to traditional biochemical data (Figures 3.39 and 3.40), demonstrated 
the efficacy of these tools, even when the outcome was not “blinded”. 
 
As mentioned previously, urea is currently the most frequently applied surrogate 
marker for assessing the haemodialysis adequacy, whereas creatinine can also be used 
to assess the nutritional status of HD patients. It is well known that the prescribed 
dialysis dose differs from the actually delivered dialysis dose (Manzoni et al, 1996; 
Keshaviah, 2002). Therefore, it is necessary to quantify the delivered dialysis dose 
because the adequacy of the dose has a profound effect on patient morbidity and 
mortality (Manzoni et al, 1996; Shak, 1999). For the quantification of the dialysis 
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dose two parameters are most commonly used, namely the urea reduction ratio (URR) 
and the normalised dose of dialysis (Kt/V) (Lowrie, 2000; Lindsay and Sternby, 
2001). Both parameters are based on urea. The URR is calculated from the pre-
dialysis and post-dialysis blood urea nitrogen value, whereas the Kt/V value is derived 
from urea kinetic modelling (Kemp et al, 2001; Levy et al, 2001). In the past several 
studies showed that an increased Kt/V index leads to a reduced morbidity and 
mortality risk in HD patients. Held et al (1996) analysed 7,096 patients and saw an 
average 7 % decrease in mortality for every increase in Kt/V of 0.1 up to a value of 
1.3. Similar results were reported by Parker et al (1994) who found a lower mortality 
when the Kt/V index was increased from 1.2 to 1.4. However, there is a controversial 
discussion about whether these parameters are appropriate or not (Lowrie, 2000; 
Vanholder et al, 2002). It has been shown that oversimplification of the “dialysis 
dose” to the Kt/V index might lead to dramatic underdialysis (Canaud et al, 2000). Le 
Febvre et al (1991) showed that the Kt/V value delivered was less than the prescribed 
value by around 5 % in approximately 60 % of dialysis treatment. In addition, the 
Kt/V value assesses only the removal of small water-soluble compounds from the 
body (Vanholder et al, 2002). Hence, the molecular size of urea means that 
convective and/or diffusive transport of larger molecules is unlikely to be described 
by urea kinetics (Vanholder et al, 2002; Lowrie, 2000).  Both values (Kt/V and URR) 
assume a dialysis frequency of three times per week. However, recently published 
data suggest that 5 % of all American patients skip a dialysis session in any month 
(De Palma and Pittard, 2001). Other pitfalls in using the URR or Kt/V value come 
from the incorrect post-dialysis blood sampling such as urea-rebound effect, sample 
dilution with dialysis fluid or blood recirculation. (De Palma and Pittard, 2001). 
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However, careful post-dialysis blood sampling minimises the influence of these 
problems (Levy et al, 2001).  
 
In contrast, the electronic nose detects numerous compounds simultaneously. 
Among the possible candidates (see previous section) are the volatiles p-cresol, 
phenols, reactive carbonyl compounds and benzylalcohol that have also been found 
and implicated as uraemic toxins, and potentially these compounds are being detected 
by the EN. As illustrated in Figure 3.43 the electronic nose pattern (or signature) does 
not reflect the traditional way of assessing the treatment adequacy. In other words, no 
correlation between volatile shift (as shown for instance in Figures 3.28 or 3.33) and 
urea reduction ratio could be established. On one hand, urea itself does not contribute 
to the sensor response (Figures 3.30 and 3.31). On the other, it was possible to follow 
the volatile shift occurring during a single HD session as illustrated in Figures 3.33 
and 3.35. Although not analysed by GC-MS, the EN pattern of response is likely to be 
to many compounds rather than one, and importantly the toxicity of uraemia similarly 
will be to many compounds rather than just one. Currently definition of the response 
in terms of identifying the compounds has not been performed, and this of course 
could produce a much more detailed picture. However, an equally valid approach is to 
define the profile of blood or dialysate, which is associated with better clinical 
outcomes. This approach has the advantage that it produces a pattern of information 
about the concentrations of compounds, but also information regarding concentrations 
relative to other detected compounds. The measurement of one potential toxin without 
regards for other compounds, or their potential interactions in the uraemic milieu, may 
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produce a false impression and the overall pattern or balance between substances may 
be more important.  
 
In the past only a few applications have been described in the literature where 
electronic noses have been used for renal diseases. Among these is the work of Lin et 
al (2001), who applied an electronic nose for the diagnosis of uraemia. This group 
found marker substances in the breath of chronic renal failure patients such as di- and 
trimethylamine, which allowed the differentiation between healthy controls and 
uraemic patients. They concluded that the electronic nose is a potential tool for 
diagnosis of uraemia, however, they did not utilise these finding to develop an on-line 
monitoring system based on breath analysis. Di Natale et al (1999) were able to detect 
traces of blood in urine. However, they could not give an explanation which volatiles 
are responsible for the sensor response. Interestingly, they found a qualitative 
correlation between the first principal component and the amount of blood present in 
urine.  
 
The presented method is not fully optimised yet. The electronic nose, however, 
was reliably able to distinguish blood samples of HD patients from those of normal 
control subjects. During the dialysis procedure a profile shift towards the control 
profile was observed. A similar phenomenon is detectable in dialysate samples. The 
sensors showed good reproducibility apart from sensor 11 and 14. It offers the 
possibility to monitor potential uraemic toxins as an automated, on-line system and 
hence improve the quality/efficacy of haemodialysis. 
  
 
 
 
Chapter 4 
Electronic nose for the early detection of 
pulmonary tuberculosis 
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4.1 INTRODUCTION  
 In 1993, the World Health Organisation (WHO) declared tuberculosis (TB) a 
global emergency. It is estimated that over 1/3rd of the world’s population is infected 
with Mycobacterium tuberculosis. An estimated 8 – 9 million new cases occur each 
year with over 2 million deaths (Dolin et al, 1994; Frieden et al, 2003). The majority 
of cases occur in sub-Saharan Africa, South and Southeast Asia, Latin America and 
the Caribbean (Raviglione et al, 1992; Raviglione et al, 1995; Shafer and Edlin, 
1996). The recent increase in the global TB burden is related to the continuous 
increase in HIV infections (Frieden et al, 2003). The early diagnosis of TB followed 
by appropriate treatment can dramatically reduce the mortality. Currently, TB is 
diagnosed by chest X-ray, staining of mycobacteria in sputum (Ziehl-Neelsen), and 
culture. These methods are not satisfactory. Chest X-ray is not specific enough. A 
suspected chest X-ray can be caused by other lung diseases and previous TB. 
Microscopy can detect mycobacteria in sputum but species identification is 
impossible and it lacks sensitivity (Perkins, 2000). Culture and identification of the 
isolated mycobacteria is the gold standard. However, this can take up to 4 – 8 weeks 
to get a final result (Perkins, 2000). Nevertheless, the WHO and the International 
Union against Tuberculosis and Lung Disease (IUTALD) recommend the Ziehl-
Neelsen staining for new case findings (Perkins, 2000; Frieden et al, 2003). The 
staining of a sputum smear sample (followed by microscopic examination is an 
inexpensive method and is very specific in high prevalence environments. The 
shortcomings of ZN microscopy such as its low sensitivity, especially in HIV positive 
patients, the operator dependency and preparation time limit the quality of this 
diagnostic tool in high burden countries (Perkins, 2000; Cleeff et al, 2003). In the 
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past, new research was undertaken to develop new diagnostic tests fulfilling the 
requirements set by the WHO. These include: high sensitivity and selectivity, 
inexpensiveness, robustness and simplicity (WHO report, 1997). The main focus was 
direct towards antibody/antigen detection assays or nucleic acid amplification 
reactions (Frieden et al, 2003). Against this background, we investigated the 
possibility of an electronic nose as an early detection system for M. tuberculosis in 
both culture and sputum samples.  
 
4.2 SPECIFIC MATERIAL AND METHODS 
4.2.1 BACTERIA ISOLATES , SPUTUM AND CLINICAL SPECIMENS 
Bacteria isolates 
All Mycobacterium spp (Mycobacterium tuberculosis, RIVM myc 4514; 
Mycobacterium avium, RIVM myc 3875; Mycobacterium scrofulaceum, RIVM myc 
3442) were obtained from the National Institute of Public Health and the Environment 
(RIVM) (Bilthoven, NL). Pseudomonas aeruginosa (AMC 23123) was isolated at the 
Academic Medical Centre (AMC, Amsterdam, NL). 
 
Sputum samples 
Sputum samples (1 ml) were collected from non-TB patients attending the chest 
unit of the AMC. A sputum pool (N=25) was prepared by thoroughly mixing 
individual sputum samples for 12 hours at 4 °C. The sputum pool was stored at - 70°C 
until the analysis was performed. 
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Clinical Specimens 
337 sputum samples were obtained from patients attending The Yeta District 
Hospital in Sesheke, Zambia (87), South Africa (200) (through the WHO Specimen 
Bank) and the AMC.  All patients were examined by ZN staining, liquid culture and 
chest X-ray examination. Culture was used as the “gold standard” in this study for 
tuberculosis. Furthermore, from all patients the HIV status and their smoking habits 
were investigated (Table 4.1). Seven TB negative patients had confirmed pneumonia. 
The collected sputum samples were stored at -70°C until the analysis was performed. 
 
Table 4.1: Details of clinical samples showing the median age with interquartile 
range, TB status (culture), HIV status and smoking habits. The total number is given 
in parenthesis.  
 Median age 
(1st, 3rd quartile) 
TB+ (N) HIV and TB+  
(Total HIV+) 
Smokers and TB + 
(Total smokers) 
Male 36 (29 – 47.5) 126 (210) 63 (83) 55 (68) 
Female 36 (31 – 46) 62 (120) 38 (60) 4 (4) 
Total 36 (29 – 47) 188 (330) 101 (143) 59 (72) 
 
 
4.2.2 SAMPLE PREPARATION 
Preparation of culture samples 
All bacteria isolates were cultured in Middlebrook 7H9 medium with OADC 
enrichment. The bacteria were incubated at 37 °C until an optical density (420 nm) of 
0.15 (» 1 x 108 bacteria ml-1) was reached. Subsequently, the liquid culture was cooled 
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to 4 °C and allowed to equilibrate for at least 20 minutes to minimise the loss of 
volatiles during the transfer into smaller headspace vials. 2 ml of the “cold” culture 
was transferred into a 5 ml headspace vial (Macherey and Nagel, UK) and 
immediately sealed with a silicon/teflon crimp cap (Jaytee Bioscience Ltd., UK). The 
headspace was allowed to equilibrate for 45 minutes at 37 °C.  
Dead bacteria were obtained by heating the M. tuberculosis suspension for 30 
minutes at 60 °C. No growth was obtained after inoculation of 108 bacteria ml-1 in 
Middlebrook 7H9 or Loewenstein-Jensen medium.  
 
Preparation of spiked sputum samples 
The sputum pool (N=25) was spiked with various numbers of different bacteria 
isolates including M. tuberculosis, M. avium and P. aeruginosa as well as a mixture 
of M. tuberculosis and P. aeruginosa, which served as a mixed infection sample 
(50:50). All bacteria were cultivated in Middlebrook 7H9 (+OADC). The sputum 
samples were spiked as follows: 1 x 108 mycobacteria ml-1, 1 x 107 mycobacteria ml-1, 
1 x 105 mycobacteria ml-1 and 1 x 104 mycobacteria ml-1. 1 ml of sputum and 1 ml of 
the “cold and equilibrated” culture were transferred into a 5 ml headspace vial 
(Macherey and Nagel, UK) and subsequently sealed with a silicon/teflon crimp cap 
(Jaytee Bioscience Ltd, UK). The headspace was allowed to equilibrate for 120 
minutes at 37 °C. As control samples served unspiked sputum and control medium 
(Middlebrook 7H9 + OADC).  
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Clinical sputum samples 
The frozen sputum samples were defrosted on ice to minimise the loss of volatiles. 
An aliquot of 0.5 ml of “well-mixed” sputum was transferred into a sterile 5 ml 
headspace vial (Macherey and Nagel, UK) and mixed with 0.5 ml of a 1 M NaCl 
solution (4 °C) and subsequently sealed with a crimp cap with Silicon/Teflon septum 
(Jaytee Bioscience Ltd, UK).  
Positive control samples (spiked sputum) were prepared by mixing 0.5 ml of the 
sputum pool with 0.5 ml of a Mycobacterium tuberculosis suspension (2 x 108 
bacteria ml-1). Negative control samples were prepared by mixing 0.5 ml of the 
sputum pool with 0.5 ml of a 1 M NaCl solution (4 °C). All samples were incubated at 
37 °C for 330 minutes prior to the headspace analysis. 
The protocol for clinical sputum samples was slightly modified compared to 
protocol for spiked sputum samples. This was necessary due to the small sample 
volume (< 1ml) obtained from the WHO specimen bank.  
 
4.2.3 HEADSPACE ANALYSIS  
The incubated sample vials were connected to the electronic nose by inserting a 
needle into the headspace of the sample (see chapter 2). The sampling profiles used in 
this study are summarised in Table 4.2. The adsorption and desorption time was 
increased for the analysis of sputum samples compared to the profile used for liquid 
culture samples. This was necessary due to the higher complexity, variability and 
heterogeneity of sputum. 
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Table 4.2: Sampling profiles used for the analysis of liquid culture and sputum 
samples (Pavlou et al, 2004). 
 
 Samples 
 Liquid  Sputum 
Time delay (s) 5 5 
Adsorption time (s) 6 7 
Desorption time (s) 14 21 
Baseline length (s) 5 5 
Hold time (s) 0 0 
 
 
4.2.4 DATA ANALYSIS  
The original data sets were pre-processed by normalising the sensor response to 
vector length one. Principal component analysis and discriminant function analysis 
were used for liquid culture samples and spiked sputum samples. For the 
determination of the detection limit, the sensor response was not normalised.  
For clinical specimens, principal component analysis and an artificial neural 
network (ANN) were applied.  The ANN was trained using 70 % of the original 
samples (Table 4.3). In this study, a backpropagation network with a sigmoid transfer 
function was applied. The performance of the ANN was evaluated using the test set 
(Table 4.4). The training and evaluation of the artificial neural network was based on 
the clinical samples, i.e. no “artificial” samples were involved (pos. and neg. 
controls). Due to the small sample size pneumonia cases in the original sample set, 
they were excluded from the ANN analysis.  
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Table 4.3: Details of patients used to train the neural network (training set). 
 
Median age 
(1st, 3rd quartile) 
TB+ (N) 
HIV and TB+  
(Total HIV+) 
Smokers and TB + 
(Total smokers) 
Male 37 (29 – 48) 86 (126) 49 (64) 41 (51) 
Female 36 (29 – 47) 47 (70) 29 (43) 2 (2) 
Total 36.5 (29 – 47.5) 133 (196) 78 (107) 43 (53) 
 
 
Table 4.4: Details of patients used to validate the neural network (test set). 
 
Median age 
(1st, 3rd quartile) 
TB+ (N) 
HIV and TB+  
(Total HIV+) 
Smokers and TB + 
(Total smokers) 
Male 34.5 (32 – 50) 40 (84) 14 (19) 14 (17) 
Female 36 (33 – 42) 15 (50) 9 (17) 2 (2) 
Total 36 (32 – 45) 55 (134) 23 (36) 16 (19) 
 
 
4.3 RESULTS 
4.3.1 ANALYSIS OF LIQUID CULTURE SAMPLES 
Analysis of Mycobacterium spp. and Pseudomonas aeruginosa 
The “smell” of three Mycobacterium spp. cultures (M tuberculosis, M. avium, M. 
scrofulaceum) and one Pseudomonas aeruginosa culture were analysed and compared 
to the “odour” of blank medium. The EN raw data were analysed by PCA followed by 
DFA. The PCA plot (Figure 4.1) illustrates that it is possible to distinguish between 
the different bacteria isolates in vitro.  
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Figure 4.1: Principal component analysis showing the distinguished clusters of 
liquid cultures of M. tuberculosis (triangles, 12 samples), M. avium (crosses, 12 
samples), M. scrofulaceum (diamonds, 12 samples) and P. aeruginosa (circles, 12 
samples) and blank medium (squares, 12 samples).  
 
 
The DFA model was built on the first four principal components. Figure 4.2 
shows the result of the DFA analysis. It was possible to distinguish between the 
different bacteria classes using the first two discriminant functions (S1, S2). The three 
different Mycobacterium spp. were grouped closely together, but still allowing 
discrimination (Figure 4.2). The DFA model was validated by the analysis of 15 
“unknown” samples. All unknown samples were correctly classified as either one of 
the three Mycobacterium spp., P. aeruginosa or blank medium.  
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Figure 4.2: Discriminant function analysis of liquid cultures of M. tuberculosis 
(triangles, 12 samples), M. avium (green squares, 12 samples), M. scrofulaceum 
(diamonds, 12 samples) and P. aeruginosa (circles, 12 samples) and blank medium 
(red squares, 12 samples). Cross-validation: 15 samples (three from each group) were 
withheld from building the DFA model but subsequently assigned correctly once the 
model was built (open symbols). 
 
Determination of the detection limit for M. tuberculosis 
The detection limit of the electronic nose for M. tuberculosis was determined in 
culture. Six different concentrated M. tuberculosis suspensions (1 x 103 mycobacteria 
ml-1 – 1 x 108 mycobacteria ml-1) were analysed and compared to blank medium. The 
EN raw data were analysed by PCA followed by DFA.  
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The result of the PCA analysis is shown in Figure 4.3. As can be seen, samples 
with a concentration equal or higher than 1x104 mycobacteria ml-1 can be 
distinguished from blank medium. Samples with a concentration of 1x103 
mycobacteria ml-1 formed one cluster with blank medium. This indicates that the 
detection limit is 1 x 104 mycobacteria ml-1 as indicated by the dashed line in Figure 
4.3. It is also observable that samples with the same concentration form a separate 
cluster and that different clusters can be discriminated from each other.  
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Figure 4.3: PCA plot showing the distinguished clusters of liquid cultures of 
different concentrated M. tuberculosis suspensions. The dashed line indicates the 
detection limit. 
Key: Blank medium (brown squares), 1x103 mycobacteria ml-1 (blue circle, green 
background), 1x104 mycobacteria ml-1 (red diamonds, orange background), 1x105 
mycobacteria ml-1 (blue triangles), 1x106 mycobacteria ml-1 (orange diamonds), 1x107 
mycobacteria ml-1 (light blue squares), 1x108 mycobacteria ml-1 (purple circles) 
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Based on PCA analysis, a classification model was built. The result of the DFA 
analysis is shown in Figure 4.4. The DFA model was validated by the analysis of 12 
“unknown” samples. Two out of 12 unknown samples were incorrectly classified as 
blank medium (Figure 4.4). Both incorrectly classified samples belonged to the group 
containing 1 x 103 mycobacteria ml –1.  All other unknown samples were correctly 
identified. Therefore the detection limit was determined to be as low as 1 x 104 
mycobacteria ml-1 (Figure 4.4). 
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Figure 4.4: Discriminant function analysis showing the different concentration of 
M. tuberculosis in culture. Six different concentrations ranging from 1 x 103 to 1 x 108 
mycobacteria ml-1 were analysed (seven samples for each concentration and seven 
blanks). Cross-validation: 14 samples (two samples from each group) were withheld 
from building the DFA model.  Samples containing more than 1 x 104 mycobacteria 
ml-1 were correctly assigned (open symbols). In contrast, blank medium and samples 
containing 1 x 103 mycobacteria ml-1 could not be distinguish from each other.  
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Determination of the influence of “dead” bacteria on the sensor response 
The main problem in real samples is the unknown proportion of dead M. 
tuberculosis bacteria. Therefore, we investigated the influence of dead bacteria on the 
sensor response to find out, if dead bacteria cause a sufficient sensor response 
allowing discrimination from blank medium. The result of this analysis is shown in 
Figure 4.5. As can be seen, there is an observable difference in smell of blank 
medium, dead bacteria, living bacteria and a mixture of dead and living bacteria. 
There is a slight overlap between the cluster containing the mixture samples and the 
cluster containing the “living” bacteria (Figure 4.5). The difference between living 
and mixed samples is not as distinct as between dead and living samples.  
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Figure 4.5 Principal component analysis showing the distinguished clusters of a 
living M. tuberculosis suspension (14 samples, circles), a dead M. tuberculosis 
suspensions (14 samples, triangles), and a mixture of it (14 samples, diamonds) 
compared to blank medium (14 samples, squares).  
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A classification model was built on 48 samples (12 of each). The result of the 
DFA analysis is shown in Figure 4.6. This shows that it was possible to discriminate 
between the four different types of samples. The DFA model was validated by 
analysis of 12 “unknown” samples. 11 unknown samples were correctly classified as 
blank medium, “dead” sample, and “living” sample or as mixture. One  “mixture” 
sample was mistakenly classified as a living sample (Figure 4.6). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6: Discriminant function analysis of a living M. tuberculosis suspension 
(circles, 15 samples), a dead M. tuberculosis suspension (triangles, 15 samples) and a 
mixture of it (diamonds, 15 samples) compared to blank medium (squares, 15 
samples). Cross-validation: 12 samples (three of each group) (open symbols). 
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4.3.2 ANALYSIS OF SPIKED SPUTUM SAMPLES 
Analysis of Mycobacterium spp. and Pseudomonas aeruginosa 
The collected sputum samples were pooled and spiked with M. tuberculosis, M. 
avium, P. aeruginosa and a mixture of M. tuberculosis and P. aeruginosa. All 
samples were spiked to obtain a final concentration of 1 x 108 bacteria ml-1. The 
normalised raw data were analysed by PCA followed by DFA. It was possible to 
distinguish between “unspiked” sputum and “spiked” sputum samples. Within the 
“spiked” sputum samples, a difference in smell was observable for the different 
bacteria classes (Figure 4.7).  
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Figure 4.7: Principal component analysis showing the distinguished clusters of 
sputum samples spiked with M. tuberculosis (triangles, 12 samples), M. avium (green 
squares, 12 samples), P. aeruginosa (circles, 12 samples), and a mixture of M. 
tuberculosis and P. aeruginosa (diamonds, 12 samples) and blank medium (red 
squares, 12 samples). 
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Based on the PCA, a classification model was built using 50 samples (10 of each 
class). The result of the DFA is shown in Figure 4.8. The model was validated by the 
analysis of 10 unknown samples. All unknown samples were correctly identified as 
unspiked sputum or spiked sputum. Within the spiked sputum samples all unknown 
samples were correctly assigned to one of the four “sub-clusters” representing the 
different bacteria classes (Figure 4.8). 
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Figure 4.8: DFA analysis of sputum samples spiked with M. tuberculosis 
(triangles, 12 samples), M. avium (green squares, 12 samples), P. aeruginosa (circles, 
12 samples), mixed infection (diamonds, 12 samples) and blank sputum (squares, 12 
samples). Cross-validation: 10 samples (two from each group) were withheld from 
building the DFA model but subsequently assigned correctly once the model was built 
(open symbols).  
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Determination of the detection limit for M. tuberculosis 
The detection limit of M. tuberculosis in spiked sputum samples was determined. 
This was done, since sputum is the usual source of diagnosis TB in high-burden 
countries. A sputum pool was divided into two parts. One part was spiked with a M. 
tuberculosis suspension containing 1 x 104 mycobacteria ml-1 (compare Figures 4.3 
and 4.4), the other part was used as control sputum. The EN raw data were analysed 
by PCA followed by DFA.  
The result of the principal component analysis is shown in Figure 4.9. This 
demonstrates the ability of the EN to discriminate spiked sputum (1 x 104 
mycobacteria ml-1) from control sputum and control medium (Middlebrook 7H9).  
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Figure 4.9: Principal component analysis showing the separate clusters of spiked 
sputum (20 samples, triangles), control sputum (20 samples, diamonds) and control 
medium (20 samples, squares). The sputum was spiked with 1 x 104 mycobacteria ml-1.  
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The DFA classification model was build using 48 samples. Figure 4.10 shows that it 
was possible to distinguish between spiked, unspiked samples and control medium. The 
DFA model was validated by the analysis of 12 “unknown” samples. All “unknown” 
samples (open symbols) were correctly classified (Figure 4.10). The variability within 
the unspiked samples is higher than within the spiked samples.  
 
  
 
 
 
 
 
 
 
Figure 4.10: Discriminant function analysis showing the separate clusters of 
spiked sputum (triangles), control sputum (diamonds) and control medium (squares). 
The sputum was spiked with 1 x 104 mycobacteria ml-1. Cross-validation: 12 samples 
(four samples of each group) were withheld from building the DFA model but 
subsequently assigned correctly once the model was built (open symbols).  
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4.3.3 ANALYSIS OF CLINICAL SPECIMENS 
The PCA analysis of 50 positive control samples (spiked sputum), 50 negative 
control samples (non-TB sputum) and 280 clinical samples (see Table 1 for details) is 
shown in Figure 4.11. It was possible to obtain a good discrimination between 
negative control samples and positive control samples. It is, however, much more 
important to achieve this separation with real samples. As shown in Figure 4.11, TB 
negative samples can be found on the left hand side, whereas TB positive samples are 
on the right hand side. Nevertheless, no clear separation could be obtained as 
indicated by the overlapping circles in Figure 4.11. In both groups (TB positive and 
TB negative), a sub-cluster could be identified. These sub-clusters contained the 
samples of smoking patients. However, not all smokers were present in this sub-
cluster (89 % present). Patients suffering from pneumonia formed a separate cluster 
(Figure 4.11). 
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Figure 4.11: Principal component analysis showing the analysis of negative 
control samples (50 samples, red diamonds), positive control samples (50 samples, 
violet triangles), pneumonia samples (7 samples, green squares) and clinical samples 
(92 TB negatives samples, open red squares; 188 TB positive samples, squares with 
grey background).  
 
 
After training the neural network with 70 % of the original samples, the 
remaining 30 % (84 samples) were used to validate the model. Among the 84 samples 
were 55 culture confirmed TB samples, of which 51 were ZN positive and 4 ZN 
negative. The result of the artificial neural network (ANN) is summarised in Table 
4.5.  
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Table 4.5: Performance of the electronic nose – neural network system in comparison 
to culture.  
 
 Culture  
confirmed TB  
Culture 
TB negative 
Total 
EN positive 49 7 56 
EN negative 6 72 78 
Total 55 79 134 
 
 
 
The neural network was able to predict 49 TB positive patients out of 55 correctly. 
Six TB positive suspects gave a false negative result. Among these six false negatives 
were four ZN negative and 2 ZN positive patients. All six false negatives were culture 
positive. Three of the four ZN negative false negatives were HIV positive and one 
was a smoker. Among the ZN positive false negatives were one HIV positive patients, 
who was also a smoker.  
The neural network was also able to predict 72 TB negative suspects correctly. 
Seven TB negative patients gave a false positive result. One false positive was HIV 
positive and a smoker.  
The sensitivity for the detection of culture proven TB was 89% (95% confidence 
interval [95%CI] 80-97%), the specificity was 91% (95%CI 85-97%) and the positive 
and negative predictive values were 88 % (95%CI 78-96) and 92% (95%CI 86-98), 
respectively.  
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4.4 SPECIFIC DISCUSSION 
At present global tuberculosis (TB) control programs depend on the early 
detection of new cases followed by adequate treatment. However, current laboratory 
methods do not fully fulfil the requirements published by the WHO for high burden 
countries (Perkins et al, 2001).  The detection of acid-fast bacilli in a sputum smear 
(Ziehl-Neelsen stain) is still the main mean of identifying new TB cases in low-
income countries.  
Here we showed that volatile detection through electronic nose technology is able 
to identify M. tuberculosis in culture and sputum. It is long established, that smell can 
be used to diagnose disease such as diabetes and uraemia (Ping et al, 1997; Lin et al, 
2001). Pavlou and Turner (2000) were among the first who applied electronic noses in 
medical diagnostics.  They showed that different bacteria such as H. pylori, E. coli 
and P. mirabilis generate a unique ”smell” and can therefore be differentiated from 
each other allowing a diagnosis.  
Electronic nose technology offers certain advantages such as low detection limit 
(5 – 0.1 ppm) (Schiffman et al, 1997), cost and time effectiveness, robustness, 
simplicity and operator independency in contrast to molecular or immunological 
based assays. Therefore, we investigated the ability of an electronic nose to detect 
Mycobacterium spp. and other lung pathogens in culture and sputum. In the past, the 
work of several groups revealed that “smell” could be used as an indicator for 
bacterial infections. Worthwhile is the work of Aathithan et al (2001) who used an 
Osmetech Microbial Analyser to diagnose bacteriuria. Analysing 534 clinical urine 
specimens, the sensitivity and specificity were 83.5% and 87.6%, respectively 
compared to culture. Among the first who used electronic nose technology to detect 
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M. tuberculosis in culture were Pavlou and Turner (2000). In this study, we could 
show that Mycobacterium spp. and Pseudomonas aeruginosa emit characteristic 
volatiles allowing discrimination between the different bacterial classes in both 
culture and sputum (Figures 4.1, 4.2, 4.7 and 4.8). The intra-group (classes) variability 
is bigger in sputum compared to culture (Figures 4.1 and 4.7). The reasons leading to 
this observation are not clear. The volatility of molecules is influenced by parameters 
such as sample viscosity, equilibrium temperature and concentration (Seto, 1994). 
Since the incubation parameters for liquid and sputum sample were similar, we 
assume that the higher viscosity, the heterogeneity and/or a stronger background 
“smell” of sputum might be responsible for it. As shown in Figures 4.7 and 4.8, by 
adding M. tuberculosis to sputum an additional “odor” was introduced into the sample 
headspace leading to a reduced intra-group variability. This indicates that 
Mycobacteria release enough volatiles into the headspace even in a complex matrix 
(sputum) allowing a diagnosis at low concentrations (1 x 104 mycobacteria ml-1). This 
result is of extreme importance for clinical diagnostic, where sputum is the usual 
source for TB detection. 
 Electronic noses show a linear relationship between sensor response and 
concentration. This concentration dependency was exploited here to determine the 
detection limit (Figures 4.3 and 4.4) (Hudon et al, 2000). The detection limit was 
found to be as low as 1 x 104 mycobacteria ml-1 in both culture and sputum. Similar 
detection limits were found for other bacterium species. Canhoto et al (2003) reported 
that a Pseudomonas aeruginosa suspension as well as an Enterobacter aerogenes 
suspension both containing 102 CFU ml-1 could be discriminated from control 
samples. Similar results were found by Magan et al (2001) who reported that it was 
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possible to discriminate between milk spoilage bacteria and yeast using an initial 
inoculum of about 103 – 104 CFU ml-1.  In contrast, McEntegart et al (2000) reported 
the detection of bacteria in liquid media, of about 5 x 108 cells ml-1 using a hybrid 
electronic nose. This relationship (concentration dependent sensor response) might 
also reveal relevant clinical information. For the treatment itself, it is not important 
how many bacteria are present in sputum, but the number of bacteria present largely 
influences the infectiousness of patients. This opens the possibility to predict not only 
the presence of TB but also the risk of patients to transmit the disease.  
As illustrated in Figures 4.4 and 4.5, dead bacteria emit enough volatiles to cause 
a sensor response. However, the amount of volatiles emitted by dead mycobacteria 
seemed to be less than from living mycobacteria, as indicated in Figures 4.4 and 4.5. 
The difference between the “smell” of a mixture (dead and living bacteria) and living 
bacteria is not as distinctive as between dead bacteria and living bacteria. This 
observation could be of value for the assessment of the treatment, i.e. for the follow-
up of patients during the treatment by analysing the odour shift from living to dead 
bacteria. This needs to be validated in a larger study with samples from patients under 
treatment which sputa are ZN positive but culture negative.  
As mentioned above, the usual mean of case finding is the Ziehl-Neelsen staining 
followed by direct microscopic examination. The sensitivity of the ZN stain compared 
to culture is under field conditions at most 60 %-70 % using three consecutively 
sampled specimens (Lipsky et al, 1984; Perkins, 2000; Cleeff et al, 2003). We 
achieved with the method presented, a specificity of 93 % and a sensitivity of 89 % 
compared to culture employing a single sputum specimen per patient. The electronic 
nose was unable to detect the four ZN negative but culture positive specimens (false 
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negatives). The bacterial load in these four specimens was most likely below the 
detection limit of the electronic nose under the current set-up, but larger number of 
ZN negative specimens need to be tested. As shown above, the detection limit of the 
electronic nose for M. tuberculosis in spiked sputum was 104 mycobacteria ml-1. 
However, the two remaining false negative specimens had a positive ZN stain (1+) 
and should therefore contain enough Mycobacteria to cause a sufficient sensor 
response. At present, we do not know the reasons for either the false-negatives or 
false-positives.  It could well be due to the non-optimised system used here or due to 
sample degradation during storing.  
Clinical specimens are more diverse than spiked samples (sputum pool) used in 
previous experiments (spiking). It is assumed that the viscosity, background smell and 
especially the heterogeneity of sputum influence the outcome of the analysis. 
Interestingly, smoking itself did not affect the analysis in terms of diagnosis TB. 
However, not all smokers were grouped in the sub-clusters shown in Figure 4.11. The 
individual smoking habits (number of cigarettes per day, last cigarette before sample 
taking) could not be established. We assume that certain smoke ingredients give rise 
to a slightly different sensor response allowing a separation.    
Seven cases of pneumonia were among the clinical specimens. As shown in 
Figure 4.11, they formed a separate cluster. This indicates that the causative agent for 
pneumonia generates a different volatile profile (smell) to Mycobacteria. This is of 
clinical importance showing the potential to differentiate between TB cases and other 
respiratory disease. 
 To date, it is unknown which volatile compounds are responsible for the 
sensor response. We assume that the sensor response is caused by the combined effect 
Diagnosis of pulmonary tuberculosis  179 
Cranfield University at Silsoe Reinhard Fend 2004 
of a) microbial metabolites and b) volatile cellular compounds. In the past, many 
research groups tried to identify volatile substances emitted from microorganism 
using gas chromatography (GC) or gas chromatography – mass spectroscopy (GC-
MS). Jantzen et al (1989) utilized a gas chromatograph to identify mycobacteria based 
on their cellular fatty acids and alcohols present in the headspace. They studied 165 
mycobacteria isolates (other than M. tuberculosis) and 24 M. tuberculosis isolates. 
Twelve characteristic lipid constituents allowed discrimination between the different 
Mycobacterium spp. All isolates belonging to the M. tuberculosis complex were 
characterized by a high level of hexacosanic acid (1 – 13 %), low concentrations of 
tetracosanoic acid (0.1 –3 %), lack of fatty alcohol and the presence of 
tuberculostearic acid. M. avium, M. intracellulare and M. scrofulaceum (MAIS 
complex) had generally high levels of fatty alcohols including 2-octadecanol (0.1 – 
5%) and 2-eicosanol (2 –21 %) and high concentrations of tetracosanoic acid (1 –
15%) and the presence of tuberculostearic acid. M. gordonae was easily identified by 
their lack of tuberculostearic acid and the presence of 2-methyl-tetradecanoic acid (2 
–12 %). The fatty alcohol 2-docosanol (2-13 %) was only found in M. xenopi isolates. 
M. malmoense strains contained the two unique compounds 2-methyl eicosanoic acid 
(1-4 %) and 2,4,6-trimethyl tetracosanoic acid (2-4 %), whereas M. kansasii were 
characterized by 2.4 dimethyl tetradecanoic acid (0.2 –1.2 %). In contrast, 
Pseudomonas aeruginosa emit sulphur compounds and esters (Gibson et al, 1997).  
The presented method is not yet fully optimised and is open to further 
improvement. The volatility of molecules is affected by many parameters including 
equilibrium temperature, concentration and viscosity (Seto, 1994). At the moment, 
only sodium chloride was added to the specimens to increase the concentration of 
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volatiles in the sample headspace due to the “salting out” effect of salts (Banat et al, 
2003). Banat investigated the vapour-liquid equilibrium of an aqueous system. They 
found an increased amount of volatiles in the vapour phase as the salt concentration 
increases, whereas the equilibrium temperature had little or no effect.  
Alternatively, Pavlou et al (2004) used an enzymatic cocktail contain porcine 
pancreas lipase and Aspergillus niger lipase to digest the mycobacterial cell wall, 
necrotic tissue and other metabolic products present in sputum. Using this sample pre-
treatment they were able to discriminate between M. tuberculosis and related M. 
avium M. scrofulaceum, P. aeruginosa and negative controls using a neural network. 
The trained neural network had a prediction rate 96% in sputum. A similar prediction 
rate was achieved with liquid culture of the same bacterial classes. However, no 
enzymatic pre-treatment was performed on liquid cultures. They assumed that 
enzymes such as lipases interact with fatty acids and create a unique volatile signature 
of the samples. A recent publication, however, reported the presence of protease 
especially serine and metallo proteases in human sputum. If this is true, it would make 
the enzymatic pre-treatment inefficient due to the degradation of the lipases by the 
proteases (Simpson et al, 2004).  
The application of sophisticated data analysis software is absolutely necessary in 
electronic nose applications. For culture and spiked sputum samples it was sufficient 
to use discriminant function analysis to discriminate between the different bacterial 
classes. However, for the clinical samples it was inevitable to apply artificial neural 
networks due to the high variability between the individual samples (variation) 
(Figure 4.12). Freeman et al (1994) applied an artificial neural network to distinguish 
between M. tuberculosis and M. bovis based on pyrolysis mass spectra. In contrast, 
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Veropoulos et al (1999) used neural networks in conjunction with fluorescence 
microscopy of stained sputum smears. The images were captures with a digital camera 
and via image processing software and neural network, they were able to identify M. 
tuberculosis in the smear sample. This preliminary study achieved a sensitivity of 94 
%.  
 
The described method is not fully optimized yet. Nevertheless, it potentially 
fulfils all requirements for a new diagnostic tool for TB (Perkins, 2000) including 
robustness, simplicity, sensitivity and cost-effectiveness. Among many advantages are 
the simple sample preparation and its amenability to automation. Together with an 
appropriate classification model, this method has the potential to become rapid and 
automated system for the early diagnosis of respiratory diseases through sputum or 
even breath analysis. It might also be possible to improve or modify currently 
available sensors towards specific M. tuberculosis markers, which would simplify the 
optimisation of such as system. 
 
 
 
 
 
 
  
 
 
 
Chapter 5 
General Discussion 
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5.1 INTRODUCTION  
The aim of the project was to investigate the possibility of using a gas sensor as a 
point-of-care medical device. In particular, two applications were examined. The first 
application was aimed to use the electronic nose as a new monitoring device for 
haemodialysis to replace current tools, which are based on urea monitoring. In the 
second application the gas sensor array was utilised to diagnose tuberculosis and 
therefore replace the Ziehl-Neelsen stain followed by direct microscopy.  
Clinical chemistry and immunoassays make up the largest proportion of the 
diagnostic market (Table 5.1). The world clinical diagnostics market is approximately 
$19 billion in sales. The annual growth rate is approximately 5% worldwide. For the 
last decade, improving technology has led to the availability of a wide variety of rapid 
diagnostics for use in GP surgeries, emergency rooms and bedside testing in hospital 
wards. Technology now allows the health professionals to accurately obtain many 
results without waiting for blood or urine specimens to be analysed in centralised 
laboratories. However, point-of-care (POC) testing is still not fully implemented in 
routine practice. Famous examples of POC testing are diabetes monitoring and 
pregnancy testing. A summary of the worldwide diagnostic market is given in Table 
5.1. The worldwide POC market is estimated to be growing at an annual rate of 10 to 
11% (Pavlou, 2002).  
In the industrialised world, hospital laboratories are usually well equipped with 
modern automated instruments performing the routine tests. However, some tests are 
still time and labour consuming and therefore are still expensive, e.g. many 
microbiological tests. In contrast, in less developed countries, the situation looks 
different. Most people are only able to attend remote field clinics, which are in most 
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cases poorly equipped and the staff is not well trained. There is an urgent need in both 
industrialised and developing countries for new point-of-care devices that are not only 
cheap and robust but also simple to operate. In this research project, a novel approach 
based on gas-sensing technology was taken to investigate the suitability of such as 
system as a point-of-care device. 
 
Table 5.1: Worldwide Diagnostics Market by Discipline (adapted from Pavlou, 
2002). 
Type of test Sales ($ millions) Annual growth rate (%) 
Immunoassays 7,200 4 
Clinical Chemistry 3,100 0 
Blood gas/Electrolytes 600 2 
Haematology/Flow cytometry 1.800 4 
Coagulation 700 6 
Nucleic acid tests 500 25 
Microbiology 1,300 2 
Diabetes 2,800 3 
Urinalysis 500 0 
Histology/Cytology 500 8 
Total 19,000 5 
 
 
5.2 GAS SENSING BASED DIAGNOSTICS 
The association of specific odours with distinct pathological conditions has been 
recognised for centuries, and odour recognition has played an important part in 
clinical diagnosis (Mitruka, 1975). The level of human olfactory sophistication 
however has remained relatively poor compared to many mammals, but the 
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development of the electronic nose however has broadened our olfactory horizons.  
Pavlou and Turner (2000) identified three key parameters for gas-sensing based 
diagnostics: 
· A generating mechanism for generating volatiles 
· Gas injection system and sensorial detection system 
· Complex pattern recognition system 
 
5.2.1 VOLATILE GENERATING MECHANISM 
In every gas-sensing based diagnostic test, there is an inevitable need to generate 
a unique set of volatiles, which in turn represent the samples of interest. This unique 
volatile pattern (for each sample group) is subsequently detected by an array of gas 
sensors. The main target specimens, which can be used as potential odour pools are 
urine, blood, sputum, sweat and gastric fluids. 
The simplest way of obtaining volatiles is to utilise the naturally present volatile 
organic compounds (VOCs) in a specimen. As we have shown in this report, there are 
enough volatile compounds naturally present in clinical specimens. For instance, it 
was possible to discriminate “uraemic” blood from control blood and more 
importantly pre- from post-dialysis blood purely based on volatiles accumulated in 
blood. In a similar way, volatiles generated by bacteria were released by incubating 
the samples in the presence of salt. Sodium chloride was added to a complex matrix 
such as sputum to enhance the concentration of volatiles in the headspace (salting-out 
effect). Using this methodology, it was possible to discriminate between different 
Mycobacterium spp. and other lung pathogens (e.g. Pseudomonas aeruginosa). Most 
other investigators used similar methodologies to analyse the headspace (gaseous 
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phase) of samples. Among the many groups using electronic nose technology are 
Aathithan et al (2001), and Di Natale et al (1999). Aathithan and his group (2001) 
utilised the natural produced volatiles by bacteria such as E. coli and Proteus spp. to 
diagnose bacteriuria. One possible indication of kidney disease is the presence of 
blood in urine. This circumstance was exploited by Di Natale et al (1999) who used 
an electronic nose to detect the natural occurring volatiles in urine. They were able to 
distinguish between urine samples of healthy subjects and urine sample containing 
blood purely on the basis of volatile detection emitted by the different specimens.   
In contrast, other investigators suggested the chemical or enzymatic degradation 
of a sample to generate volatiles. For instance, gas chromatographic determination of 
fatty acids requires a pre-column derivatisation step to convert the fatty acids into 
volatile derivates (Pauschmann, 1990). Chandiok et al (1997) treated human vaginal 
tissue with KOH to generate amino compounds, which in turn are specific for 
bacterial vaginosis. In contrast, Pavlou et al (2004) suggested the enzymatic treatment 
of bacteria. They treated M. tuberculosis bacteria with lipases to utilise the unique set 
of mycolic acids synthesised by Mycobacterium spp. A number of proteases, lipases 
and lipooxygenases have been reported to liberate volatile esters, fatty acids and 
convert unsaturated fatty acids to certain flavours (Berger, 1997). In addition, natural 
pills or solutions could be taken orally before each test in order to interact specifically 
with pathogens or infected tissues. For instance, radioactive labelled urea is used as a 
biochemical in vitro substrate to enable Helicobacter pylori infection diagnosis (Urea 
Breath Test) (Phillips, 2002).  
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5.2.2 GAS INJECTION SYSTEM AND SENSORIAL DETECTION SYSTEM 
Another crucial factor during the development of a novel gas sensing based 
diagnostic tool is the complete reproduction and safe delivery of the headspace 
sample into the sensory unit. Several workers dealing with clinical specimens have 
used standardised conditions, by using a water bath or gas carrier atmospheres 
(Distelheim, 1973). To date numerous artificial nose systems have used models of 
static headspace analysis in laboratory bags (Chandiok et al, 1997) or sealable sample 
vials (Di Natale et al, 1999). However, such a common technique is considered as a 
quick method of analysis but bears little relationship to mammalian odour delivery, 
and if not performed with consistency it may adversely influence pattern recognition 
reproducibility. On the contrary, automatic control systems such as flow injection 
analysis (FIA) are more efficient in terms of delivering repetitive volatile patterns to 
the sensor panel due to their higher similarity to the biological olfactory system 
(Pearce, 1997b).  
The current system is based on the static headspace sample procedure due to its 
simplicity in terms of automation. The samples were incubated in headspace vials and 
the sample headspace was delivered to the gas sensor by placing a needle into the 
sample headspace. A second needle has to be placed in the liquid phase of the sample 
to drive the volatiles into the headspace by a carrier gas (Pavlou et al, 2000). On one 
hand, the composition of the samples used herein, hampered the utilisation of a carrier 
gas system due to the blockage of the gauge of the second needle (e.g. blood cells or 
sputum). On the other hand, in terms of point-of-care testing especially for TB 
diagnosis in remote field clinics, it was considered as impractical to develop a gas 
injection system based on FIA. Nevertheless, the sampling point, the headspace, and 
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liquid volumes were kept constant in addition to a continuous monitoring of 
environmental conditions at the sampling point. Although a prototype system, it 
managed to derive relatively reproducible patterns, being fast, cheap and yielding 
rapid results 
As mentioned previously, the main sensor types used in electronic noses are either 
conducting polymers or metal oxide sensors. The precise physico-chemical properties 
of the sensor surface of conducting polymers and the mechanism of volatile 
interactions remain unknown. Specific doping materials can make each sensor 
response unique to a certain volatile mixture, whereas a sensor array can employ a 
much broader overlapping selectivity and functions at room temperature (Gardner and 
Bartlett, 1994). Conducting polymers are now being used in many commercial 
applications ranging from food monitoring to medical diagnostics. As shown in this 
report, conducting polymers were responding to different volatiles derived from either 
blood samples or bacteria. The sensor array was selective enough to enable 
discrimination between the different sample types (pre- and post-dialysis blood or 
different bacteria classes) independent of the source from which the volatiles were 
derived. In the past, conducting polymers were applied to diagnose urinary tract 
infections (Pavlou et al, 2002) or H. pylori infection (Pavlou et al, 2000) to detect 
milk spoilage (Magan et al, 2001), and for the characterisation of coffee (Pardo et al, 
2000) or virgin olive oil (Guadarrama et al, 2001), and thus makes conducting 
polymers an attractive solution for point-of-care devices due to their low power 
consumption, but long-term drift and humidity sensitivity remain some of the major 
drawbacks (Persaud et al, 1996). In contrast, metal oxide sensors are not as sensitive 
and are operated at around 400 °C (Dickinson et al, 1998) and thus require a larger 
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sample volume and much more power, which in turn makes metal oxide sensors less 
attractive for point-of-care devices.   
 
5.2.3 COMPLEX PATTERN RECOGNITION  
A typical gas sensor array comprises up to 32 gas sensors, which each provides 
five parameters describing the sensor response. However, not all parameters provided 
by the sensor are reliable and therefore only two were used in this report, namely the 
maximum step response and the area under the curve. The electronic nose responses 
can only be expressed as a pattern  (sample signature) unique to a sample class. The 
majority of groups used principal component analysis (PCA) as the initial data 
analysis technique. As shown in this report, PCA was able to reveal hidden 
relationships within sample groups as well as between different sample classes. A 
clear separation could be obtained between the different samples using PCA. 
McEntegart et al (2000) found distinctive clusters of Enterobacter aerogenes and E. 
coli in a two-dimensional PCA plot. In addition, the same group showed that it was 
possible to trace the growth of bacteria. They presented a two dimensional PCA chart 
with clearly discriminated clusters where each cluster represented a different 
incubation time ranging from two to six hours. The first principal component showed 
a qualitative correlation to the incubation time. This finding is in agreement with the 
results presented in the report. As shown in Figures 3.33 and 4.3 the first principal 
component was able to separate the samples according to time (pre- and post-dialysis, 
shift observed during HD session, see section 3.3.4) and concentration (different 
concentrated M. tuberculosis suspensions, see section 4.3.1). Hierarchical cluster 
analysis (HCA) is as PCA an exploratory data analysis technique aimed to visualise 
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data. In the work presented, it was mainly used to visualise the difference, expressed 
as the Euclidean distance, between samples, which allowed a visual assessment of the 
difference.   
After having confirmed that the electronic nose is providing sufficient 
information to distinguish between the samples of interest either by PCA or HCA, it 
was possible to build a classification model. Two well established methods used in 
this report are discriminant function analysis and artificial neural networks (ANN). 
These methods use training data to build a mathematical definition for each class of 
odour (Saini et al, 2001). Unknown samples can then be classified according to the 
definition which the match most closely (Saini et al, 2001). Artificial Neural 
Networks (ANN) are a useful classification tool, as they can model more complex 
relationships than Discriminant Function Analysis. On the other hand, they are more 
difficult and time consuming to train and optimise (Bartlett and Hines, 1997; Saini et 
al, 2001).  
As demonstrated in this report, discriminant function analysis (DFA) is a useful 
tool to classify samples such as spiked samples, liquid culture samples or even 
“uraemic” blood samples. However, DFA is not useful for more complex patterns 
derived from clinical sputum samples (see section 4.3.3) or from samples taken over a 
long period of time (see section 3.3.4). Due to the huge variability within individual 
patients it was necessary to apply more sophisticated methods such as ANN. As 
shown in Chapter 3 and 4, ANNs are able to cope with more variability (Tables 3.4 
and 4.5). Selecting and constructing the right learning data (input variables) is crucial 
in pattern recognition methods. Each class must be composed of representative and 
reproducible samples. The quantity of these samples does not increase the 
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discrimination-confidence instead it is the "quality" of representation carried in each 
input sample that determines pattern recognition performance (Otto, 1999). Aathithan 
et al (2001) confirmed the power of ANN when analysing 534 clinical urine 
specimens of patients suspected for bacteriuria achieving a specificity of 87.6 % and a 
sensitivity of 83.5 %, respectively. Once the ANN is trained, it can be easily 
implemented into a point-of-care device providing the operator with the result directly 
displayed on the screen.  
 
5.3 ELECTRONIC NOSES AS POINT OF CARE DEVICE 
Effective clinical care requires decision making based upon multiple data inputs 
e.g. gross symptoms, previous history, and biochemical tests. Rather surprisingly, 
such a broad approach has been the main approach for the development of point of 
care testing, which generally rely on a “one target – one result” approach. Under 
certain circumstances, it is possible to use single marker molecules to monitor a 
disease. Famous examples are blood glucose monitoring in diabetic patients and home 
pregnancy testing.  
Microbiology, clinical chemistry and immunoassays are still the traditional means 
of diagnosing diseases. However, the facilities to perform these tests are normally 
only available at centralised hospital laboratories and not where they are most 
required. These methods are absolutely necessary in medical diagnostics as in many 
cases act as the “gold standard”. Nevertheless, they are time and labour consuming, 
expensive, and require skilled personnel, which makes them unattractive for point-of-
care testing. In contrast, electronic noses are simple to perform, robust, cheap and 
amendable to automation. The applications of electronic noses are widely spread 
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ranging from monitoring the quality of food packaging (Forgren et al, 1999) and dairy 
products (Schaller et al, 1999), sausage fermentation (Eklov et al, 1998), wastewater 
treatment (Bourgeois et al, 2001) to medicine (Aathithan et al, 2001; Di Natale et al, 
2003; Pavlou et al, 2004) Yet, no medical applications have been implemented in 
routine practice, but as outlined in this report, there is potential in revolutionising 
point-of-care testing using gas-sensors. Chronic renal failure and tuberculosis are two 
diseases, where people could benefit from new point-of-care devices.  
As mentioned previously, chronic renal failure patients have to undergo 
intermittent haemodialysis to counter loss of kidney function. Currently the 
assessment of the treatment adequacy is based on the marker substance urea and 
expressed either as the urea reduction ratio (URR) or the normalised dialysis dose 
Kt/V. None of these two parameters is satisfactory, since the uraemic syndrome is not 
attributable to the retention of a single molecule. The electronic nose offers the 
possibility to assess the treatment adequacy based on a wide range of molecules (see 
chapter 3). The information provided by the gas sensor array can be gained on-line 
and in real-time as demonstrated by Bourgeois et al (2001) for waste-water treatment. 
Together with an appropriate mathematical classification model, it could provide the 
health professions in a dialysis unit with the relevant information necessary to ensure 
optimal treatment. Nevertheless, one of the biggest challenges will be to correlate a 
certain sample profile (pattern) to a clinical outcome (morbidity or mortality). In 
addition, the classification model can be fed with other relevant clinical information 
such as urea concentration or weight as long as the parameters are available on-line 
and thus might reflect a better clinical picture compared to a single parameter.  
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Gas sensor arrays are able to detect multiple pathogens as shown in Figure 4.1 
(e.g. M. tuberculosis, M. avium, M. scrofulaceum, P. aeruginosa) compared to 
immunoassays, which can only detect one specific target or automated instruments 
which are only able to detect bacterial growth without the ability to determine the 
species (Thorpe et al, 1990). In this respect, the electronic nose offers a powerful 
alternative to the current available techniques. The electronic nose as presented in this 
report, yet not fully optimised, cannot compete with molecular techniques (e.g. PCR, 
in situ hybridisation) in terms of sensitivity and specificity. However, the current 
method is still open to further improvements, which will hopefully increase both 
sensitivity and specificity. Recently, Kivihya-Ndugga et al (2004) compared PCR 
with the Ziehl-Neelsen staining procedure for diagnosing pulmonary tuberculosis 
(TB). They concluded that PCR is a powerful tool to diagnose TB but its limitation 
include high maintenance of equipment, water supply, short shelf life of PCR kits and 
high costs. This makes PCR unattractive for implementation as a routine test for TB in 
high-prevalence countries. Currently, the electronic nose is able to detect M. 
tuberculosis and other respiratory pathogens in culture and sputum. However, recent 
findings suggest that patients suffering from TB emit volatiles with their breath which 
are associated with the diseases. Currently, a group in Africa utilises the extraordinary 
olfactory system of giant rats to diagnose TB (New Scientist, Dec. 2003). The 
electronic nose could be used to replace the giant rats, which in turn would be a more 
patient friendly technique. This technology will hopefully be available in the future as 
a diagnostic tool.  
The company, Osmetech plc, followed a different route for point-of-care testing. 
Osmetech has received 510(k) approval from the FDA for the use of its microbial 
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analyser as a UTI sensor device. Offering both a centralised laboratory based 
instrument and a smaller “point-of-care” option, Osmetech’s view is that the device 
should enable negative samples to be screened out within minutes enabling the 
number of cultured samples to be greatly reduced, resulting in cost savings 
(Woodman and Fend, 2004). However, the results presented in this report and by 
others, indicate that the electronic nose is not only able to detect negative samples but 
also detect the causative agent of an infectious disease.  
In terms of point-of-care testing, electronic noses have also potential as a non-
invasive screening tool for cancer based on breath analysis. Phillips et al (2003 a, b) 
investigated marker molecules of oxidative stress as possible indicators for breast and 
lung cancer using GC-MS. Both cancers are accompanied by increased oxidative 
stress. Among elevated breath VOC were nonane, tridecane, octane, and dodecane. In 
contrast, Di Natale et al (2003) used an electronic nose to identify patients with lung 
cancer. They found distinctive groups for patients with lung cancer and healthy 
volunteers. A simple point-of-care test based on electronic nose technology could 
replace current screening procedures and thus reducing the risk due to reduced 
exposure to X-rays.  
  
 
 
  
Chapter 6 
Conclusions and Future Work 
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6.1 CONCLUSIONS 
The overall aim of this study was to evaluate the potential of an electronic nose as 
a point-of-care device for renal medicine and pulmonary tuberculosis. As 
demonstrated in this thesis, the aim and hence, the individual objectives were 
achieved.  The conclusions are as follows: 
  
6.1.1 ELECTRONIC NOSE IN RENAL MEDICINE 
· The electronic nose is able to distinguish between control blood and “uraemic” 
blood. Furthermore, the gas sensor array is not only capable of discriminating pre- 
from post-dialysis blood but also can follow the volatile shift occurring during a 
single haemodialysis session. 
 
· The electronic nose can be used for both dialysate side and blood-side monitoring 
of haemodialysis.  
 
· The sensor response showed a slight day-to-day variation (except sensor 11 and 
14) with a maximum of 15% deviation and thus the sensor drift was considered as 
negligible.  
 
· To date it is unknown which exact compounds are responsible for the sensor 
response, but as demonstrated in this report, urea and creatinine do not contribute 
to the sensor response 
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· The volatile shift occurring during haemodialysis was not correlated with the urea 
reduction ratio.  
 
· The pattern observed for post- and pre-dialysis blood might reflect the health 
status of the patients and can therefore be related to the long-term outcome 
(morbidity and mortality risk). 
 
· To follow haemodialysis patients over a longer period of time, traditional 
chemometric tools such as principal component analysis or discriminant function 
analysis are not sophisticated enough. In contrast, artificial neural networks are 
capable to distinguish between pre- and post-dialysis blood with high accuracy (97 
% correct classified).  
 
 
6.1.2 ELECTRONIC NOSE FOR THE EARLY DETECTION OF PULMONARY TB 
· The electronic nose was able to discriminate between Mycobacterium spp. and 
other lung pathogens such as Pseudomonas aeruginosa. More importantly the gas 
sensor array was capable of resolving different Mycobacterium tuberculosis, M. 
scrofulaceum, and M. avium in both liquid culture and spiked sputum samples.  
 
· The detection limit for M. tuberculosis in both sputum and liquid culture is 1 x 104 
mycobacteria ml-1 and therefore partially fulfils the requirement set by the WHO.  
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· The electronic nose has the potential to follow up patients during treatment to 
assess the efficiency of the treatment as indicated by the different smell of “dead” 
bacteria and living bacteria suspension (Figures 4.6 and 4.7) 
 
· The sensitivity for the detection of culture proven TB was 89% (95% confidence 
interval [95%CI] 80-97%), the specificity was 91% (95%CI 85-97%) and the 
positive and negative predictive values were 88 % (95%CI 78-96) and 92% (9%CI 
86-98), respectively.  
 
· The analysis time (incl. preparation time) for detecting M. tuberculosis in liquid 
culture is approximately 60 minutes, and in sputum approximately five hours. 
However, most of the time is used for incubation and thus does not require labour. 
 
· The exact compounds, which cause the sensor response, could not be established.  
 
 
The promising studies presented herein indicate that there is a real potential 
for electronic noses at point of medical delivery, where they could be used as a rapid 
screen for specific diseases or disorders. However it is the combination of the “point-
of-care” environment with the opportunity to gather data remotely and use advanced 
information-technology approaches, mobile communication and web-based 
knowledge systems to transfer them back to centralised facilities either for processing 
or disease management which add another dimension to this technology. 
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6.2 FUTURE WORK 
6.2.1 ELECTRONIC NOSE IN RENAL MEDICINE 
· GC-MS studies to identify the key volatiles responsible for causing the sensor 
response.  
· Use the knowledge gained from the GC-MS studies to customise the sensor array 
towards these key volatiles. 
· Identify a volatile pattern, which correlates with a better clinical outcome, i.e. a 
lower morbidity and mortality risk. 
· Correlate key volatiles (potential uraemic toxins) to the volatile shift observed in 
HD.  
· Develop a flow-cell and associated parts, which allows the on-line monitoring of 
HD sessions. 
· Develop a model which is able to predict the “optimal” end point for each 
treatment session 
· Develop a protocol and device for monitoring haemodialysis based on breath 
analysis.   
 
 
6.2.2 ELECTRONIC NOSE FOR THE EARLY DETECTION OF PULMONARY TB 
· GC-MS studies to identify the key volatiles responsible for causing the sensor 
response.  
· Use the knowledge gained from the GC-MS studies to customise the sensor array 
towards these key volatiles. 
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· Increase the sensitivity and specificity of the electronic nose by altering the 
sample pre-treatment and sensor panel. 
· Try to identify Mycobacterium spp. other than M. tuberculosis in clinical 
specimens and other relevant respiratory pathogens.  
· Evaluate the performance of the electronic nose in Ziehl-Neelsen negative 
samples (e.g. in HIV co-infected patients).  
· Investigate the potential of an electronic nose as a monitoring tool for treatment 
success.  
· Develop a protocol, so that the electronic nose is able to identify multiple drug 
resistance strains.  
· Develop a protocol and device for breath sampling and subsequent breath analysis 
for diagnosing pulmonary tuberculosis. 
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APPENDIX A 
 
A.1 CONSENT FORM FOR VOLUNTEERS 
 
Consent Form 
 
Donation of blood for the analysis of volatile compounds  
using an electronic nose 
  
 
·  I give my consent for the Medical Centre at Cranfield University to 
take 10 ml of my blood and for it to be used in medical research. 
 
·  I consent for the blood to be analyzed by an electronic nose for 
 volatile compounds as well as the preparation of a biochemical profile.  
 
· I understand that I will not be informed of any results from this 
research.  
 
_____________________________   _________________ 
Name of Donor:  Date:   Signature of Donor: 
    
   
_______________________________ 
Signature of Medical Centre Representative 
  
  
 
_______________________________ 
Signature of Scientist receiving the blood 
 
Appendices  XXIX 
Cranfield University at Silsoe Reinhard Fend 2004 
A.2 CONSENT FORM FOR PATIENTS 
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APPENDIX B 
B.1 GAS SENSORS USED IN THIS STUDY 
The gas-sensing unit was developed in the Department of Biochemistry and 
Molecular Biology at Leeds University (UK) and is being commercialised by 
Bloodhound Sensors Ltd. (UK).  
 
Gibson et al (1997) and Bloodhound’s US Patent 5,928,609 report that the 
company’s sensors were prepared by electro-polymerising the different monomers 
(Table B.1) onto interdigitated gold electrodes. The resulting polymer structures were 
electrically conducting and show different sensitivities to volatile odour compounds. 
The interaction between odour compounds and polymer structure is indirectly 
measured by the alteration of the applied potential or current due to changes in 
resistance, impedance or capacitance of the polymer film. To obtain overlapping 
specificities toward volatile compounds, the individual polymers were doped with 
different chemicals (Table B.1).  
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Table B.1: Monomers and dopants used in the Bloodhound BH114 system  
(adapted from Gibson et al, 1999). 
 
Sensor Polymer monomer Dopant 
1 Ethylaniline Sulphate   
2 Aniline Sulphate   
3 Aniline  Sulphate   
4 Tryptophan    Sulphate   
5 Tryptophan    Sulphate   
6 2-methoxy-5- nitroaniline Sulphate   
7 Thiophene and thiophene-3-
tetrabutyl-ammonium carboxylic acid  Perchlorate 
8 Aniline Ethanol sulphate 
9 Pyrrole       Octanoic acid ethyl ester  
10 Pyrrole CO4 
11 1, 4-phenlene diamine  Chloride  
12 1, 4-phenlene diamine  Chloride  
13 Pyrrole Chloride  
14 Pyrrole Tetrabutyl-ammonium perchlorate 
   
Note:  
 Sensor 7:  co-polymer 
 Sensor 10: with upper Octanoic acid ethyl layer of poly-tryptophan ester dopant 
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APPENDIX C 
C.1 DIALYSATE COMPOSITION 
 
Table C.1: Usual composition of dialysis fluid (Levy et al, 2001). 
 
Sodium 132 – 155 mmol/L 
Potassium 0 – 4 mmol/L 
Calcium 1.25 – 2 mmol/L 
Magnesium 0.25 – 0.75 mmol/L 
Chloride 90 – 120 mmol/L 
Bicarbonate 27 – 40 mmol/L 
Dextrose 0 – 5.5 mmol/L 
pH 7.1 – 7.3  
 
 
At Gloucester Royal Hospital the following two bicarbonate concentrations are in 
use: 35 mmol/L or 40 mmol/L 
 
C.2 HAEMODIALYSIS AT GLOUCESTSHIRE ROYAL HOSPTIAL 
 
At Gloucestershire Royal Hospital (GRH) two Fresenius dialysers are in use, 
namely F6 and F8 dialysers. The difference is the surface area of the polysulfone 
membrane; the F6 dialyser has a surface area of 1.3 m2, whereas the F8 has a surface 
area of 1.8 m2. 
 
The blood flow rate varies between 200 and 350 ml/min, depending on the 
patient. The dialysate flow rates are the same for all patients at 500 ml/min. The 
majority of the patients at GRH are dialysed for 4 hours three times a week.  
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The routine monitoring includes: 
 
· Monthly blood samples (pre- and post-dialysis blood) è dialysis dose, adequacy 
· Measurement of blood pressure as well as weight. Both parameters are determined 
before and after the treatment session è they are used to determine the excessive 
body fluid, which has to be removed from the patients body by Haemodialysis 
(HD). 
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APPENDIX D 
D.1 LONG-TERM PERFORMANCE (STABILITY) 
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Figure D.1: Principal component analysis (1st and 3rd principal component) of 
control blood (45 volunteers, squares), post – dialysis (99 samples, triangles) and pre-
dialysis blood (99 samples, circles). The blood samples of 11 HD patients were taken 
at nine consecutive dialysis sessions. 
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D.2 COMPARISON OF TRADITIONAL BIOCHEMICAL MARKERS WITH ELECTRONIC 
NOSE DATA  
 
Table D.1: Biochemical data of the three patients with similar pre- and post-
dialysis biochemical profile (see page 133). 
  Post-dialysis Pre-dialysis 
Urea (mmol l-1) 9.3 12.0 
Creatinine (mmol l-1) 434 549 
CO2 (mmol l-1) 31 29 
Phosphate (mmol l-1) 0.88 0.9 
Patient 9 
Ca2+ PO42- (mmol l-1) 2.2 2.1 
    
Urea (mmol l-1) 11.4 7.2 
Creatinine (mmol l-1) 659 887 
CO2 (mmol l-1) 28 28 
Phosphate (mmol l-1) 1.46 1.66 
Patient 15 
Ca2+ PO42- (mmol l-1) 3.9 4.1 
    
Urea (mmol l-1) 9.2 11.8 
Creatinine (mmol l-1) 489 548 
CO2 (mmol l-1) 28 26 
Phosphate (mmol l-1) 0.81 0.79 
Patient 25 
Ca2+ PO42- (mmol l-1) 1.95 1.90 
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APPENDIX E 
E.1 COMPOSITION OF THE MIDDLEBROOK 7H9 MEDIUM WITH OADC ENRICHMENT 
 
Middlebrook 7H9  4.7 g 
Tween 80   0.5 g 
Water    900 ml  
 
 
OADC enrichment 
Oleic Acid    50 mg 
Albumin, Fraction V, bovine 5 g 
Dextrose    2 g 
Catalase (Beef)   3 mg 
Sodium chloride   0.85 g 
WR 1339, Triton   0.25 g 
Water    100 ml 
 
 
Sterilisation: Autoclave at 121 oC for 10 min, cool to 45 oC and add aseptically 
100 ml of Middlebrook OADC enrichment solution. 
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E.2 FORMULA FOR CALCULATING SENSITIVITY, SPECIFICITY, PPV AND NPV 
 
Table E.1: Table for calculating sensitivity, specificity, PPV and NPV.  
 Disease  
positive 
Disease 
negative 
Total 
Test positive a b a + b 
Test negative c d c + d 
Total a + c b + d a+b+c+d 
 
 
  
 100*
ca
a
ySensitivit
+
=  
 
 100*
db
b
ySpecificit
+
=  
 
 100*
ba
a
PPV
+
=  
 
 100*
dc
d
NPV
+
=  
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1.  Reinhard FEND, Conrad Bessant, Anthony J Williams, and Anthony C 
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2.  Reinhard FEND, Conrad Bessant, Anthony J Williams, and Anthony C 
Woodman, An Electronic Nose to Monitor Haemodialysis, (submitted Nephrol 
Dial Transplant) 
 
3.  Reinhard FEND, Arend HJ Kolk, Conrad Bessant, Paul R Klatser, and Anthony 
C Woodman, Early detection of M. tuberculosis infections in culture and sputum 
using electronic nose technology, (submitted J Clin Microbiol) 
 
4. Reinhard FEND, Arend HJ Kolk, Conrad Bessant, Paul R Klatser, and Anthony 
C Woodman, Electronic nose technology for the diagnosis of tuberculosis,  
(submitted J Clin Microbiol) 
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